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ABSTRACT 
 
Aberrantly expressed carbohydrates occur on cancer cells and are antigenic. This 
thesis is focused on studies to elucidate two elusive hybridoma-defined, cancer-
associated carbohydrate antigens: a prostate cancer-associated antigen F77 and a 
broadly distributed epithelial cancer-associated antigen AE3. 
 
The key experiments performed are microarray analyses with mucin-type 
glycoproteins and generation of designer arrays, multidimensional chromatographies 
and mass spectrometry of O-glycomes. Antigen-positive sequences assigned are 
corroborated with focused arrays of natural and chemically synthetized 
oligosaccharides or glycolipids and products of glycosidase treatments. 
 
The F77 antigen is assigned as blood group H type 2 on a 6-linked branch of a poly-
N-acetyllactosamine backbone (structure a). This sequence is shown to occur on O-
glycans and on glycolipids. The F77 antibody can bind, with lower intensities, to the 
blood group A and B analogues of structure a. The minimum F77 antigenic sequence 
is shown to be a pentasaccharide (underlined in structure a). The close association 
of F77 antigen with prostate cancer is proposed to be a consequence of up-
regulation of branching enzymes together with persistent expression of H antigen. 
This may account for the prevalence of F77 antigen in prostate cancers irrespective 
of the patients‘ ABO blood group status.  
 
 
 
There appear to be two distinct forms of AE3 antigen as evidenced by the ability of 
AE3 antibody to bind: (i) the O-glycan structure b, known as T antigen, which is 
joined by α-linkage to serine on mucin-type glycoproteins, and (ii) a sulphated 
glycolipid known as SM1a (structure c) in which ―T‖ sequence is joined by β-linkage 
to galactose. An O-glycan analogue of structure c (structure d), has not been 
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reported so far. Chemo-enzymatic synthesis of structure d will shortly be attempted 
for antigenic analysis.  
 
 
 
With knowledge of details of these two antigens, the biosynthetic pathways, the 
biological functions and clinical applications can now be rationally pursued. 
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LCA Lens culinaris agglutinin 
PNA Peanut agglutinin 
RCA120 Ricinus Communis agglutinin I 
UEA-I Ulex Europaeus agglutinin I 
WGA Wheat Germ agglutinin 
 
Abbreviations for amino acids 
Asn asparagine N 
Ser serine S 
Thr  threonine T 
Pro proline P 
Isoleucine Ile I 
 
Other abbreviations 
AFP α-fetoprotein 
ADCC  antibody dependent cell-mediated cytotoxicity  
ADHP N-aminoacetyl-N-(9-anthracenylmethyl)-1,2-
dihexadecyl-sn-glycero-3-phosphoethanolamine 
AOPE aminooxy-functionalized DHPE 
BSA  bovine serum albumin  
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CA 15-3 cancer antigen 15-3 
CA 19-9 cancer antigen 19-9 
CAR chimeric antibody receptor  
CCR chimeric costimulatory receptor 
CD  cluster of differentiation  
CDC  complement dependent cytotoxicity  
CEA carcinoembryonic antigen 
Cer ceramide 
CFG Consortium of Functional Glycomics 
CID collision induced dissociation 
CTCs circulating tumour cells 
CRD carbohydrate-recognition domain 
DAB 3,3‘-diaminobenzidine 
DC-SIGN dendritic cell-specific intercellular adhesion molecule 3-
grabbing non-integrin 
DHPE 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine 
EGF epidermal growth factor 
ELISA  enzyme-linked immunosorbent assay  
ERK extracellular signal-regulated kinases 
ES electrospray 
FACS  fluorescence activated cell sorter  
Fc constant region  
Fv  variable fragment  
GAG glycosaminoglycan 
GPI  glycosylphosphatidylinositol  
HBS HEPES buffered saline 
HCA human carcinoma antigen 
HCC hepatocellular carcinoma 
HPLC high performance liquid chromatography 
HPTLC high performance thin layer chromatography 
HRP  horseradish peroxidase  
HUVEC  human umbilical vein endothelial cell  
Ig  immunoglobulin  
mAb  monoclonal antibody  
MS mass spectrometry 
MALDI matrix-assisted laser desorption/ionization 
MIC micronemes 
MICA MHC class I-related chain A 
MUC1  Mucin-1  
MUC5Ac Mucin-5Ac 
NGL neoglycolipid  
NHS  N-hydroxysuccinimide  
NKG2D natural killer group 2 member D 
PBS phosphate buffered saline 
PRRs pattern recognition receptors  
PSA prostate-specific antigen  
PSCA prostate stem cell antigen 
PSGL-1  P-selectin glycoprotein ligand 1  
PSM porcine stomach mucin 
PSMA prostate-specific membrane antigen 
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scFv single chain variable region 
Siglec sialic acid-binding immunoglobulin-type lectins 
SIGN-R specific intercellular adhesion molecule 3-grabbing 
non-integrin-related 
SPR surface plasmon resonance 
SSEA stage specific embryonic antigen 
SU sulphate 
TGF-β transforming growth factor beta 
TLC thin-layer chromatography 
TM transmembrane domain 
TNF tumour necrosis factor 
TRAIL TNF-related apoptosis-inducing ligand 
VEGF  vascular endothelial growth factor  
VEGFR2 vascular endothelial growth factor receptor-2 
VNTR variable number of tandem repeat 
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Chapter 1  
INTRODUCTION 
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1.1 General introduction to carbohydrates 
 
As one of the major classes of molecules of a living organism, carbohydrates are 
ubiquitously distributed. Ranging in size from monosaccharide to polysaccharides of 
thousands of units (1,2), carbohydrates serve crucial biological roles. For instance, 
mammals utilize monosaccharide glucose as the major source of metabolic fuel and 
polysaccharide glycogen for energy storage. Carbohydrates coat most cells in the 
form of glycoconjugates, e.g. glycoproteins, glycolipids and proteoglycans. Many 
proteins, secreted or inside cells, have oligosaccharides that modulate their 
properties and activities. Apart from serving as structural components, these glycan 
chains also play key roles in almost every biological process and, directly or indirectly, 
in almost every major disease (3-5).  
 
The numerous functions of carbohydrates are based on their structural diversity. 
Compared with nucleotides and amino acids, monosaccharides can be linked 
together in many ways. Each monosaccharide can theoretically be linked in either an 
α- or a β- linkage (anomers) to one of several positions on another monosaccharide 
or to another type of molecule. Thus carbohydrates have enormous structural 
complexity and heterogeneity in terms of, for example, monosaccharide composition, 
linkage position, branching pattern and anomeric configuration. Moreover, the 
structural diversity can be further expanded by modifications such as sulphation and 
phosphorylation (6,7). 
 
Unlike the protein sequences, which are primary gene products, glycan structures 
are not encoded directly by the genome but are products of a cohort of sequentially 
acting and competing glycosyltransferases and glycosidases. Therefore, even with 
information in the expression levels of the relevant genes in a given cell type, the 
precise prediction of all the glycan structures is unachievable. Additionally, 
biosynthesis of the glycans is dynamically changed by metabolism, signal 
transduction and cellular status (8,9). This variable and dynamic nature of 
glycosylation potentially makes glycans more difficult to study than nucleic acids and 
proteins. It also results in a myriad of complex glycoconjugates of biological 
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importance. The structural characteristics of glycoconjugates and their biological 
functions are reviewed in the sections that follow. 
 
1.1.1 Major classes of glycoconjugates 
 
According to the type of carrier molecule (aglycone), the common classes of 
glycoconjuates found in or on eukaryotic cells are defined as glycoproteins, 
proteoglycans and glycosphingolipids as shown in Figure 1.1. The glycans of 
different classes have distinctive core regions whereby they are connected to the 
aglycones. 
 
 
Figure 1.1 Common classes of mammalian glycans. The common core structures of each class are boxed in 
grey. Sequences are representative structural variations in mammalian cells. Taken from (10).  
 
A glycoprotein is a glycoconjugate in which one or more glycans are covalently 
attached to a polypeptide backbone via N- or O-linkages. N-glycans are sugar chains 
covalently linked to asparagine (Asn) residues of a polypeptide chain. N-glycan is 
linked through an N-acetylglucosamine (GlcNAc) residue to peptide sequence Asn-X-
Ser/Thr, where X can be any amino acid except proline. The biosynthesis of N-
glycans starts on the cytoplasmic face of the ER membrane and continues inside the 
endoplasmic reticulum (ER) and Golgi (Figure 1.2). N-glycans share a common 
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pentasaccharide core region and can be generally divided into three main classes: 
oligomannose (or high-mannose) type, complex type, and hybrid type (Figure 1.3). 
The most common O-glycans are linked to a serine or threonine residue on 
polypeptide backbones via core N-acetylgalactosamine (GalNAc). They are 
synthesized in the Golgi, initiated by addition of GalNAc by polypeptide-N-acetyl-
galactosaminyltransferases (ppGalNAcTs). These O-glycans (also called O-GalNAc 
glycans) can be divided into many subtypes (core 1 to 8) based on their common 
core regions (Table 1.1). Some glycoproteins, such as mucins, carry many O-glycans 
in clustered form (2). There are also several other non mucin type O-glycans such as 
O-mannose, O-fucose and O-GlcNAc (3). 
 
 
Figure 1.2 Biosynthesis and processing pathway of N-linked oligosaccharides. Taken from (11).  
 
 26 
 
 
Figure 1.3 Sequences of the oligomannose, complex, hybrid and bisecting type of N-glycan. They all share 
the common core Man3GlcNAc2Asn. Figure is  adapted from (12). Symbols are in Figure 1.1.  
 
Table 1.1 Core sequences of common O-GalNAc glycans. 
Core type Sequence 
Core 1        Galβ-3GalNAcα-Ser/Thr 
Core 2 
  GlcNAcβ-6 
                     │ 
                 GalNAcα-Ser/Thr 
                     │ 
        Galβ-3 
Core 3 GlcNAcβ-3GalNAcα-Ser/Thr 
Core 4 
 GlcNAcβ-6 
                     │ 
                 GalNAcα-Ser/Thr 
                     │ 
 GlcNAcβ-3 
Core 5 GalNAcα-3GalNAcα-Ser/Thr 
Core 6 
GlcNAcβ-6 
                     │ 
                 GalNAcα-Ser/Thr 
Core 7 
GalNAcα-6 
                     │ 
                 GalNAcα-Ser/Thr 
Core 8        Galα-3GalNAcα-Ser/Thr 
 
A proteoglycan is a glycoconjugate that has one or more glycosaminoglycan (GAG) 
chains attached to the hydroxyl group of a serine residue of a carrier protein. The 
typical core region of a proteoglycan is xylose-galactose-galactose-glucuronic acid 
(Xyl-Gal-Gal-GlcA). GAGs are linear polysaccharides with disaccharide repeating 
units normally consisting of an uronic acid and an amino sugar with sulphate 
substitution. Some proteoglycan polypeptides can carry both GAGs and O- and N-
glycans. 
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Glycolipids can be classified into glycosphingolipids, glycosylphosphatidylinositols 
(GPIs) and glyco-glycerolipids distinguished by their lipid moieties. In vertebrates, the 
most abundant glycolipids by far are glycosphingolipids and are often called 
glycolipids for convenience. Glycosphingolipids consists of a glycan connected to the 
terminal hydroxyl group of the lipid moiety ceramide (Cer), which is composed of a 
long carbon chain base (sphingosine) and a fatty acid. Although ceramide also varies 
in length, hydroxylation and saturation of both sphingosine and fatty acid moieties, 
the major structural and functional classifications have been based on the glycans. 
Two types GlcCer and GalCer are distinguished based on the difference of the first 
sugar (Glc or Gal) linked to ceramide. Further extension of the former gives rise to a 
series of backbone structures (Table 1.2), ganglio-, lacto-, neolacto- and globo-series. 
Their patterns of expression are mostly tissue specific. Glycolipids can be neutral or 
anionic depending whether they have sialic acid or sulphate. Traditionally, 
glycosphingolipids containing one or more residues of sialic acid are called 
gangliosides, regardless of whether they are based on the ganglio-series backbone 
structure. 
 
Table 1.2 Core sequences of major vertebrate glycosphingolipids.  
Subfamily series Sequence 
Ganglio- 
GalNAcβ1-4Galβ1-4Glcβ-Cer 
Galβ1-3GalNAcβ1-4Galβ1-4Glcβ-Cer 
Lacto- 
GlcNAcβ1-3Galβ1-4Glcβ-Cer 
Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ-Cer 
Neolacto- Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ-Cer 
Globo- 
Galα1-4Galβ1-4Glcβ-Cer 
GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Cer 
 
As the main subject matter of this thesis is glycoproteins and glycolipids, GAGs, GPIs 
and other types of glycoconjugates are not discussed further in this thesis. 
 
1.1.2 Glycan sequences common to different glycoconjugates 
 
Although different glycan classes have unique core regions by which they are 
attached to proteins, the backbone and peripheral regions are often shared.  
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1.1.2.1 Backbone regions 
 
Two types of backbone regions are common to N- and O-glycans and some 
glycolipids. Presence of Gal in β1-3 linkage to the terminal GlcNAc residue forms a 
type 1 chain Galβ1-3GlcNAc (Figure 1.4), whereas its β1-4 linked analogue, Galβ1-
4GlcNAc, constitutes a type 2 chain (also called N-acetyllactosamine, LacNAc, 
Figure 1.4). These backbone sequences are often further modified by addition of 
peripheral sequences such as fucose (Fuc), sialic acid and sulphate to form many 
antigenically or biologically active carbohydrate determinants such as the major 
blood group A, B, O (H) and  Lewis antigens which are discussed below. In humans, 
expression of type 1 and type 2 chains is often regulated in a tissue- or lineage-
specific manner. Type 1 backbone is said to be predominantly expressed in cells 
derived from the endoderm, whereas its type 2 counterpart is widely distributed in 
cells derived from the ectoderm and mesoderm (13). Indeed, type 1 backbone is 
mostly found in epithelial tissues of gastrointestinal or reproductive tracts but type 2 
backbone is more broadly expressed (14). The regulation is the consequence of the 
differential expression and competition of seven β1-4 galactosyltransferases 
(β4GalT1-7) and five β1-3 galactosyltransferases (β3Gal-T1, -T2, -T5, -T8 and 
possibly -T4) in human beings. The occurrence of the multiple isoforms of the two 
types of enzymes suggests that the regulation of the two types of backbones is very 
complicated.  
 
 
Figure 1.4 Sequences of type 1 and 2 backbones and the elongated linear and branched poly-LacNAc.  
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The LacNAc chain can be elongated sequentially by the addition of β3GlcNAc and 
β4Gal by the corresponding glycosyltransferases to form a linear poly-N-
acetyllactosamine (poly-LacNAc) backbone (Figure 1.4). The linear poly-LacNAc 
backbone can become branched by addition of β1,6-linked GlcNAc to an internal Gal 
(Figure 1.4). Formation of the branched poly-LacNAc backbone is catalysed by β1,6-
N-acetylglucosaminyltransferases GCNT2 (central I branching enzyme, cIGnT) or 
GCNT3 (distal I branching enzyme, dIGnT, Figure 1.5A); and the β1,6-linked GlcNAc 
branch allows for subsequent poly-LacNAc generation. In contrast to poly-LacNAc, 
tandem repeats of type 1 sequence are less common, although poly-LacNAc 
sequences are sometimes terminated with a type 1 unit in the peripheral region. The 
linear and branched poly-LacNAc backbones are antigenic structures that express 
the i and I antigens, respectively. They are found on N- and O-glycans and 
glycolipids. On N-glycans they are preferentially expressed on multi-antennary N-
glycans, particularly on the β1-6GlcNAc branch of the pentasaccharide core. This 
process is controlled by mannosyl (alpha-1,6-)-glycoprotein beta-1,6-N-acetyl-
glucosaminyltransferase (MGAT5, Figure 1.5B). On O-glycans, poly-LacNAc 
backbones often occur on the β1-6GlcNAc branch on the core GalNAc and are 
regulated by β1-6 glucosaminyl (N-acetyl) transferases (GCNT1, GCNT3 and 
GCNT4, Figure 1.5B). These poly-LacNAc sequences serve as scaffolds to present 
monosaccharides such as sialic acid, Fuc, Gal, GlcNAc at peripheral region, most of 
which are α-linked capping domains of the β-linked backbone. These poly-LacNAc 
sequences can be recognized as ligands of some endogenous carbohydrate-binding 
proteins, i.e. galectins (15-18). Changes in the expression of poly-LacNAc bearing i 
and I antigens occur during embryonic development and in carcinogenesis (19). A 
detailed discussion follows in Chapter 3. 
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Figure 1.5 Key enzymes responsible for the biosynthesis of the I-antigens (A) and the β6-branches on N- 
and O-glycans (B). 
 
1.1.2.2 Peripheral region 
 
Type 1 and type 2 backbones are often decorated by α1-2 linked Fuc on the terminal 
Gal, with or without further additions of α1-3 linked GalNAc or Gal, forming the O(H), 
A and B blood group antigens, respectively (Figure 1.6). These antigens were 
discovered in the beginning of the twentieth century by Karl Landsteiner and 
colleagues (20,21) but it was not until 1950s that Morgan and Watkins, Kabat and 
their colleagues determined the structures of the carbohydrate epitopes of the A, B, 
O (H) blood groups (22-24). These antigens are not only expressed on the surface of 
red cells, but also on cells of many tissues including the vascular endothelium and a 
variety of epithelia and on some soluble, secreted glycoproteins and glycolipids. 
Therefore they are also known as histo-blood group antigens (25).  
 
The A, B, and H antigens are formed by the concerted action of glycosyltransferases 
encoded by three genetic loci [the ABO, H and Secretor (Se) locus]. The synthesis 
starts from transfer of α1-2 Fuc to Gal catalysed by α1,2-fucosyltransferases (α1-
2FucTs). Human genome encodes two α1-2FucTs, FUT1 and FUT2, encoded by H 
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and Se gene, respectively. FUT1 is predominantly expressed on red cells, vascular 
endothelium and primary sensory neurons (26) and it transfers Fuc to Galβ-
4GlcNAcβ- or Galβ-3GalNAcβ- to form the H antigen. FUT2 transfers Fuc 
preferentially to Galβ-3GlcNAcβ- and Galβ-3GalNAcα- to form the H antigen (27) in 
epithelia lining the lumen of the gastrointestinal, respiratory, urinary and reproductive 
tracts, and some exocrine glands e.g. salivary glands (14). Individuals with an active 
Se gene express A, B, H antigens in their secretions such as saliva and are 
designated secretors. Individuals with an inactive Se gene do not express A, B, H 
antigens in their secretions but only the backbone sequences and are termed non-
secretors. It has been found that the secretor status is associated with susceptibility 
to some diseases, i.e. Crohn‘s disease (28), and infections such as Helicobacter 
pylori and HIV. Rare humans that have inactive H and Se genes are called Bombay 
phenotype; their sera contain antibodies against red cells from all donors. A related 
phenotype is termed para-Bombay. People of para-Bombay type have an inactive H 
gene but one functional Se allele (29,30).  
 
The ABO locus contains three alleles A, B and O. A allele encodes α1-3 N-
acetylgalactosaminyltransferase (GTA) adding α1,3-linked GalNAc to Gal residue. B 
allele encodes α1-3 galactosyltransferase (GTB) that transfers α1,3-linked Gal to Gal 
residue to form blood group B determinant. O allele encodes a functionally inactive 
A/B glycosyltransferase that leaves the unmodified Fucα1-2Gal- epitope (Figure 1.6). 
The distribution of A and B antigens in tissues and their expression patterns during 
development has been reviewed in detail (13,25,31). Moreover, the expression of 
ABH antigens changes greatly during human oncogenesis. This is reviewed in 
Section 1.2.3. Other mammals such as pigs and cows have non-fucosylated αGal [so 
called B-like, (32)] which is synthesized by a different α1-3 galactosyltransferase from 
GTB. Humans lack the enzyme activity as the gene encoding this α1-3 
galactosyltransferase is inactive (33). Human sera contain high titre anti-αGal 
antibodies which reject any nonhuman blood or organs. They are the major barrier to 
xenotransplantation of pig organs in humans (34). 
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Figure 1.6 Major peripheral modifications common to different glycoconjugates.  
 
Another common decoration in the peripheral region is the transfer of α1-3/α1-4 
linked Fuc to the penultimate GlcNAc to form Lewis antigens. Combined with the 
backbone sequence and expression of α1-2 linked Fuc, in humans there are four 
Lewis antigen types named Lea, Leb, Lex and Ley (Figure 1.6), which are synthesized 
by eight α1-3/α1-4 fucosyltransferases (FUT3-7, FUT9-11). There also occurs 
sialylation or sulphation to these Lewis antigens forming 3‘-sialyl Lewisa (sLea), 3‘-
sialyl Lewisx (sLex), 3‘-sulpho-Lea, 3‘-sulpho-Lex etc (Figure 1.6). Among them, only 
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two FUTs, FUT3 and FUT5 can generate the type 1 based sequences Lea, Leb, and 
sLea. In vivo these determinants seem to be controlled only by FUT3, which is 
encoded by Lewis (Le) locus. FUT5 is a silent enzyme which is not expressed in any 
tissues except in male spermatozoa (35-37). Thus, the concerted action of Le and Se 
loci determines the expression of type 1 based Lewis glycans synthesized in an 
individual. Indeed, expression of Lea and Leb is mainly restricted to the epithelia of 
gastrointestinal or reproductive tracts, where Se is also expressed. The type 2 based 
Lex, Ley and sLex determinants are synthesized by actions of α1-3 
fucosyltransferases such as FUT3-7 and FUT9.  
 
Sialic acid is a common capping modification of glycans. There are mainly three 
types of sialylated modifications, α2-3, α2-6 and α2-8. The α2-3 and α2-6 linked sialic 
acids can be found on N-glycans, O-glycans and glycolipids, but α2-3 sialylation is 
more ubiquitously distributed on glycans. In humans, only glycans with terminal Gal 
can be further modified by one of the six different α2-3 sialyltransferases (ST3Gal-I to 
-VI) to generate the α2-3 sialylated structures. These sequences are generally not 
further elongated or capped with α1-2Fuc, α1-3Gal or α1-3GalNAc. The α2-6 linked 
sialylated sequences are found on terminal Gal, terminal or penultimate GlcNAc, and 
internal GalNAc. These are the products of at least six α2-6 sialyltransferases 
(ST6Gal-I and -II, and ST6GalNAc-I to -IV). These sequences are normally not 
modified further except where there is poly α2-8 sialic acid capping. The α2-8 
sialylated glycans are expressed in nervous system and in other tissues during 
embryogenesis, generated by at least six α2-8 sialyltransferasese (ST8Sia-I to VI). 
The α2-8 sialylation can occur on α2,3-linked sialic acid to form di- or trisialic acid 
sequences on gangliosides. The repeated α2-8 linked sialic acids of 200 or more 
occur on α2-3 or α2-6 sialylated N-glycans to form polysialic acid, specifically by 
ST8Sia-II (STX) or ST8Sia-IV (PST-1 or PST). Glycolipids carry single or multiple 
α2,8-linked sialic acid catalysed by ST8Sia-I, -III and -V. Apart from the linkage, 
modifications also occur to the neuraminic acid structure, such as O-acetylation, O-
sulphation, O-methylation, de-N-acetylation (38). Sialic acids play important 
biological roles biologically and pathologically. These have been carefully reviewed 
by Varki and colleagues (39,40). The relevance to cancer is discussed in Section 
1.2.5. 
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One well-known example of differential recognition of α2-3 or α2-6 sialylated 
sequences is by the human and avian influenza viruses. The haemagglutinin in the 
envelope of influenza viruses binds to sialic acid-bearing cellular receptors, and this 
binding is followed by release by neuraminidase, both of which are important for 
infection. Viruses infecting birds and pigs more commonly recognize α2,3-linked 
sialic acid, whereas those infecting humans prefer the α2,6-linked form. A single 
amino acid change to the haemagglutinin may change its specificity predisposed to a 
human influenza pandemic (41,42).   
 
Another important peripheral sequence is Sda/Cad (Figure 1.6). It is expressed on 
glycoproteins of erythrocytes or in urine (i.e. Tamm-Horsfall glycoprotein) of many 
mammals, as well as on glycolipids of various gastrointestinal tissues (43,44). It 
shares the same precursor [NeuAcα-3Galβ-4(3)GlcNAc-] as sLea or sLex in its 
biosynthesis. The key glycosyltransferase for the generation of Sda/Cad is 
β1,4GalNAc-transferase that transfers GalNAc to the Gal of the 2,3-sialylated type 2 
units. Expression of Sda is found in developing germ cells and spermatogonia in 
several species (45), suggesting this glycan sequence is a good marker for these 
cells. As both β1,4GalNAc-transferase and fucosyltransferase utilize the same 
acceptor, increased expression of Sda/Cad is often accompanied by reduction in 
expression of sLea or sLex, which are involved in cancer cell adhesion mediated by 
selectins. Restoration of Sda expression could markedly decrease the adhesion of 
cancer cells and suppress the metastatic potential (46).    
 
Sulphation is usually found on Gal, GlcNAc, GlcA and GalNAc at internal or terminal 
positions in vertebrates. The most abundant sulphated glycans are GAGs i.e. heparin, 
heparan sulphate, chondroitin sulphate and keratan sulphate on proteoglycans - a 
detained discussion of which is beyond the scope of this thesis. Many sulphated 
sequences such as 3‘-sulpho-Lex, 6‘-sulpho-sLex, 6-sulpho-sLex and 6,6‘-sulpho-sLex  
(Figure 1.6) are expressed on O-glycans of high endothelial venules (Figure 1.6). 
They are ligands for L-selectin on lymphocytes. Homing of lymphocytes to HEV is 
mediated by binding of L-selectin to sulphated sialylated Lewis sequences (47,48). 
Another example of a sulphated glycan ligand found on N-glycans and O-glycans, as 
well as GAGs and glycolipids, is HNK-1 epitope, which is composed of a 3-O-
sulphated GlcA attached in α1-3 linkage to a terminal LacNAc (Figure 1.6). The HNK-
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1 epitope is expressed on a variety of neuronal cell glycoproteins in the vertebrate 
nervous system and serves as ligand for laminin, L-selectin, P-selectin, and a 
cerebellar adhesion protein termed amphoterin. The epitope is expressed on O-
mannosyl-glycans among brain glycopeptides (49). Sulphation is normally catalysed 
by specific sulphotransferases. Dozens of sulphotransferases have been described 
with various substrate specificities. Among them, the sulphation of GlcA on HNK-1 is 
generated possibly by carbohydrate sulphotransferase 10 (CHST10). 
 
Other capping modifications of glycan backbones such as Galα1-3Gal- and 
GalNAcβ1-4GlcNAc- (LacdiNAc) are not within the scope of this thesis and are not 
discussed further. But they are also common modifications and may play important 
roles in physiological and pathological settings. 
 
1.1.3 Biological functions of glycans 
 
The biological functions of carbohydrates are very diverse: some are crucial for 
growth, development or survival of human beings and other living things, but others 
are more subtle. Generally, these biological roles can be divided into two categories: 
(1) the structural and modulatory roles, which normally do not require binding by 
other molecules and (2) the specific recognition of epitopes that needs the binding by 
other molecules such as glycan-binding proteins (GBPs). In this regard, the structural 
information contained in the entire complement of glycans (glycome) is deciphered 
by these GBPs, resulting in various biological effects including host-pathogen 
interactions, cell trafficking and transmembrane signalling (50). According to the type 
of recognition, the second category can be further subdivided into two groups: (1) the 
endogenous recognition system (2) the exogenous recognition system of host-
pathogen interactions. These aspects are discussed below. 
 
1.1.3.1 Structural and modulatory roles of glycans 
 
Many proteins have glycan chains attached to them. These glycans influence the 
glycoproteins through indirect mechanisms on their conformation, stability, 
oligomerization, folding, turnover and even recognition specificities (51).  
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Many glycans expressed on therapeutic proteins have modulatory functions. 
Alterations of these glycans by glycoengineering have a great impact on the 
biological activities and half-life of these glycoproteins. Erythropoietin (EPO), for 
instance, carries three sialylated complex forms of N-glycans and one sialylated O-
glycan. Alpha2,3-sialylated EPOs have longer half-life than the non-sialylated 
analogues in the circulation. This is because in the liver, galactose-terminated 
glycoproteins can be bound by galactose-binding asialoglycoprotein receptor. The 
α2,3-linked sialic acid blocks this interaction and prevents the glycoprotein from rapid 
clearance from the circulation thereby prolonging the effective circulating time in vivo 
(52). Similar to EPO, optimization of glycosylation of many recombinant glycoproteins, 
e.g. recombinant monoclonal antibodies (mAb) and cytokines is desirable as glycan 
chains often have great impact on the stability, activity, antigenicity and 
pharmacodynamics. 
 
To date, all licensed recombinant mAbs have been of the IgG class. Human IgG is a 
glycoprotein with N-glycans attached at Asn297 in the Fc region (Figure 1.7). There 
are, in total, 32 possible N-glycan sequences on each glycosylation site on the heavy 
chain, and the two heavy chains can be differently glycosylated (53). This gives rise 
to a very diverse profile of glycosylation for IgG. Most of the N-glycans are neutral, 
with <10% of structures being monosialylated or disialylated (53,54). Some of the 
immunological functions of antibodies are crucially dependent on these N-glycans on 
IgG Fc. 
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Figure 1.7 Modelling structure of the IgG molecule. The glycan chain is integral to the protein structure and 
has a defined conformation. CH, constant heavy; Fab, antigen-binding fragment; Fc, crystallizable fragment. 
Taken from (53) with permission. 
 
Studies have shown that both antibody-dependent cellular cytotoxicity (ADCC) and 
complement-dependent cytotoxicity (CDC) are dependent on appropriate 
glycosylation (55,56). In order to increase ADCC and CDC of these therapeutic 
antibodies, many researchers have tried to manipulate the glycan structures by using 
engineered host cells such as Chinese hamster ovary (CHO) and human embryonic 
kidney (HEK) cells. For example, recombinant mAbs with bisecting N-glycans (Figure 
1.8) were generated by transfecting CHO cells with β-1,4-N-
acetylglucosaminyltransferase III (GnTIII or MGAT3). The antibodies produced in 
these cells exhibited a substantial increase in ADCC and Fcγ receptor III (FcγRIII) 
binding, thus improving the efficacy for treatment of cancer such as neuroblastoma 
(57). Given that the formation of bisecting GlcNAc prevents the enzymatic functions 
of other GlcNAc-transferases and fucosyltransferase which leads to the decrease of 
mutiantennary N-glycans and core-fucosylation [(58), Figure 1.8], the relationship 
between non-fucosylated N-glycans and enhanced Fcγ receptor binding was further 
investigated. Some variants of CHO cells and rat hybridoma cells were used to 
generate non-fucosylated IgG and these antibodies showed enhanced ADCC (59-61). 
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Furthermore, reduction or removal of the α1-6 fucosyltransferase (FUT8) that is 
responsible for transferring the core Fuc in the host cells boosted ADCC (62,63). 
Although the molecular basis for the increased affinity of non-fucosylated IgG Fc for 
FcγRIII has not been clear, it was proposed that the Fuc on IgG Fc may affect the 
binding between the heavily glycosylated FcγRIII with Fc by steric inhibition (64). 
 
 
Figure 1.8 Scheme of further modification of biantennary N-glycan by MGAT-3, MGAT-5 and FUT-8 to form 
the bisecting, triantennary and core fucosylated N-glycan. The bisecting GlcNAc prevents the formation of 
triantenary and core fucosylated N-glycans. Highlighted in red are the glycosidic bonds that can be formed by the 
three glycosyltransferases. MGAT-5 and FUT-8 can only act in the absence of bisecting GlcNAc.  
 
Distinct from the cytotoxic activity, the IgGs can also display anti-inflammatory activity 
through inhibitory Fc receptors such as FcγRIIB. Intravenous immunoglobulin (IVIG) 
has been widely used for decades to treat a variety of acute and chronic autoimmune 
diseases (65). High doses (1-2 g/kg) of IgG purified from sera of thousands of 
healthy donors were given to patients in order to treat auto-immune diseases such as 
immune thrombocytopenia, rheumatoid arthritis and systemic lupus erythematosus. 
The anti-inflammatory activity has been found to be associated with the N-glycans on 
IgG Fc fragment and particularly, a minor fraction containing α2-6 sialylated 
biantennary N-glycans. These sialic acid-containing antibodies showed decreased 
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affinity to the activating receptor FcγRIII but induced the expression of the inhibitory 
receptor FcγRIIB (66,67). The low percentage of sialylated IgG among the total pool 
IgGs explained the requirement of high dose for IVIG. This was further demonstrated 
using a recombinant human IgG1 Fc with a α2-6 sialylated biantennary glycan. The 
glycoengineered IgG Fc recapitulated the in vivo anti-inflammatory activity of intact 
IVIG, but a much lower dose was required (68).  
 
Although existence of specific receptors for recognition of the IgG N-glycans cannot 
be ruled out, the crystallographic analysis of the IgG Fc region has shown that the N-
glycans mainly display modulatory effects to the IgG glycoproteins. The N-glycans on 
Asn297 are located in a hydrophobic patch and form multiple non-covalent 
interactions with IgG Fc (Figure 1.7), with only the Manα1-3 branch protruding into 
the space between the Fc domains (69). These intramolecular interactions help to 
maintain the conformation of Fc, which is essential for binding by FcγRs. Some 
reports showed that binding sites of Fc for FcγRs only involves protein moiety. 
However, recognition of FcγRs is markedly influenced by N-glycans on Fc as 
different oligosaccharides show different modulatory abilities to the conformation of 
IgG Fc (53). There were reports on the binding to the sialylated Fc by receptors other 
than FcγRs, i.e. C-type lectin, specific intercellular adhesion molecule 3-grabbing 
non-integrin-related 1 (SIGN-R1) and dendritic cell-specific intercellular adhesion 
molecule 3-grabbing non-integrin (DC-SIGN; also known as CD209) in mouse and 
human, respectively (70,71). It was proposed that binding of SIGN-R1 or DC-SIGN to 
the sialylated glycans on Fc triggered downstream signalling which resulted in the 
increased ratio of inhibitory- versus activating-FcγR on the vicinal effector cells, 
thereby attenuating autoimmunity (68). The conclusion, however, is based on cellular 
studies. Involvement of other molecules on the cell surface in the recognition cannot 
be excluded. SIGN-R1 or DC-SIGN showed strong binding to mannose-type and 
Lewis-type carbohydrates but weak or no binding to sialylated glycans (72-74). 
Therefore it would seem likely that other proteins or other mechanisms are involved 
in the recognition of IgG N-glycans. 
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1.1.3.2 Recognition in cell-cell interactions 
 
At the centre of deciphering the ‗glyco codes‘ are the interactions between glycan 
ligands and their receptors, i.e. glycan binding proteins (GBPs). The vast diversity of 
glycan structures provides recognition epitopes for GBPs which are involved in many 
biological activities including both cell-cell interactions and cell-microbe interactions. 
Among the best-characterized examples are the binding of the C-type lectins, 
selectins, in early cell adhesion events, e.g. tethering and rolling of leukocytes on 
vascular surfaces at the initial stages of the inflammation reaction. 
 
Selectins are a family of three membrane proteins comprising E-, P- and L-selectins. 
The three selectins have different expression patterns: E-selectin is expressed on 
activated endothelial cells; P-selectin is additionally expressed on activated platelets; 
L-selectin constitutively expressed on leukocytes. Each selectin has a carbohydrate-
recognition domain (CRD) at the amino terminus with a canonical calcium ligating 
elements that mediates carbohydrate binding. This is followed by an epidermal 
growth factor (EGF)-like domain and various numbers of short consensus repeats 
composed of sushi domains (also known as complement control protein modules). In 
the carboxyl terminus, the selectins have a cytoplasmic domain and a single 
transmembrane domain (TM) (75). Binding to carbohydrate is directed by the CRDs, 
which recognize sialylated or sulphated sequences with α1-3/4-linked fucose 
residues.  
 
Based on the knowledge that E- and P-selectins bind granulocytes and monocytes 
which express Lex and sLex, these two glycans, together with sLea (Figure 1.6), 
which is an isomer of sLex, were first examined as candidate carbohydrate ligands for 
the two selectins. Indeed the latter two were shown to be recognized by all three 
selectins (76,77). In addition, L- and P-selectins were shown to be able to interact 
with a second class of ligands with L-selectin binding to sulphatides (sulphated Gal-
Cer) and sulphotyrosine (77,78), and P-selectin binding to sulphotyrosine (78,79).  
 
A glycoprotein, called ―P-selectin glycoprotein ligand-1‖ (PSGL-1, CD162) is the 
major counter-receptor on leukocytes for P- and L-selectin and is also an important 
ligand for E-selectin. It is a homodimeric, disulphide-bonded, O-glycosylated protein 
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containing many decapeptide repeating units in the ectodomain which is heavily 
glycosylated (80). The amino terminus of the ectodomain has been suggested to be 
vital for selectin binding. It contains three potentially sulphated tyrosine residues and 
an adjacent O-glycosylation site bearing an sLex motif (81-83). Synthetic 
glycosulphopeptides of N-terminal domain of PSGL-1 with sLex and tyrosine 
sulphation at the terminal region were bound by P-selectin with the same high affinity 
(~300 nM) as that of native PSGL-1. Crystallographic study of co-complexed P-
selectin and the PSGL-1-derived glycosulphopeptide confirmed the complex and tight 
association between these two binding partners (84).  
 
In addition to PSGL-1 as the major counter-receptor common for all the three 
selectins, several glycoproteins bearing sLex can also interact with E-selectin. These 
include a glycoprotein called ―E-selectin ligand-1‖ and CD44. Another family of 
selectin ligands, namely, the 3‘-sulpho-Lea and 3‘-sulpho-Lex (Figure 1.6) were 
discovered (85). By NMR studies of the sialyl-Lea and sulpho-Lea in solution, it was 
found that the carboxyl group of the sialyl-Lea and the sulphate of the sulpho-Lea 
occupied the same position in their conformation (86) suggesting a similar role for the 
two acidic moieties.  
 
L-selectin mediates lymphocyte homing through interaction with peripheral node 
addressins, which are a group of O-glycosylated proteins expressed on high 
endothelial venules (HEV) of lymph nodes. These addressins include CD34, 
GlyCAM-1 and MAdCAM-1. On these glycoproteins, the ligands for L-selectin are 
sulphated glycans, e.g. 6-sulpho-sialyl-Lex (Figure 1.6). Initially 6‘-sulpho-sialyl-Lex, 
6-sulpho-sialyl-Lex, and 6‘,6-sulpho-sialyl-Lex (Figure 1.6) were found on the L-
selectin counter-receptor GlyCAM-1 but it was not possible to compare their relative 
potencies as ligands due to limited amounts of oligosaccharides that could be 
obtained from this glycoprotein (87). Chemical synthesis of lipid-linked forms of these 
glycans enabled a detailed comparison of their ability to support L-selectin binding 
(88). The results established that the sulphate at C6 of subterminal GlcNAc 
enhances the L-selectin binding elicited by sLex, whereas sulphate at C6 of terminal 
Gal markedly impaired the binding. Co-transfection of an α1-3 fucosyltransferase 
(FUT7) and one or other of two N-acetylglucosamine β6-sulphotransferases 
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(GlcNAc6ST-1 or GlcNAc6ST-2) into cell lines lacking L-selectin ligands led to the 
reconstruction of L-selectin ligands (89,90).  
 
Many cancers overexpress sLex or sLea which may mediate metastasis through 
interactions with E- and L-selectin. This is discussed in Section 1.2.4. Other than the 
sialylated oligosaccharide epitopes, some heparin and heparan sulphate-containing 
proteoglycans are also found to be bound by P- and L-selectins (91,92). The 
physiological significance of this binding has not been clear but one possible 
explanation is that heparan sulphate and heparin display high densities of carboxylic 
acid groups and 6-O-sulphate, which resemble the sequence of 6-sulpho-sialyl-Lex. 
Regardless of the physiological meaning, this has led to the exploitation of heparin, 
which is an approved therapeutic reagent by FDA to suppress selectin activities 
(93,94) in cancer metastasis. 
 
1.1.3.3 Recognition in cell-microbe interactions 
 
In addition to functions in endogenous recognition, glycans play a pivotal role in 
many microbial pathogen-host interactions.  
 
As a prerequisite to colonization, many microorganisms use their surface 
carbohydrate-binding proteins to mediate adhesion to their host cells. Many viruses, 
for instance, have GBPs that bind to terminal sialylated sequences on the host cell 
surface. An example previously mentioned is the specific recognition of sialylated 
glycans by haemagglutinin on influenza virus. Many other viruses such as rotavirus, 
adenovirus, reovirus and polyomavirus also use sialylated glycans for adhering to 
host cells (95). Bacteria often express more than one type of adhesins that bind 
directly to cell surface glycoconjugates or matrix glycoproteins or mucins, thereby 
determining tropism. Helicobacter pylori bacteria, for example, express many 
adhesins including BabA and SabA that recognize fucosylated blood group H type 1 
and Leb (96,97), and sLex (98), respectively. The expression of blood group H type 1 
and Leb in gastric secretions is controlled by secretor phenotype which is a 
determinant of infection by H. pylori strains that express BabA (99). This tropism of 
the bacteria is dependent on glycosylation patterns in gastric mucosa. The bacteria 
are mainly found at the surface of epithelial cells where there is expression of fucose-
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containing Lewis antigens, but not the deeper gastric glands where there is less 
fucosylation and glycans capped by α-4GlcNAc are highly expressed. This is 
because the terminal α-4GlcNAc could inhibit the synthesis of α-glucosylcholesterol, 
an important element of the bacterial cell wall, therefore suppressing bacterial growth 
(100). Recently, a new adhesin was discovered and designated as LabA which 
recognizes LacdiNAc motif (GalNAcβ1-4GlcNAc) (101). It was suggested the tissue 
tropism of these strains of H. pylori may be due to the restricted expression of 
LacdiNAc in gastric mucosa.  
 
Parasites also utilize glycans as receptors for adhesion. Apicomplexan parasites 
such as Toxoplasma gondii, have unique organelles termed micronemes (MIC). They 
use MIC proteins to penetrate host cells. A novel fold of microneme adhesive repeat 
on the MIC1 was identified by crystallographic studies. With the help of carbohydrate 
microarray analysis, it was found that a wide range of sialylated oligosaccharides 
could be bound by this domain (102). This explained the capability of T. gondii to 
infect a wide range of warm blooded animals. This study was followed by the finding 
of a threonine residue crucial for sialic acid-binding in microneme adhesive repeat, 
which is not only found on MIC1, but also on other proteins of the same family in 
other apicomplexan parasites (103). These MIC proteins have different binding 
specificities toward sialylated glycans which correspond to the glycans expressed on 
the host cells of these parasites (102-104). 
 
Most microorganisms are covered by glycoconjugates. In most cases, humans have 
immune responses, innate and acquired, towards these structures. Structures such 
as mannan and lipopolysaccharide (LPS) constitute pathogen-associated molecular 
patterns, which are recognized by pattern recognition receptors (PRRs). Some of the 
PRRs such as Toll-like receptors trigger the intracellular signalling leading to the 
secretion of pro-inflammatory cytokines. Other PRRs such as C-type lectins, e.g. DC-
SIGN, Dectin-1 and the mannose receptor, can mediate endocytosis and 
phagocytosis or activate the complement system.  
 
Some pathogens camouflage themselves as ―self‖ to avoid immune recognition by 
presenting common host glycan structures, such as sialic acid. Neisseria 
gonorrhoeae, for instance, can utilize tissue CMP-sialic acid to generate poly sialic 
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acid-containing capsules, which help to evade immune surveillance. A possible 
explanation is by presenting these sialylated structures, the bacterium can recruit 
host factor H which binds to sialic acid so as to negatively regulate the alternative 
complement pathway (105,106). Alternatively, it has also been proposed that the 
terminal sialic acid on the pathogens interact with proteins of the host Siglec family, 
and thereby sending a negative signal to the innate immune cells (107). The host 
cells have also evolved to avoid being recognized by the pathogen GBPs. They 
secrete soluble sialylated mucins at the surface of intestinal mucosa to prevent the 
microorganisms from binding to the epithelial cell membrane. The microorganisms 
are thus removed with the secreted mucins. 
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1.2 Changes in expression of carbohydrate structures and 
glycosyltransferase activities in cancer 
 
Ubiquitously expressed in humans, the diverse carbohydrate sequences are under 
dynamic changes. Altered or abnormal protein glycosylation is a universal feature of 
cancer cells (108,109), and many of such glycan structures are potential cancer 
biomarkers in both tissue and serum assays (110). Changes in glycans may occur in 
the core region, the backbone and the peripheral regions. These include but may not 
be confined to the following patterns: incomplete biosynthesis, abnormal elongation, 
aberrant branching of backbone regions and neosynthesis of glycan sequences that 
are inappropriate for the cell or tissue in question (111,112). Many of these aberrant 
structures reflect the altered expression or function of the corresponding 
glycosyltransferases.  
 
1.2.1 Truncated O-glycans and associated antigens on mucins 
 
Aberrant forms or amounts of mucins have long been described in epithelial cancer 
cells (113). Mucins are a family of high molecular weight proteins produced by 
various epithelial cells, either secreted or membrane-associated. The hallmark of 
mucin is variable number of tandem repeat (VNTR) domains, which are rich in serine 
and threonine that are heavily O-glycosylated. The compositions and biological 
functions of mucins, as well as the glycan chains have recently been reviewed in 
detail (114). In malignant cells, loss of cell polarity results in the incorrect topology of 
the transmembrane and secreted mucins (115). Overexpression of membrane-
associated mucins can be exploited by malignant cells to modulate growth and 
survival signalling through various receptors such as receptor tyrosine kinase ERBB2. 
Some transmembrane mucins such as MUC1 and MUC16 can be released to blood 
plasma instead of to the epithelial lumen, and often, these contain glycan chains that 
are distinct from the normal form. 
 
Abnormal glycosylation of mucins has been reported in many carcinomas such as 
those of breast, cervix, endometrium, ovary, bladder, prostate, lung, oesophagus, 
stomach, colon and pancreas (116-122), as detected by lectins or monoclonal 
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antibodies. These changes range from absence or truncation of O-glycans such that 
Tn, T and sialyl Tn antigens are expressed (Figure 1.9) (108,116). In fact, it is 
estimated that Tn and sialyl Tn are expressed in more than 80% of human 
carcinomas (123,124). The expression of these antigens on mucins has been 
associated with poor prognosis of breast, cervical, lung, stomach and colorectal 
cancers (125-131). Mucins containing truncated O-glycan sequences can elicit 
autoantibodies, which together with the aberrant glycoforms, have been extensively 
investigated as cancer biomarkers for diagnostic and prognostic purposes, and 
targets in cancer therapies. These are reviewed in Section 1.2.7. 
 
 
Figure 1.9 Biosynthesis pathways of O-glycans in the core region. The symbols are in Figure 1.1. 
 
Simple though their structures are, the molecular mechanisms for regulation of 
expression of these O-glycans are complicated (Figure 1.9). Upon formation of the 
Tn antigen, i.e. the addition of core GalNAc by one of the 24 members of ppGalNAcT 
family, further modifications occur in three competitive ways (132): addition of β1,3-
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linked Gal to generate core 1 (T-antigen), formation of core 3 with β1,3-linked 
GlcNAc and generation of sialyl-Tn by addition of α2,6-linked  sialic acid. Key 
enzymes in these processes are core 1 β3GalT (T-synthase), core 3 β1,3-N-
acetylglucosaminyltransferase (core 3 β3GlcNAcT) and α2,6-sialyltransferase 
(ST6GalNAc-I), respectively (Figure 1.9).  
 
Among the three pathways, the core 3 synthase transcripts have restricted 
expression in gastrointestinal tract (133) and the activity is down-regulated in colon 
carcinoma (134). Core 1-based further elongation and formation of core 2 glycans 
occur in normal cells. However, in cancer cells, generation of core 1 is often 
abrogated, particularly due to the malfunction of core 1 β3-galactosyltransferase-
specific molecular chaperone (Cosmc, Figure 1.9). This chaperone is required for the 
correct folding of the T-synthase (135). The turning-off of the other two biosynthesis 
pathways results in the accumulation of Tn and sialyl Tn, as the latter cannot be 
further modified. Overexpression of ST6GalNAc I in breast cancer cell line, MDA-MB-
231, can induce the expression of sialyl Tn and the overall change of O-glycan 
profiles which results in the decreased adhesion and increased migration in vitro and 
increased tumour growth in a mouse model (136). The expression of core 3 synthase 
is associated with the suppression of the growth and metastasis of colon (134) and 
pancreatic cancer cells (137), partly by suppression of sialyl Tn expression.  
 
1.2.2 Altered branching of N- and O-glycans and expression of I/i 
antigens 
 
High expression of β1,6-linked branches on both N- and O-glycans has been 
associated with human cancers (138). MGAT5 synthesizes the β1,6-linked GlcNAc 
on β1,6-Man branch on the backbone of N-glycans (Figure 1.8) which can be 
immuno-stained with plant lectin L-phytohemagglutinin (L-PHA). Increased 
expression of β1,6-GlcNAc has been reported in many cancer specimens including 
those of breast, colon, melanomas, esophageal and stomach (139-143). Transfection 
of MGAT5 cDNA to immortalized lung epithelial cell line Mv1Lu resulted in a series of 
cellular transformations including loss of contact-inhibition and increased 
tumourigenicity in nude mice (144). Remarkably, knockout of MGAT5 in mice showed 
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reduced tumour growth and metastasis in a polyomavirus induced breast cancer 
model (145). A mouse model with overexpressed MGAT5 showed increased 
endothelial-mesenchymal transition and keratinocyte migration (146). 
 
The increased activity of MGAT5 and its glycan products have been closely 
associated with epithelial cancer cell growth, decreased cell-cell and cell-matrix 
adhesion, increased cell motility, and increased invasiveness and metastasis, as 
reviewed by Taniguchi and Korekane (146). Many investigations have been 
performed toward understanding how phenotypic changes are caused by the β1,6-
GlcNAc branch on N-glycans. Functions of the cell surface glycoproteins such as 
cytokine receptors, adhesion receptors and solute transporters are found to be 
regulated by their β1-6 branch of N-glycans through tuning the life cycles of these 
receptors. Examples include EGF and transforming growth factor beta (TGF-β) 
receptors (147) and T cell receptors (148). The increased β1-6 branching attenuates 
signalling from adhesion receptors such as integrins and cadherins (149-151).  
 
The formation of β1,6-GlcNAc is often followed by subsequent elongation of poly-
LacNAc and terminal decorations such as sLex. The poly-LacNAc and sLex 
sequences are potentially ligands of endogenous lectins, i.e. galectins and selectins. 
Many studies did not differentiate the β1,6-branching point per se from the 
subsequent modifications following the increased β1,6 branching. For instance, a 
recent study indicated galectin-1 engaged vascular endothelial growth factor 
receptor-2 (VEGFR2), leading to VEGF-like signalling and enhanced angiogenesis in 
tumours refractory to anti-VEGF treatment. It appeared that galectin-1 binding was 
associated with the expression of MGAT5 (152). In fact, rather than binding to the β1-
6GlcNAcβ1-6Man- branching point, galectin-1 interacted with the poly-LacNAc that is 
subsequently added to the β1,6-GlcNAc. It has long been known that poly-LacNAc-
rich glycoconjugates are good ligands for galectin-1, termed calf heart lectin (16). 
The branching point per se, which is a consequence of MGAT5, is an important 
prerequisite for the expression of poly-LacNAc. 
 
As mentioned previously (Figure 1.8), there is an interesting competition for glycan 
acceptors in biosynthesis between MGAT5 and MGAT3. The formation of bisecting 
GlcNAc by MGAT3 prevents the enzymatic functions of other GlcNAc-transferases, 
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thus resulting in the decrease of β1,6-branched N-glycans. In many cancers, 
overexpression of MGAT3 has been found to suppress cancer metastasis (153). The 
bisecting GlcNAc branch and its glycosyltransferase were suggested to be 
associated with supressed cell adhesion and migration via adhesion molecules and 
extracellular matrix such as E-cadherin, laminin, and integrin. In one particular 
example of endometrioid ovarian carcinoma, MGAT5 transcripts were found 
upregulated by 2-3 fold, but only small amounts of β1-6 linked N-glycan products 
were detected by L-PHA binding. This was due to the competition by much larger 
(13-fold) increase of MGAT3, resulting in mainly the bisected N-glycans (154,155).  
 
Other branched sequences such as core 2 on O-glycans, I-branching on both 
glycoproteins and glycolipids, and linear i antigen-related poly-LacNAc sequences 
are also aberrantly expressed in many cancer types. These are discussed in Chapter 
3. 
 
1.2.3 Loss or retention of ABO (H) blood group antigens 
 
Expression of A, B, and O (H) and related antigens also undergoes changes during 
cellular differentiation, development and aging, as well as pathological progress, 
such as carcinogenesis (156,157).  
 
It has long been noted that deletion or reduction of A and B antigen occurs in many 
types of human cancers and the decrease has been correlated with degree of 
malignancy and metastatic potential in gastrointestinal (158), lung (159), cervical 
cancers (160), oral (161), bladder carcinomas (162) and haematological 
malignancies (163,164). Transfection of cDNA encoding GTA or GTB into various 
H/Ley-expressing human tumour cell lines significantly reduces their directional 
(haptotactic) motility (165). A follow-up experiment further separated blood group A 
positive from A negative clones among the GTA transfected colorectal carcinoma 
SW480 cells and HT29 cells. The blood group A negative clones of both cell lines 
showed much higher motility than the A positive clones (166). Furthermore, this 
phenotype change was suggested to be correlated with the A/B glycosylation of 
integrin chains α3, α6, and β1 (165,166). Interactions between the α and β subunits 
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may be affected by the A/B glycosylation, which in turn controls haptotactic motility of 
colonic tumour cells. As regards H antigen expression, loss of A and B in cancer 
reveals the precursor H antigen. But the transformation of H to Leb and Ley by adding 
α1-4/α1-3 linked Fuc also influences the level of H antigen detection in cancer. Thus 
factors determining the overall expression are complex. The mechanism underlying 
the suppressed expression of A, B, O (H) antigens is not clear although some 
evidence showed that the blood group ABO glycosylation change was regulated by 
ABO allelic expression at mRNA level (167,168).  
 
People‘s blood group, A, B, O (H), has been linked with the individual‘s susceptibility 
to some carcinomas, such as gastric and pancreatic cancers. A cohort study showed 
patients of blood group A had a higher risk of gastric cancer (169). Wolpin et al 
systematically investigated the relationship between the susceptibility to pancreatic 
cancer and blood groups in genome-wide studies. The results showed that the ABH 
genotypes were significantly associated with pancreatic cancer risk; patients of blood 
groups A or B had an increased risk compared to group O patients (170-173). 
 
1.2.4 Altered expression of Lewis-related antigens 
 
The expression patterns of Lewis-related antigens in cancer tissues are very 
complicated. Although it is difficult to draw a general conclusion about the expression 
pattern of Lewis-related antigens in tumourigenesis, I highlight below a few examples 
where changes in expression of these antigens have had a clear impact. 
 
As mentioned in Section 1.1.2.2, there are eight α1-3/α1-4 fucosyltransferases 
(FUT3-7, FUT9-11) in total with distinct tissue-specific expression patterns. The 
expressions of these α1-3/α1-4 fucosyltransferases, together with those of α1-2 
fucosyltransferases, make a diverse combination of Lewis structures on the cell 
surface, not to mention the impact of other competing glycosyltransferases (e.g 
sialyltransferase), the availability of precursors and donors and the existence of 
glycosidases. According to a review by Le Pendu et al (156), Lex and Ley 
expressions are often increased in carcinomas with the exception of endometrial 
cancer for the former and endometrial and pancreas cancers for the latter; Lea is 
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upregulated in many carcinomas but with more exceptions such as colon, breast and 
prostate; Leb shows a similar pattern to that of A and B antigens. The biological roles 
of these antigens in tumour progression are still not well-understood. 
 
Competition between H/Ley generating α1,2-fucosyltransferase and sialyl Lewis 
forming α2,3-sialyltransferase has also been reported. Transfection of α1,2-
fucosyltransferase, FUT1, induced the expression of H and Ley antigens and 
suppressed sialyl Lewis antigen expression in human pancreatic cancer cell line 
BxPC-3, obviating E-selectin-mediated adhesion and decreasing gastrointestinal 
metastasis (174,175). This is because the type 1 or type 2 LacNAc backbone 
sequences are common substrates for α1,2-fucosyltransferases and α2,3-
sialyltransferase. The expression of these competing enzymes results in the 
modulation of the glycans on tumour cell surface. 
 
Overexpression of sLex and sLea on both glycoproteins and glycolipids has been 
confirmed in many adenocarcinomas, such as lung (176), colorectal (177), gastric 
(178) and pancreatic carcinomas (179). As mentioned in section 1.1.2.2, these 
glycans are involved in the adhesion events in the lymphoid and vascular system. 
Tumour cells hijack the interaction system between selectins and leukocytes to 
mediate cancer cell extravasation and metastasis. 
 
Expression of sLex and sLea has been reported to be associated with the potency of 
adhesion of cancer cells to the vascular endothelium via E-selectin (180,181). Using 
either anti-E-selectin antibodies or anti-sLex antibodies, this adhesion was clearly 
inhibited (176). In a transgenic mouse model, metastasis of tumour cells expressing 
E-selectin ligands could be redirected to a tissue expressing E-selectin (182). Colon 
cancer cells transfected by antisense RNA directed at α1-3/4fucosyltransferase lost 
expression of sLex and sLea, and this in turn abolished colonization of the cancer 
cells to the liver (183,184). 
 
In summary, the general changes in the expression of A, B, O (H) antigens, Lewis 
antigens and sialyl Lewis antigens in tumour progression from precancerous stage to 
metastatic stage were proposed by Le Pendu et al (156) and shown in Figure 1.10.   
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Figure 1.10 Schematic diagram of expressions of blood group A, B, H, Le
b
, Le
y
, sialyl Le
a
 and sialyl Le
x
 in 
different stages of cancer. Redrawn from reference (156) with permission. 
 
1.2.5 Changes in expression of sialic acid forms 
 
It has long been known that cell-surface sialic acid content is increased on tumour 
cells, as evidenced by the increased binding of wheat germ agglutinin (WGA) (185-
187) which has specificity for sialic acid and GlcNAc terminating sequences. 
Increased sialylation is believed to be a mechanism whereby tumour cells have 
protection from activation of the alternative pathway of the complement system by 
recruiting factor H (188). Factor H could inhibit the activation of the alternative 
pathway by accelerating the decay of the key players, C3b convertase, and acting as 
cofactor for the factor I to inactivate C3b (189). 
 
Modifications to the neuraminic acid structure have been reported, such as 
acetylation and de-N-acetylation on C9 and C5, respectively (Figure 1.11). In colon 
carcinomas, a decreased amount of acetylation was observed (190) and was 
proposed as an early sign of colon cancer progression (191), whereas in melanoma 
cells increased acetylation is found on neuraminic acid on gangliosides GM2 and 
GD3 [(192), see Figure 1.12 for sequences]. In addition to the modifications to 
neuraminic acid, the expression of α2,6-linked sialic acids on type 2 backbones is 
increased, as revealed by the staining with the plant lectin Trichosanthes japonica 
agglutinin I (193). It has been suggested that cell surface β1 integrin is involved as 
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the carrier of the aberrant sialylation (194). The biological effects of these 
modifications and overexpression are not clear at present.  
 
Figure 1.11 Modifications of sialic acid structure in cancer. Arrow indicates the position of C9 acetylation. 
Dashed line shows the C5 de-N-acetylation. Circle indicates the difference between Neu5Ac and Neu5Gc form of 
sialic acid.  
 
There is an aberrant expression of the N-glycolyl form of neuraminic acid (Neu5Gc) 
in some human tumour cells [(195), Figure 1.11]. The accumulation of the Neu5Gc in 
tumours is thought to be due to uptake from dietary sources as the hydroxylase 
enzyme responsible for converting Neu5Ac to Neu5Gc is lacking (mutated) in 
humans (196). The expression of Neu5Gc in tumours may be an explanation for the 
presence of ―Hanganutziu-Deicher‖ antibodies (antibodies to Neu5Gc gangliosides) 
in some patients (197).  
 
1.2.6 Changes in expression of sialo-glycolipids (gangliosides) and 
globosides and biological effects 
 
The sialic acid-containing glycolipids, gangliosides, are often aberrantly expressed by 
a range of tumours particularly those of neuroectodermal origin such as melanoma 
and neuoblastoma (198,199). They can be detected in sera of patients with 
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mammary carcinomas, neuroblastomas, sarcomas, melanomas, small-cell lung 
carcinomas and lymphomas (199). Gangliosides may influence tumour and host cell 
interactions through modulating cellular differentiation, adhesion, angiogenesis and 
invasion (108,200,201).   
 
Figure 1.12 Sequences of ganglioside that are aberrantly expressed in cancer and their biosynthetic 
pathways. Cer is ceramide, the rest of the symbols are as in Figure 1.1. 
 
A monosialoganglioside GM3 (Neu5Acα-3Galβ-4Glcβ-Cer, Figure 1.12) has been 
extensively studied for its tumour inhibitory activity. An initial study showed that the 
addition of GM3 inhibited the growth of human epidermoid carcinoma cell lines such 
as KB and A431 (202). Further studies indicated that GM3 expression was 
associated with enhanced apoptosis (203) and reduced cell motility (203,204). GM3  
was suggested to be the key factor in attenuating metastasis of human hepatoma 
cells to lymph nodes; and this effect was suggested to be the result of inhibition of 
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EGFR phosphorylation and PI3K/AKT signalling (205). Addition of GM3 was found to 
be able to counteract the pro-angiogenic effects of VEGF and reduce the 
phosphorylation of the VEGFR2 (200). Other receptors have also been implicated in 
angiogenesis. These include those receptors of insulin-like growth factor-1, basic 
fibroblast growth factor, epidermal growth factor and platelet-growth factor, as 
reviewed in (206). Carbohydrate-carbohydrate interactions were suggested to be the 
underlying mechanism in the engagement between EGFR and GM3. There was 
some evidence showing that N-glycans on EGFR could interact with GM3, thereby 
inhibiting the activation of EGFR tyrosine kinase (207,208). Other mechanisms such 
as regulating metastasis suppressor gene products CD82 and CD9 were also 
suggested (203,209). A cell surface sialidase ―Neu3‖ was found to be upregulated in 
human colon cancer, resulting in the hydrolysis of sialic acid in gangliosides including 
GM3. This in turn led to the accumulation of desialylated backbone lactosylceramide 
(Lac-Cer), which was suggested to inhibit apoptosis through increased bcl-2 and 
decreased caspase expression (210). 
 
In contrast to the above mentioned ―simple‖ form, more complex gangliosides 
containing longer oligosaccharide chains than GM3 can often enhance tumour 
progression. It has long been noted that a mixture of glycolipids enhances xenograft 
tumour growth and metastasis (198). As reviewed in (211), the disialoganglioside 
GD3 (Figure 1.12) was found to be overexpressed in many types of cancer cells, not 
only of neuroectodermal origin, but also in epithelial carcinomas including breast, 
prostate and many others, also in acute T-cell lymphoblastic leukemia. Studies 
showed that when GD3 knockout cell line F-11 was injected into mice, they produced 
less VEGF and the vascularization was significantly reduced compared to the normal 
cell line, suggesting that GD3 could promote VEGF production and was involved in 
angiogenesis, thereby facilitating tumour progression (212). Interestingly, GM3:GD3 
ratio is an important indicator of prognosis in human melanoma. Patients with higher 
GM3:GD3 ratio survive significantly longer (213). GD2 (elongated GD3, Figure 1.12) 
is uniformly expressed in neuroblastoma and most melanoma, gliomas, but little 
expressed in normal tissues. It has now been exploited as a target in immunotherapy 
(214). This is reviewed in Section 1.2.7.1 and Chapter 5. 
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Gangliosides are also important regulators in the formation of cell membrane lipid 
rafts, which facilitate the formation of EGFR complexes. In breast cancer, GM1 was 
found to promote the formation of heterodimer Erbb2-Erbb3 receptor and this 
oligomerization of tyrosine kinase receptor can in turn regulate the growth of tumour 
cells through EGFR-mediated signalling (215).   
 
In addition to gangliosides, aberrant expression of globosides (Figure 1.13) has also 
been found in human cancers. Gb3Cer, also known as Pk antigen and CD77, is 
highly expressed on immature B-cells and Burkitt‘s lymphoma (216), pancreatic and 
colon adenocarcinomas (217), and ovarian carcinoma (218). Gb5Cer (also known as 
stage specific embryonic antigen-3 or SSEA-3 antigen) and its monosialylated and 
fucosylated forms, sialyl-Gb5Cer (also known as SSEA-4 antigen) and Globo H, 
respectively (Figure 1.13), are also expressed on many cancer cells including breast 
cancer cells and breast cancer stem cells (219,220). Recently, Chi-Huey Wong group 
performed a thorough survey of expressions of SSEA-3, SSEA-4 and Globo H in 
various cancer cell lines by flow cytometry (221). These include cancers of brain, 
lung, breast, mouse, oesophagus, stomach, liver, bile duct, pancreas, colon, kidney, 
cervix, ovary and prostate. SSEA-4 was broadly expressed in every type of cancer 
cell line, sharing most of them with SSEA-3. Globo H was less commonly distributed 
than SSEA-4 but was also widely detected (221). In addition, SSEA-4 was found on 
glioblastoma multiforme cell lines and human glioblastoma multiforme cancer 
specimens (221). 
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Figure 1.13 Sequences of globoside glycolipids. 
 
Although the above mentioned globosides are widely distributed, understanding of 
their functions remains limited. Gb4Cer was reported to bind to another glycolipid 
nLc4 (Galβ-4GlcNAcβ-3Galβ-4Glcβ-Cer) through carbohydrate-carbohydrate 
interaction, which was suggested to promote the activity of transcription factors AP1 
and CREB in cell adhesion processes (222). Another study indicated Gb4Cer 
promoted the ERK signalling through interaction with EGFR (223). A cytoplasmic 
protein, FKBP4 [FK-506 (Tacrolimus, an immunosuppressive drug) binding protein 4], 
which was detected in breast cancer cells, was also found to bind to SSEA-4 but the 
biological significance has not been clear (224).  
 
1.2.7 Clinical relevance 
 
1.2.7.1 Diagnosis and prognosis  
 
The search for carbohydrates as potential human cancer-associated biomarkers has 
been ongoing for many years. This has been discussed in numerous reviews (225-
227). However, the outcomes have been less fruitful than expected. Although there 
are numerous reports of inappropriate expression of certain carbohydrate structures 
for given cell types, they are almost always normal antigens in other cell types, which 
are referred to as ―onco-foetal‖ or ―onco-developmental‖ antigens (228). Therefore, 
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few of the candidate cancer-associated carbohydrate antigens have stood up to 
critical assessments for cancer diagnosis and prognosis.  
 
Cancer antigen 19-9 (CA19-9) is a carbohydrate tumour-associated antigen sLea, 
which was originally isolated from a human colorectal cancer cell line by Koprowski et 
al (229) in 1979. CA 19-9 assay has been established to monitor colorectal, stomach, 
and particularly pancreatic cancers in clinical (206). A recent study showed high 
serum concentrations of both CA 19-9 and E-selectin significantly correlated with low 
5-year survival rate of patients with colorectal cancer (230). One of the major 
limitations is that the expression of CA 19-9 is highly dependent on the enzyme FUT3, 
which is encoded by Lewis gene. About 10% of the Caucasians are Lewis-negative 
and cannot produce CA 19-9 antigen (231). In these populations, a sialylated 
precursor, Neu5Acα-3Galβ-3GlcNAc- is expressed and can be detected by antibody 
DU-PAN-2. 
 
Many glycoproteins and glycopeptides have been exploited as cancer biomarkers, 
such as carcinoembryonic antigen (CEA) for colon cancer, prostate-specific antigen 
(PSA) for prostate cancer, cancer antigen 15-3 (CA 15-3, MUC1) for breast cancer, 
cancer antigen 125 (CA 125, MUC16) for ovarian cancer, and cancer antigen 72-4 
(CA 72-4, tumour associated glycoprotein-72) for gastrointestinal cancer. Serological 
studies have been established to measure the quantity of these glycoconjugates. So 
far the most important application of these biomarkers has been monitoring tumour 
progression, regression and efficacy of treatment but not diagnosis. CA 15-3, for 
example, is an abnormally expressed mucin (MUC1) bearing truncated O-glycans 
such as Tn, T and sialyl Tn. The aberrantly glycosylated MUC1 is shed into 
circulation and can be detected in serum in a CA 15-3 assay. MUC1 level has been 
shown to be useful in monitoring cancer progression in some late stage patients with 
metastatic breast cancer (232,233); the role of this marker in decision-making for 
treatment is not clear, thus it was not recommended by American Society of Clinical 
Oncology for cancer screening and diagnosis (234). One exception, however, is CA 
125, which is elevated in 50% of patients with stage I ovarian cancer and in 25% of 
serum samples collected 5 years before diagnosis of ovarian cancer (235). It has 
also been shown to be useful in evaluating and monitoring prognosis of ovarian 
cancer (236). 
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Most of these glycoconjugate biomarkers have both altered polypeptide and altered 
glycosylation. One can use specific glycoforms of these glycoproteins to improve the 
sensitivity and specificity of the biomarkers. Therefore, a new strategy trying to 
identify aberrations in glycoforms of these glycoproteins or glycopeptides highly 
specific to malignancy has been investigated. A glycoprotein α-Fetoprotein (AFP) has 
been used as a serum biomarker in clinical diagnosis of hepatocellular carcinoma 
(HCC) (237). A detailed study showed that the total AFP can be separated into three 
glycoforms AFP-L1,-L2 and -L3 according to the differential affinities to lectin Lens 
culinaris agglutinin (LCA). Among the three glycoforms, AFP-L3 with core-fucosylated 
N-glycan has been shown to be highly associated with hepatocellular carcinoma 
(238).  
 
It should be noted that sometimes the aberrantly glycosylated proteins cannot be 
detected shed in the serum. For example, it is known that the truncated glycoforms 
such as Tn and T on MUC1 are clearly associated with many types of cancers. 
However, these glycans could not be detected on MUC1 in serum of patients with 
early stage breast cancer using antibody-based ELISA assay (239). It is thought that 
MUC1 carrying these glycoforms is cleared by autoantibodies that are elicited, as 
well as scanvenger lectin receptors. Therefore careful investigation is needed when 
any of these glycoforms is proposed to be used as biomarkers. 
 
As the aberrant glycosylation is the reflection of the abnormally expressed 
glycosyltransferases and/or glycosidases, these enzymes themselves have been 
suggested to be able to serve as biomarkers (240). Good examples, as mentioned 
above in Section 1.2.2, are the overexpression of β1-6 branching enzymes MGAT5 
and GCNT1, and the malfunction of the core 1 O-glycan synthase chaperone Cosmc. 
 
Autoantibodies can be found prior to the manifestations of cancer symptoms (241), 
thereby are considered ideal cancer biomarkers for early cancer detection (242). Blixt 
et al (243) developed a platform to display large numbers of glycopeptides with 
various aberrant glycoforms based on chemoenzymatic synthesis. With this platform, 
autoantibodies to Tn and sTn glycosylated MUC1 and MUC4 can be detected in sera 
from patients with colon cancer but not in controls, which shows promise (244). They 
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later developed a new microarray containing Tn (GalNAcα-), STn (Neu5Acα2-
6GalNAcα-), ST (NeuAcα2-3Galβ1-3GalNAcα-) and extended core 3 (GlcNAcβ1-
3GalNAcα-) glycoforms based on two 20mer tandem repeat sequences of MUC1 
glycopeptides. The array was used for a screen of sera from 395 breast cancer 
patients, 108 benign breast cancer patients and 99 healthy controls. The results 
showed that autoantibodies were present and in higher levels in sera of early stage 
breast cancer patients. There was also correlation between high levels of 
autoantibodies against core 3- and sTn-MUC1 and a better prognosis in terms of 
reduced rate and longer time to metastasis (245). However, a follow-up study 
showed no significant difference in binding activity between the sera from patients 
who subsequently developed invasive breast cancer and those from the control 
group (246). Although autoantibodies to truncated glycoforms on MUC1 could be 
indicative as prognostic marker, they would seem inappropriate at least for the early 
screening of cancers such as breast, ovarian, lung or pancreatic cancers. 
 
1.2.7.2 Therapy 
 
The aberrant glycosylation occurring during cancer progression has for long been 
considered a potential target for cancer therapy.  
 
One application under investigation is to target cancer-associated carbohydrate 
antigens in both the active and passive immunotherapy (247). The disialoganglioside 
GD2 (Figure 1.12) is an excellent target for vaccine development and for cancer 
treatment using mAbs. It is uniformly expressed in tumours of neuroectodermal origin 
such as neuroblastoma, melanomas and osteosarcoma but only restrictedly 
expressed in normal tissues (248). Numerous anti-GD2 antibodies have been 
developed and now in clinical trials (249). Among them, a humanised antibody 
ch14.18 has been found very promising for cancer treatment. Results of phase III 
clinical trial indicated that adding ch14.18 to standard treatment improved survival in 
patients with neuroblastoma (214). Moreover, ch14.18 consolidation immunotherapy 
after the induction therapy prevented the relapse and prolonged long-term survival 
rate, compared to the oral maintenance chemotherapy and to no consolidation (250). 
Other anti-carbohydrate mAbs have been produced targeting gangliosides GD3, 
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GM2 and to other glycans such as Ley and Lex but have not been as successful as 
ch14.18.   
 
Another application is to exploit the aberrantly expressed glycoconjugates in design 
of cancer vaccine. Although poor in immmunogenicity, many glycolipids have been 
used to elicit immune response in patients and some of them have resulted in 
promising results (251). But a lot of vaccines against GD2 and GD3 have yet to yield 
positive clinical results (252). Some vaccines have been developed based on 
conjugated oligosaccharides. A vaccine designated Theratope, based on sialyl Tn 
disaccharide in conjugation with the keyhole limpet hemocyanin has been on clinical 
trial but could not pass phase III (123). It did not show improved median time to 
disease progression nor overall survival in patients with metastatic breast cancer 
(253). More recently, advances in synthetic chemistry have made possible the use of 
fully synthetic glycopeptides as vaccines to generate immunoreactions against 
homogeneous targets (254). A good example under investigation is the MUC1-based 
glycopeptides with aberrant glycoforms such as Tn and sTn (255). 
 
In conclusion, in spite of the great efforts being put into investigating carbohydrates 
and their derivatives as biomarkers or targets for cancer therapy, there has been 
limited success and the need for better cancer biomarkers is still very evident. 
Success requires a better understanding of the biological functions of the 
carbohydrates in the context of cancer, especially a better understanding of how 
these glycans could modulate key events of cancer cells such as growth, apoptosis, 
angiogenesis, adherence, through interactions with their binding proteins. 
Investigations of two cancer-associated carbohydrate antigens F77 and AE3, defined 
by two hybridoma monoclonal antibodies, are the subjects of Chapter 3 and Chapter 
4. It is hoped that the study of the these two cancer-associated antigens would not 
only help in better understanding aberrant glycosylation in epithelial cancers and the 
biological relevance, but also provide potential cancer biomarkers and novel 
therapeutic tools. 
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1.3 Methods for investigating expression of carbohydrate 
antigens 
 
From the discussions above, it is clear that the interactions between glycans and 
GBPs play important roles in numerous biological and pathological events, including 
cancer (256). It is desirable therefore to have effective methods to assign the 
carbohydrate ligands of GBPs. In this section I discuss the challenges in the 
identification of carbohydrate ligands/antigens and strategies applied to tackle these 
problems. Emphasis will be placed on the neoglycolipid (NGL)-based array 
technology developed in the Glycosciences Laboratory (257-259) in which the 
majority of the work within this thesis was performed.  
 
1.3.1 Challenges 
 
Structural heterogeneity and complexity is a big challenge to the investigation of 
GBP-glycan interactions. It is estimated that the human glycome contains ~3000 
glycan species on glycoproteins and glycolipids, and ~4000 theoretical 
pentasaccharide sequences on GAGs (7) but only a small proportion of these 
sequences are currently available for bioactivity studies. Due to the complexity of 
their structures, many glycans cannot be synthesized in sufficient amounts within a 
short period of time, although big progress has been made (260-263).  
 
Isolation of glycans from natural sources is an alternative choice. As glycans are very 
heterogeneous in biological systems and the quantities of each glycan that can be 
isolated for ligand analyses are rather small, there is a need for powerful separation, 
sequencing methods with high sensitivity. Recent progress has been made in both of 
these fields (264-268).  
 
Another obstacle to overcome in studying carbohydrate ligands is the typically low 
affinity of the interaction between GBPs and glycans. In the natural state this 
interaction normally relies on multivalency, accomplished by clustered presentation of 
ligands and/or carbohydrate recognition domains to provide increased binding avidity. 
In vitro, the clustering of glycans can be achieved chemically by using scaffolds such 
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as proteins, peptides, lipids and other molecules and nanoparticles (269) and, as 
adopted by the neoglycolipid approach, in the form of liposomes (see below).  
 
1.3.2 Historical aspects of carbohydrate binding assays 
 
In 1931, Landsteiner and van der Scheer established the principles of inhibition 
assay (270) and this has been summarized by Watkins in her review (271): 
substances with a structure closely related to or identical with, the immunological 
determinant (haptenic) group of an antigen can combine with the antibody and 
thereby competitively inhibit the reaction between antigen and antibody. Shortly 
before 1931, the first study of quantitative precipitation was reported by Heidelberger 
and Kendall (272,273) and it was further improved by Heidelberger and Macpherson 
(274). These have become the basis of many immunological methods such as 
inhibition of precipitation (24) and haemagglutination inhibition (275) to uncover the 
structure of an unknown antigen or surface ligand.  
 
The two approaches haemagglutination inhibition and inhibition of precipitation were 
used in the assignment of the major blood group A, B, O (H) epitopes by Morgan and 
Watkins, and Kabat and colleagues between 1950‘s and 1970‘s. Important reagents 
used in these assays included antisera, obtained by immunizing rabbits or humans 
with blood group expressing materials such as peptone and porcine gastric mucin 
(276,277). Lectins were also used (278).   
 
Initially, monosaccharides Fuc and GalNAc were found by Morgan and Watkins to 
inhibit the haemagglutination of O cells by eel Anguilla Anguilla (279) and that of A 
cells by plant  lectins (22), respectively. Independently, Kabat laboratory found that 
GalNAc could inhibit the precipitation between human anti-A antibody and A 
substance from pig stomach mucin (24). In addition, Gal was found to inhibit the 
precipitation of B substance from human saliva or horse B stomach by human anti-B 
reagents (24). With the help of acidic and alkaline degradation and chromatographies 
such as paper chromatography and charcoal-celite column chromatography, O-
glycans were released from ovarian cyst glycoproteins, purified, and tested as 
inhibitors one by one. The blood group antigen epitopes A, B and O were 
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characterized on O-glycans (280-282). Thereafter, blood group-active glycolipids 
(283,284) and N-glycans (285) were also isolated. 
 
Radioimmunoassays were first described in the 1950‘s. Feizi and colleagues later 
applied this technique to the investigation of the interactions between GBPs and 
carbohydrates. Materials under investigation were tested as inhibitors of the binding 
of the antibodies (antisera) and radio-iodinated antigen-positive glycoproteins 
(286,287). Compared with the conventional inhibition of precipitation, inhibition 
assays based on a radiolabelled reference improved sensitivity by several orders of 
magnitude and, therefore, smaller amounts of inhibitors could be used (288). This 
method could also be used to determine the epitopes on glycolipids when they were 
analysed in the form of liposomes complexed with carrier lipids cholesterol and 
lecithin (289,290). Feizi and colleagues determined epitopes for the anti-I and anti-i 
antibodies and the stage specific embryonic antigen-1 (SSEA-1) by this method.  
 
Solid phase direct binding assay was then developed. Instead of labelling antigen-
positive glycoproteins for inhibition studies, the direct binding assay relies on labelling 
the GBPs or secondary antibody, which recognizes certain structural features in the 
primary antibody or GBP (291). Originally, the labels used were radio-labels. This 
enabled the antigenic analysis of glycolipids by thin-layer chromatography (TLC)-
binding assay. In early 1980s, the ganglioside GM1 was identified in total lipid 
extracts as the glycolipid ligand for the radio-labelled cholera toxin (292). Hakomori et 
al (293) corroborated the assignment of the antigenic determinant of SSEA-1 made 
by Feizi and colleagues (294). They did this by using glycolipids extracted from 
human blood cells (294). Since then, TLC-binding assay has been employed to study 
the antigenic activities of glycolipid extracts from human normal and cancer cell lines 
and tissues. Examples include the characterization of SSEA-3, SSEA-4 (295), and 
the glycolipid carriers of sLex (296), and the identification of carbohydrate receptor for 
Shiga toxin (297). For health and safety reasons radioimmunoassay technology has 
been superseded by the enzyme-linked immunosorbent assay (ELISA) which is 
widely used and is the basis of many biochemical detection methods. Binding is 
detected using an enzyme-conjugated protein (using an enzyme such as peroxidase) 
and colour development with enzyme-substrates instead of radioactivity. ELISA is 
also used in TLC-binding assays for antigenic analyses of glycolipids. In addition to 
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enzyme-conjugated proteins, fluorescence-labelled or RNA-labelled proteins are also 
used in a variety of binding assays including microarray analysis. 
 
Label free technologies such as surface plasmon resonance (SPR) have been 
developed to study the molecular interactions (298). It can also be used in the kinetic 
studies to measure the association rate and dissociation rate. This technology has 
been used in the investigation of recognitions by the lectins such as Concavalin A 
(Con A) and jacalin (299,300). 
 
1.3.3 Neoglycolipid (NGL) technology 
 
In classical inhibition of binding studies performed by Morgan and Watkins, and 
Kabat and colleagues, milligram levels of purified free glycans per tube were used for 
inhibition of binding assays (288,301). Although these amounts could be achieved in 
the investigation of blood group related antigens, it is rare to obtain sufficient purified 
material for bioactivity studies and concomitant structural determination by 
conventional methods.  
 
To address the requirement of a microscale technique to investigate directly 
interactions between GBPs and oligosaccharides, Feizi and colleagues developed 
the NGL technology (257,302). This involves microgram-scale conjugation of the 
oligosaccharides to a lipid tag, which renders oligosaccharides amphipathic. The 
hydrophobicity enables the oligosaccharides to be immobilized on solid matrices, for 
example, plastic microwells, silica thin layer chromatography plates, nitrocellose-
coated glass slides, in a clustered mode, thereby enabling the detection of binding by 
GBPs. Furthermore, similar to natural glycolipids, NGL mixtures could be resolved by 
high performance TLC (HPTLC) (also referred to as macroarray), which is a big 
advantage compared with the glycan-protein conjugates. In addition to generation of 
macroarrays of oligosaccharides released from O- and N-glycosylated proteins, the 
NGL technology makes possible to investigate the antigen or ligand activity of 
glycans of natural glycolipids after their release using endo-ceramidase or those of 
GAGs and polysaccharides derived after their partial depolymerisation.  
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Reducing oligosaccharides with free aldehyde group can be linked to an amino-
phospholipid, such as 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine (DHPE, 
Figure 1.14) by reductive amination. Reduced O-glycans released from antigen-
positive glycoproteins can also be conjugated after mild periodate oxidation (303). 
With the fluorescent lipid tag N-aminoacetyl-N-(9-anthracenylmethyl)-1,2-
dihexadecyl-sn-glycero-3-phosphoethanolamine, [ADHP, (304)], the AD-NGLs 
(Figure 1.14) can be visualized directly under UV light or by a fluorescence detector 
in an HPLC system. In addition, the NGLs have excellent ionization properties, 
enabling sequencing in situ by mass spectrometry (MS) to reveal molecular mass, 
monosaccharide sequence, branching pattern and the presence of functional groups 
such as sulphate or phosphate (85,305,306).  
 
The NGL-based techniques enable identification of antigen-positive oligosaccharides, 
or ligands, from highly heterogeneous O-glycome of epithelial mucins. A particularly 
important example was the study of the HNK-1 antigen (See Figure 1.6 for 
sequence). This antigen is a target of auto-antibodies that give rise to a 
demyelinating disease. Among the O-glycans released from glycopeptides of the 
brain, a minor population were shown to carry the HNK-1 epitope (Figure 1.6). These 
were unusual O-mannosyl sequences rather than the well-known, commonly 
occurring, O-GalNAc sequences (49). Thereafter, upon analysis of the antigen-
negative O-glycans, it was found that the O-mannose species constitute about 30% 
of total O-glycans in the brain (307). In addition, the NGL technology has contributed 
to a better understanding of the binding specificities of endogenous GBPs of the 
immune system, such as selectins. This is highlighted by the discovery of a new 
family of E-selectin ligand, sulphated Lea and Lex (3‘-sulpho-Lea and 3‘-sulpho-Lex), 
isolated from an epithelial mucin and characterized by MS (85,308). Subsequent 
studies showed that these two structures are also recognized by L-selectin and more 
strongly bound than the sialylated analogues (48,309). 
 
Generation of NGLs by reductive amination leads to the ring opening of the 
monosaccharide on the reducing terminal (DH-NGL and AD-NGL, Figure 1.14), 
limiting its application to the investigation of GBPs whose binding epitopes involve 
the reducing terminal core monosaccharide. An alternative conjugation method using 
aminooxy-functionalized DHPE (AOPE) by oxime ligation (AO-NGLs, Figure 1.14) 
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has been developed (310). A significant proportion of the AO-NGLs synthesized were 
in ring closed form, thereby enabling the binding of short-chain oligosaccharides and 
enhancing the applicabilities of the NGLs. Notably, binding of plant lectins Pisum 
sativum, which requires the fucosylated core sequence, can be detected with the AO 
form, but not with the conventional DH-NGLs (310). 
  
 
Figure 1.14 Reaction schemes for preparation of the DH-, AD- and AO-NGLs from reducing 
oligosaccharides by reductive amination and oxime ligation. Updated and redrawn from (310). 
 
1.3.4 Microarray system based on the NGL technology 
 
There was a need, however, to further miniaturize the platform to fulfil the increasing 
demand for smaller consumption and higher throughput of glycan samples during 
structural and ligand analyses. 
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In 2002, the first sequence-defined oligosaccharide microarray system based on 
NGL technology was introduced in the Glycosciences Laboratory (258). Each lipid-
linked probe is incorporated in a liposome together with carrier lipids, cholesterol and 
lecithin, and is robotically arrayed at low fmol level, on nitrocellulose coated glass 
slides (Figure 1.15). This platform features noncovalent presentation of lipid-linked 
probes in clustered display and an element of probe mobility within the liposome. 
These characteristics confer high avidity and mimick to some extent the status of 
natural glycans on the cell surface (311). The library of probes has expanded to 800, 
including NGLs and glycolipids, naturally occurring and synthetic, comprising a 
variety of mammalian type N- (high mannose, complex and hybrid forms) and O-
glycans (O-GalNAc, O-Fuc and O-Man), blood group-related sequences (A, B, H, Lea, 
Leb, Lex and Ley and their sialylated and sulphated forms), glycolipids (neutral, 
sialylated and sulphated), GAG-related sequences, as well as probes derived from 
oligosaccharides of fungal, bacterial and plant polysaccharides (259).  
 
 
Figure 1.15 Schematic representation of the NGL-based microarray. NGLs of generated from N-glycans, O-
glycans, depolymerized polysaccharides, GAGs and naturally occurring glycolipids were depicted.  Symbols were 
in Figure 1.1. Taken from (259) with permission. 
 
Applications of the microarray platform have included the study of the carbohydrate 
ligands for diverse GBPs of parasites (102,103,312,313), viruses (314-318) and 
antibodies (319-322). Of special interest were the analysis of pandemic human 
influenza A (H1N1) 2009 viruses, using a NGL-based microarray of 80 sialylated 
oligosaccharides and 6 neutral controls (323). The microarray encompassed 
sialylated sequences with different backbone types, chain lengths, branching 
patterns, and various combinations of sialylation, fucosylation and sulphation 
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patterns. Results showed that the 2009 pandemic human influenza viruses bound to 
α2,3-sialylated sequences in addition to the α2,6-sialylated sequences. In 
comparison, the seasonal human H1N1 viruses lacked binding to the α2,3-sialylated 
sequences (323). The lower respiratory tract expresses a larger proportion of α2,3-
linked sialylated glycans than the α2,6-linked, which are mainly expressed in upper 
respiratory tract. Binding to α2,3-linked sialic acid receptors may therefore account, 
at least in part, for the higher virulence of the pandemic virus. A follow-up study 
showed that binding to the α2,3-sialylated sequences was increased by an 
spontaneous single mutation of the haemagglutinin (D222G) in viruses isolated from 
fatal or severe cases of infection (41).  
 
One big advantage of the NGL technology is the so-called ‗designer‘ array approach, 
by which the probes can be generated from a targeted ligand/antigen-containing 
source so that the oligosaccharide ligands can be revealed, isolated and 
characterized. Using this approach, Palma et al. (324) determined the carbohydrate 
ligand structure of the C-type lectin-like receptor Dectin-1, an important player in the 
innate immune system against fungal pathogens. The ‗designer‘ probes were 
generated from partially depolymerized Dectin-1 ligand-positive and -negative glucan 
polysaccharides. Only β1,3-linked gluco-oligosaccharides longer than 10mer were 
bound, whereas the β1,6-linked analogues were not bound (324). The NGL-based 
carbohydrate microarray system is moreover a powerful platform which enables the 
generation of a comprehensive array of oligosaccharides from the glycomes of  
antigen- or ligand-positive cells, tissues or glycoconjugates to isolate and 
characterize the bioactive components (311). This is exemplified by the 
characterization of an elusive human prostate cancer-associated antigen F77, which 
is the subject of Chapter 3 in this thesis. 
 
Of particular importance to any microarray platform is software for data presentation, 
storage and retrieval. Dr. Mark Stoll in the Glycosciences Laboratory has developed 
dedicated software to fulfil this need (325).  
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1.3.5 Other microarray platforms 
 
Since 2002, carbohydrate microarray platforms have flourished with the need to 
rapidly probe glycan-GBP interactions. There are two glycan microarray platforms 
with the large coverage of glycan sequences. One is the Welcome Trust supported 
NGL-based carbohydrate microarray facilities in the Glycosciences Laboratory (259), 
the other is that of the Consortium of Functional Glycomics (CFG) built by National 
Institute of General Medical Sciences in the US (10,326). In addition numerous 
microarray systems containing small focused repertoires of glycan sequences have 
been set up. 
 
Overall, the existing oligosaccharide microarrays can be divided into two categories 
based on immobilization strategies: non-covalent and covalent. The NGL-based 
microarray platform is an example of non-covalent immobilization strategy. The lipid 
moiety of NGLs forms hydrophobic interactions with the nitrocellulose-coated solid 
surface (Figure 1.16A). In addition to NGLs, biotin- and oligonucleotide-conjugated 
oligosaccharides can be immobilized to streptavidin- and oligonucleotide-coated 
surfaces, both through non-covalent interactions.  
 
The other strategy is to immobilize the glycans via covalent bonds. This often 
requires a modified solid surface and glycan derivatives with special functional 
groups. These glycans are often obtained by chemical derivatization or by de novo 
chemical or chemo-enzymatic synthesis. Amine functionalized glycans, for example, 
can be immobilized to the N-hydroxysuccinimide (NHS) ester-derivatized glass slides. 
This is the basis of the CFG microarrays (Figure 1.16B) (327). So far many reactions 
have been explored to prepare glycan microarrays, including Diels-Alder reaction, 
Staudinger ligation, and click chemistry. These have been reviewed in reference 
(326). 
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Figure 1.16 Examples of the two immobilization strategies, non-convalent (A) and covalent (B), used for 
generating carbohydrate microarrays. In (A) the neoglycolipids were immobilized on the hydrophobic surface 
via hydrophobic lipid chains. In (B) the amine functionalized glycans react to the N-hydroxysuccinimide (NHS) -
coated surface by covalent bond. Taken from (326) with permission. 
 
Presentation of the glycans in the microarrays is an important consideration for all the 
carbohydrate microarray platforms. There is consensus that features of presentation, 
such as glycan orientation and density, could have a great impact on the interactions 
between glycans and GBPs. One particular factor that influences the orientation is 
the linker which connects the glycans to the solid phase. Using molecular dynamics 
simulations, Wood et al suggested that the chain length, 3D structure and the 
potential interactions of the linker with the surface could have impact on the glycan 
orientation (328). This influence cannot be neglected as it could lead to false-
negative results (329). 
 
Glycoconjugates printed onto surfaces present glycans in a multivalent form and are 
valuable for screening GBPs for binding. These include natural glycoproteins, 
neoglycoproteins, neoglycopeptides and glycodendrimers. In the Glycosciences 
Laboratory, high molecular weight mucin-type glycoproteins are immobilized after 
enrichment from crude materials and being treated with proteases. These mucin 
arrays have become unique tools for screening for ligand- or antigen-positive sources, 
which open way to the ―designer‖ array approach. Examples are discussed in 
Chapter 3 and Chapter 4.  
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A microarray strategy recently developed has been termed ―shotgun array‖ (330), a 
term Cummings and colleagues refer to, for focusing structural analyses on 
functionally important glycans in the complex glycomes of animal cells and tissues. 
There are many analogies with designer arrays. In the ―shotgun array‖ approach, 
oligosaccharides empirically from glycomes such as bovine brain gangliosides (330), 
human milk (331) and pig lung (332) have been resolved and arrayed, although the 
glycans may not be fully structurally characterized. These arrays can subsequently 
be probed with various GBPs. Those of interest are characterized using a 
combination of binding data obtained with a series of sequence-specific GBPs and 
other biochemical approaches including MS, MSn and exoglycosidase treatments of 
the glycans. Song et al prepared a shotgun array of 40 fractions of glycolipids derived 
from bovine brain gangliosides. Using this ganglioside array, they found that the 
antibody profile of sera of patients with Lyme disease was different from those of 
control group. In particular, a ganglioside GD1b-lactone was found to be bound by 
sera of the patients but not of controls (330). The most recent example was the 
generation of pig lung shotgun array for the purpose of identification of receptors for 
a panel of influenza viruses isolated from human, birds and swine (332). The glycan 
library consisted of 96 N-glycan, 62 O-glycan and 36 glycolipid fractions. Interestingly, 
the viruses tested by this method showed binding to variously sialylated N-glycans, 
but binding to O-glycans and glycolipid-derived probes was not detected (332). 
 
In sum carbohydrate microarrays now enable the studies of carbohydrate recognition 
systems at the glycome level. With accumulating knowledge on binding specificities 
of each GBP, it is anticipated that we can finally investigate GBP-glycan interaction at 
the interactome level. Comprehensive understanding of each GBP-glycan interaction 
will provide key information for further biological studies (311). 
 
1.3.6 Cell transfection with glycosyltransferases 
 
The last two decades have witnessed a boom in gene technology. In the field of 
glycobiology, the discovery and cloning of genes encoding glycosyltransferases and 
sulphotransferases enables cell transfection studies.  
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This approach has been well exemplified by the characterization of the antigenic 
determinant of HMOCC-1, which is recognized by humanized mAb HMOCC-1 raised 
against ovarian cancer RMG-I cells (333). Immunohistochemistry studies showed 
that the antibody stained 83.2% of ovarian carcinomas, also to a lesser extent some 
other epithelial tumours such as gastric, colonic, and pancreatic tumours. HMOCC-1 
could attenuate tumour metastasis by inhibiting the attachment of RMG-I cells to 
mesothelial cells (334). The researchers first identified an antigen-negative cell line, 
which was HEK293T cell in this study. A mixture of glycosyltransferases and 
sulphotransferases were transferred into the HEK293T cells to generate a new cell 
line which expresses the HMOCC-1 antigen. By subtraction and various 
combinations of these enzymes, the key enzymes responsible for antigen generation 
finally emerged to be a sulphotransferase GAL3ST3 and a glycosyltransferase 
B3GNT7. Another sulphotransferase, CHST1, could enhance the antigen intensity. 
This was complemented by gene expression analysis and knockdown of the 
identified enzymes in the HMOCC-1-positive cells. Based on the specificities of these 
enzymes, the antigen was deduced as a sulphated poly-LacNAc sequence SU-
3Galβ-4GlcNAcβ-(±SU-6)3Galβ-4GlcNAcβ-. Finally the deduction was confirmed by 
inhibition assays using four synthetic mono- and di-sulphated and non-sulphated 
oligosaccharides (333). Using the same strategy, another antigen recognized by a 
endometrial cancer-associated antibody HMMC-1 was characterized as a blood 
group H-related structure Fucα-2Galβ-4GlcNAcβ-3Galβ-3GalNAc- (335). 
 
The transfection approach can be applicable to the characterization of carbohydrate 
antigens carried on many glycoconjugate species. It can be informative and is a good 
complement to the microarray binding analysis and other approaches mentioned 
above. It gives insights to the gene expression of the relevant glycosyltransferases 
and sulphotransferases, which link the sequences of carbohydrate ligand/antigen 
(glycome) to the biosynthesis pathways (genome). The application will be further 
discussed in Chapter 3.   
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Aims of this thesis 
 
The aims of this thesis have been to characterize two cancer-associated 
carbohydrate antigens. The first is F77, which is a human prostate cancer-associated 
carbohydrate antigen, and the second is AE3, which is more broadly distributed and 
has been considered a promising serum biomarker for epithelial cancers. I 
investigate the sequences of these antigens by carbohydrate microarray approaches. 
 
I have made two approaches to elucidate these antigens. The first is the ‗designer‘ 
array approach whereby antigen-positive mucin-type glycoproteins are identified as 
sources. Glycans are released from them and converted to NGLs. Multidimensional 
chromatographies are used to isolate the antigen-positive components and mass 
spectrometric analyses are performed for sequence assignment. The second 
approach is the generation of focused microarrays of sequence-defined 
oligosaccharides (as NGLs) or glycolipids for close comparisons of the antigenic 
activities of the closely-related glycan sequences. The assignments of the F77 and 
AE3 antigens are corroborated using chemically synthesized oligosaccharides. 
 
The sequences of the two antigens and their biological relevance are discussed, as 
well as the potential clinical applications of the antigens and the corresponding 
antibodies. 
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Chapter 2  
MATERIALS AND METHODS 
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2.1 Reagents and solvents 
 
2.1.1 Solvents for HPTLC and HPLC 
 
Table 2.1 Mixed solvents for HPTLC and HPLC  
Solvent* Ratio (v/v) 
CHCl3/MeOH/H2O 
130/50/9 
60/35/8 
55/45/10 
105/100/28 
25/25/8 
50/55/18 
40/70/30 
25/70/30 
20/70/30 
15/70/30 
130/70/9 
10/20/8 
CHCl3/MeOH/0.05 M NH4OAc 25/25/8 
ACN/H2O 
80/20 
20/80 
*storage of the solvents was at ambient temperature, except for the 
two ACN/H2O solvents which are stored at 4 ˚C. 
 
2.1.2 Reagents for HPTLC staining 
 
Table 2.2 Reagents for HPTLC staining 
Name Preparation* 
Orcinol spray reagent 
Dissolve 0.9 g orcinol monohydrate (Sigma) in 25 ml H2O, 
add 375 ml ethanol, 50 ml concentrated H2SO4 with stirring 
and cool to 4 ˚C 
Resorcinol spray reagent 
Dissolve resorcinol (Sigma) in H2O to make 2 % resorcinol 
solution. Mix 5 ml of 2 % resorcinol solution with 45 ml 5 M 
HCl and 125 μl 0.1 M CuSO4 and stay for 4 h 
Primulin stock solution 
Dissolve primulin (Sigma) in acetone/H2O, 1:9 (v/v) to make 1 
mg/ml solution 
Primulin spray reagent 
Dilute the primulin stock solution to 1/100 in acetone/H2O, 4:1 
(v/v) 
Primulin TLC staining 
reagent 
Dilute the primulin stock solution to 1/100 in PBS buffer 
Ninhydrin spray reagent Dissolve 0.2 g ninhydrin (Sigma) in 100 ml ethanol 
*storage of the solvents was at 4 ˚C, except for the orcinol spray reagent and resorcinol 
spray reagent were stored at ambient temperature, and the primulin TLC staining reagent 
was freshly made. 
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2.1.3 Buffers and solutions for binding assays 
 
Table 2.3 Buffers and solutions for binding assays 
Name Recipe Preparation* 
PBS buffer 
10 mM phosphate buffer, 150 mM NaCl, 
pH 7.4 
Dilute from 10X solution (Sigma) 
HBS buffer 
5 mM Hepes, 150 mM, 5 mM CaCl2, pH 
7.4 
Add 2.5 ml 1 M Hepes (Fisher 
Scientific), 15 ml 5 M NaCl and 
2.5 ml 1M CaCl2 to 480 ml H2O 
3% BSA 3% bovine serum albumin in HBS buffer 
Dilute from 30% BSA (Sigma, 
protease free) in HBS buffer 
Casein 
1% casein in 100 mM sodium 
phosphate, 150 mM NaCl, pH 7.4 
Directly use (Pierce) 
Plexigum TLC 
overlay solution 
0.5% poly(ethyl methacrylate) in 
ether/hexane (1:5, v/v) 
Dissolve poly(ethyl methacrylate) 
(Sigma) in ether/hexane (1:5, v/v)  
Streptavidin-HRP 5 μg/ml in 3% BSA 
Dilute the 1 mg/ml streptavidin-
HRP solution (Sigma) in 3% BSA  
3,3‘- 
diaminobenzidine 
(DAB) liquid 
substrate system 
N/A 
Add 30 μl of the DAB liquid 
chromogen solution to 1 ml DAB 
liquid buffer solution (Sigma) 
FAST OPD 
0.4 mg/ml o-phenylenediamine 
dihydrochloride, 0.4 mg/ml urea 
hydrogen peroxide, 0.05 M phosphate-
citrate, pH 5.0 
Drop two tablets of the 
commercial FAST OPD (Sigma) 
into 20 ml H2O 
*These were all freshly prepared except for the casein. 
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2.2 Materials 
 
2.2.1 Antibodies and lectins 
Table 2.4 Antibodies 
Name Clone Isotype Source Cat. No. 
Dilution or 
concentration  
F77 not known mIgG3* Hongtao Zhang 170712 10 μg/ml 
AE3 
culture 
supernatant 
mIgM 
Juthathip 
Mongkolsapaya 
200711 1:3 
Anti-H type 1 17-206 mIgG3 Abcam ab3355 1:100 
Anti-H type 2 BRIC-231 mIgG1 Abcam ab33404 1:100 
Anti-A T36 mIgG3 Abcam ab3353 1:100 
Anti-B 89-F mIgM Santa Cruz sc-52371 1 μg/ml 
Anti-SSEA-1 MC480 mIgM 
Developmental 
Studies Hybridoma 
Bank, Univ of Iowa 
N/A 1:300 
Anti-Le
y
 C14 mIgM Lindy Durrant 290513 Neat 
Anti-Le
y
 FG27/18 mIgG Lindy Durrant 290513 20 μg/ml 
Ma anti-serum hIgM** Glycosciences Lab 4˚-Daniel-0 1:100 
Biotin anti-mIgG 
(whole molecule) 
polyclonal not known Sigma B7264 1:200 
Biotin anti-mIgG 
(Fc specific) 
polyclonal not known Sigma B7401 1:200 
Biotin anti-mIgM 
(μ-chain specific) 
polyclonal not known Sigma B9265 1:200 
Biotin anti-hIgM (μ-
chain specific) 
not known not known Vector BA-3020 1:200 
*m is mouse. 
**h is human. 
 
Table 2.5 Lectins 
Name Abbr. Source Cat. No. Concentration 
(μg/ml) 
Biotin Ulex Europaeus agglutinin I UEA-I 
Vector 
B-1065 50  
Biotin Aleuria Aurantia lectin AAL B-1395 2  
Biotin Peanut agglutinin PNA B-1075 5  
Biotin Ricinus Communis Agglutinin I RCA120 B-1085 5  
Biotin Wheat Germ Agglutinin WGA B-1025 2  
Biotin Helix pomatia lectin HPA Sigma L-6512 10 
 
2.2.2 Glycosidases 
 
Table 2.6 Glycosidases 
Name Buffer Source Cat. No. 
β1,4-galactosidase  
50 mM sodium citrate buffer, 
containing 100 mM NaCl (pH 6.0) 
New England BioLabs 
P0730 
β-N-
acetylglucosaminidase  
50 mM sodium citrate buffer, 
containing 1 μg/ml BSA (pH 6.0) 
P0732 
α1,2-fucosidase 
50 mM sodium citrate buffer, 
containing 100 mM NaCl and 1 
μg/ml BSA (pH 6.0) 
P0724 
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2.2.3 Glycoproteins 
 
Fifty-one preparations of mucin-rich glycoproteins were examined in this thesis 
(Table 2.7). These had been previously enriched or purified as described below and 
included in Mucin Array Set 1 (Table 3.1) and Mucin Array Set 2 (Table 4.2). 
 
Samples 1 to 31 were derived from lyophilised ovarian cystadenoma fluids and were 
from collections of Winifred Watkins and Walter Morgan at the former Lister Institute. 
These were enriched for mucin type glycoproteins by treatment at 37 ºC for up to 16 
h with pepsin, pronase or trypsin. The ratio of enzyme to dry weight was 1% w/w. 
After reaction, the samples were centrifuged (4,000 x g, 10-20 min), the supernatants 
were lyophilised and taken up in 3.5 mg/ml sodium acetate and precipitated with 
ethanol, 80% v/v at -20 ºC. After centrifugation (4,000 x g, 10-20 min), the pellets 
were washed with 80% (v/v) ethanol at -20 ºC and reconstituted in H2O. Sample 31 
had been further purified by phenol extractions (336). Samples 32 to 37 were purified 
ovarian cystadenoma glycoproteins from the Elvin A Kabat collection (Columba 
Medical Center, New York). These had been pepsin-treated and precipitated with 
various concentrations of ethanol (301,337). Samples 38-42 were from meconium 
and enriched after pronase digestion and ethanol precipitation (338). Sample 43, 
HCA, the so-called human carcinoma antigen (gift of Dr Joe Zhou, Egenix), had been 
extracted from human prostate cancer cell line PC3 by ammonium sulphate 
precipitation, followed by purification by gel filtration chromatography and affinity 
chromatography using antibody AE3 (8). Two mucin-rich milk preparations, batch #3 
and #6, were also included as sample 44 and 45. Two mucin preparations, 
designated sheep stomach (S1+S10) and new sheep pool had been obtained from 
sheep gastric mucosal scrapings after pepsin digestion and ethanol precipitation 
(339), and were included as samples 46 and 47. Samples 48-51, porcine stomach 
mucin (PSM), bovine submaxillary mucin (BSM), transferrin and invertase were from 
Sigma. 
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Table 2.7 Mucin-type epithelial glycoproteins used in this thesis 
Position Designation 
Donor red cell 
blood-group  
Secretor status 
Enriched cystadenoma glycoproteins 
1 Cys 301 (Pro)* weak A Non-secretor 
2 Cys 301 (Pep) weak A Non-secretor 
3 Cys 350 (Trp) A1 Non-secretor 
4 Cys 379 (Pro) A2B1 Non-secretor 
5 Cys 379 (Pep) A2B1 Non-secretor 
6 Cys 444 (Trp) Unknown Non-secretor 
7 Cys 444 (Pro) Unknown Non-secretor 
8 Cys 444 (Pep) Unknown Non-secretor 
9 Cys 446 (Pro) B Non-secretor 
10 Cys 446 (Pep) B Non-secretor 
11 Cys 461 (Trp) Unknown Non-secretor 
12 Cys 461 (Pro) Unknown Non-secretor 
13 Cys 461 (Pep) Unknown Non-secretor 
14 Cys 654 (Pro) B Non-secretor 
15 Cys 654 (Pep) B Non-secretor 
16 Cys 705 (Pro) Unknown Non-secretor 
17 Cys 717 (Pro) A1 Non-secretor 
18 Cys 717 (Pep) A1 Non-secretor 
19 Cys 733 (Pro) A1 Secretor 
20 Cys 745 (Pro) A Non-secretor 
21 Cys 745 (Pep) A Non-secretor 
22 Cys 754 (Pro) Unknown Non-secretor 
23 Cys 754 (Pep) Unknown Non-secretor 
24 Cys 756 (Trp) A Non-secretor 
25 Cys 756 (Pro) A Non-secretor 
26 Cys 756 (Pep) A Non-secretor 
27 Cys 762 (Trp) O Non-secretor 
28 Cys 762 (Pro) O Non-secretor 
29 Cys 762 (Pep) O Non-secretor 
30 Cys 765 (Pro) O Non-secretor 
Purified cystadenoma glycoproteins 
31 B substance (Pro) B Secretor 
32 Og 10% 2x (Pep) Unknown Non-secretor 
33 Og 10% from 20% (Pep) Unknown Non-secretor 
34 Og 20% 2x (Pep) Unknown Non-secretor 
35 N1 20% (Pep) Unknown Non-secretor 
36 Tij 10% 2x (Pep) B Secretor 
37 OC2 Unknown Unknown 
Meconia 
38 Meconium B (Pro) B Unknown  
 39 Meconium Mo (Pro) Unknown Unknown 
40 Meconium Wo (Pro) Unknown Unknown 
41 Meconium He (Pro) Unknown Unknown 
42 Meconium Pa (Pro) Unknown Unknown 
Other glycoproteins  
43 HCA Unknown  Unknown 
44 Milk batch #3 Unknown Unknown 
45 Milk batch #6 Unknown Unknown 
46 Sheep stomach (S1+S10) (Pep) Unknown Unknown 
47 New sheep stomach pool (Pep) Unknown Unknown 
48 Porcine gastric mucin  A+H (Sigma) 
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49 Bovine submaxillary mucin Unknown (Sigma) 
50 Transferrin Unknown Unknown 
51 Invertase Unknown Unknown 
* Trp, Pro and Pep refer to pronase, trypsin or pepsin enzyme treatments for solubilizing mucin type glycoproteins. 
 
2.2.4 Oligosaccharides and a glyco-amino acid 
 
The key oligosaccharides and a glyco-amino acid used in this thesis and their 
structural features are listed in Table 2.8. Ten oligosaccharides were from Elicityl and 
were purified by normal-phase HPLC using an XBridge amide column (Waters). The 
elution was with a solvent system of ACN/H2O (Solvent A: ACN/H2O, 80:20 and B: 
ACN/H2O, 20:80), with a gradient from 25% to 33%B in 33 min at a flow rate of 0.7 
ml/min. Detection was by UV at 196 nm. The oligosaccharide TFiLNO (1-2, -2, -3) 
was from Dextra and its sequence was confirmed by negative-ion ES-CID-MS/MS. A 
difucosylated decasaccharide was received from Dextra as an unknown impurity of 
TFiLNO( 1-2,-2,-3), which was later characterized by ES-CID-MS/MS and renamed 
as DFiLNO. Oligosaccharides referred to as Orsay-1 to -7 were chemically 
synthesized in the laboratory of the late Professor S. David [cited in (340)]. GSC-915 
is a nonasaccharide synthesized in Kiso Laboratory of Gifu University, Japan 
(unpublished). Four other oligosaccharides GSC-915-2 to -5 were generated by 
sequential glycosidase treatment (Section 2.10). A T disaccharide (Galβ-3GalNAc)-
containing glyco-amino acid Galβ-3GalNAcα-Ser was also purchased from Dextra.  
 
Table 2.8 Oligosaccharides and a glycoamino acid used in the thesis 
Designation Sequences Source Cat. No. Structural 
features 
H-tetra-T2 
Galβ-4GlcNAcβ-3Gal 
│ 
          Fucα-2 
Elicityl GLY032-2 H type 2 
LNFP-I 
Galβ-3GlcNAcβ-3Galβ-4Glc 
│ 
Fucα-2 
Glycoscience 
Laboratory 
N/A H type 1 
LnNFPI 
Galβ-4GlcNAcβ-3Galβ-4Glc 
│ 
Fucα-2 
Elicityl GLY033-2 H type 2 
A-penta-T2 
GalNAcα-3Galβ-4GlcNAcβ-3Gal 
                   │ 
         Fucα-2 
Elicityl GLY036-2 A type 2 
A-Hexa-T1 
GalNAcα-3Galβ-3GlcNAcβ-3Galβ-4Glc 
                   │ 
         Fucα-2 
Elicityl GLY037-1 A type 1 
A-Hexa-T2 
GalNAcα-3Galβ-4GlcNAcβ-3Galβ-4Glc 
                   │ 
         Fucα-2 
Elicityl GLY037-2 A type 2 
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B-penta-T2 
Galα-3Galβ-4GlcNAcβ-3Gal 
                   │ 
         Fucα-2 
Elicityl GLY039-2 B type 2 
B-Hexa-T1 
Galα-3Galβ-3GlcNAcβ-3Galβ-4Glc 
                   │ 
         Fucα-2 
Elicityl GLY040-1 B type 1 
B-Hexa-T2 
Galα-3Galβ-4GlcNAcβ-3Galβ-4Glc 
                   │ 
         Fucα-2 
Elicityl GLY040-2 B type 2 
Le
x
-tetra 
Galβ-4GlcNAcβ-3Gal 
                                 │ 
                       Fucα-3 
Elicityl GLY050 LeX 
Le
y
-penta 
Galβ-4GlcNAcβ-3Gal 
                     │          │ 
           Fucα-2 Fucα-3 
Elicityl GLY052 Ley 
MFLNH-I 
          Galβ-4GlcNAcβ-6  
                                     │  
                                     Galβ-4Glc 
                                     │  
          Galβ-3GlcNAcβ-3 
          │ 
Fucα-2 
Dextra L735 H type 1 
MSDFLNnH 
                Galβ-4GlcNAcβ-6  
                 │          │           │ 
      Fucα-2  Fucα-3            Galβ-4Glc 
                                           │  
NeuAcα-6Galβ-4GlcNAcβ-3 
Dextra SLN907 Le
y
 
TFiLNO  
(1-2,-2,-3) 
          Galβ-3GlcNAcβ-3Galβ-4GlcNAcβ-6 
          │                                       │            │ 
Fucα-2                              Fucα-3            Galβ-4Glc 
                                                                 │ 
                                      Galβ-3GlcNAcβ-3 
                                      │ 
                            Fucα-2 
Dextra L1001 H type 1 
DFiLNO  
          Galβ-3GlcNAcβ-3Galβ-4GlcNAcβ-6 
                                                   │            │ 
                                         Fucα-3            Galβ-4Glc 
                                                                 │ 
                                      Galβ-3GlcNAcβ-3 
                                      │ 
                            Fucα-2 
Dextra N/A H type 1 
Orsay-1 Galβ-4GlcNAcβ-6Gal Serge David N/A 
Type 2 
backbone 
Orsay-2 Galβ-4GlcNAcβ-3Gal Serge David N/A 
Type 2 
backbone 
Orsay-3 Galβ-3GlcNAcβ-6Gal Serge David N/A 
Type 1 
backbone 
Orsay-4 Galβ-3GlcNAcβ-3Gal Serge David N/A 
Type 1 
backbone 
Orsay-5 
                GlcNAcβ-6  
                                │  
                                Gal 
                                │  
     Galβ-3GlcNAcβ-3 
Serge David N/A 
Type 1 
backbone 
Orsay-6 
     Galβ-4GlcNAcβ-6  
                                │  
                                Gal 
                                │  
     Galβ-4GlcNAcβ-3 
Serge David N/A 
Type 1 
backbone 
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Orsay-7 
     Galβ-4GlcNAcβ-6  
                                │  
                                Gal 
                                │  
     Galβ-3GlcNAcβ-3 
Serge David N/A 
Type 2 & 1 
backbone 
GSC-915 
          Galβ-4GlcNAcβ-6  
          │                         │  
Fucα-2                         Galβ-4GlcNAcβ-3Galβ-4Glc 
                                     │ 
          Galβ-4GlcNAcβ-3 
Kiso 010514 H type 2  
GSC-915-2 
          Galβ-4GlcNAcβ-6  
          │                         │  
Fucα-2                         Galβ-4GlcNAcβ-3Galβ-4Glc 
                                     │ 
                     GlcNAcβ-3 
Enzymatic 
treatment 
N/A H type 2 
GSC-915-3 
          Galβ-4GlcNAcβ-6Galβ-4GlcNAcβ-3Galβ-4Glc 
          │ 
Fucα-2  
Enzymatic 
treatment 
N/A H type 2 
GSC-915-4 Galβ-4GlcNAcβ-6Galβ-4GlcNAcβ-3Galβ-4Glc 
Enzymatic 
treatment 
N/A 
Type 2 
backbone 
GSC-915-5                     GlcNAcβ-6Galβ-4GlcNAcβ-3Galβ-4Glc 
Enzymatic 
treatment 
N/A N/A 
pLNH Galβ-3GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glc 
Glycoscience 
Laboratory 
N/A 
Type 1 
backbone 
pLNnH Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glc 
Glycoscience 
Laboratory 
N/A 
Type 2 
backbone 
T-Ser Galβ-3GalNAcα-Ser Dextra GS203 T antigen 
 
2.2.5 Glycolipids 
 
A glycolipid extract of prostate cancer cell line PC3 was prepared as described (341) 
and provided by our collaborator Dr. Hongtao Zhang in Professor Mark Greene‘s lab 
of University of Pennsylvania. Other glycolipids and their structural features are 
shown in Table 2.9. Four human red cell-derived blood group H and A-active 
glycolipids were from archival collections of Professor Michiko Fukuda of Sanford-
Burnham Medical Research Institute. They were further purified by semi-preparative 
HPTLC as described in Section 2.7. The branched blood group A-active glycolipid Ad 
was de-fucosylated by α1,2-fucosidase as described in Section 2.10 to remove the 
minor H residue to ensure the absence of H-activity. Two branched blood group B-
active glycolipids BIII and BIV, a B-like decaglycosylceramide and an I-active 
octaglycosylceramide were from Dr. Peter Hanfland of University of Bonn. Two 
sulphated glycolipids, SM1a and SB1a, were chemically synthesized in Professor 
Makoto Kiso Lab in Gifu University. 
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Table 2.9 Glycosylceramides used in this thesis 
Designa-
tion 
Sequences Source Ref Structural 
features 
H2* 
          Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
         │ 
Fucα-2 
Michiko 
Fukuda 
(342) H type 2 
H3* 
          Galβ-4GlcNAcβ-6  
         │                        │  
Fucα-2                         Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                    │ 
          Galβ-4GlcNAcβ-3 
         │ 
Fucα-2 
Michiko 
Fukuda 
(342) H type 2 
Ab* 
GalNAcα-3Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                 │ 
        Fucα-2 
Michiko 
Fukuda 
(343) A type 2 
Ad* 
                            GalNAcα-3Galβ-4GlcNAcβ-6  
                                              │                       │  
                                     Fucα-2                        Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                                                        │ 
GalNAcα-3Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3 
         │ 
Fucα-2 
Michiko 
Fukuda 
(343) A type 2 
B-III 
dodeca 
Galα-3Galβ-4GlcNAcβ-6 
          │                       │  
 Fucα-2                        Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                    │ 
Galα-3Galβ-4GlcNAcβ-3 
          │ 
 Fucα-2 
Peter 
Hanfland 
(344) B type 2 
B-IV 
tetradeca 
                             Galα-3Galβ-4GlcNAcβ-6  
                                       │                       │  
                               Fucα-2                       Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                                                 │ 
Galα-3Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3 
         │ 
Fucα-2 
Peter 
Hanfland 
(344) B type 2 
B-like 
decaglycos
ylceramide 
Galα-3Galβ-4GlcNAcβ-6 
                                     │  
                                     Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                     │ 
Galα-3Galβ-4GlcNAcβ-3 
Peter 
Hanfland 
(345) B-like 
I-active 
octaglycos
ylceramide 
Galβ-4GlcNAcβ-6 
                          │  
                          Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                          │ 
Galβ-4GlcNAcβ-3 
Peter 
Hanfland 
(346,
347) 
Type 2 
backbone 
SM1a 
Galβ-3GalNAcβ-4Galβ-4Glc-Cer 
                            │ 
                      SU-3 
Kiso (348) 
sulphate/ 
T 
disaccharid
e 
SB1a 
Galβ-3GalNAcβ-4Galβ-4Glc-Cer 
│                           │ 
SU-3                      SU-3 
Kiso (349) disulphate 
*A minor component with an additional fucose residue was detected in H2, Ab and Ad preparations and a minor 
component lacking one fucose residue was detected in H3, by MALDI-MS analysis. 
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2.3 Release of O-glycans in reduced form from mucins 
 
For typical experiments of reductive and non-reductive O-glycan release, 800-1,000 
mg and 20-250 mg (dry weight) of mucin were referred to as large-scale and small-
scale hydrolysis, respectively. 
 
Reductive release was performed using the alkaline borohydride degradation method 
established by Carlson (350,351). Powder of lyophilised mucin was taken up in 0.05 
M NaOH-1 M NaIO4 at a final concentration of 25 mg/ml and heated at 45 °C for 16 h. 
After the reaction, AcOH/H2O (1:1) was added to destroy borohydride and the 
mixture was then passed through a column of AG50W-X8 (H form, Bio-Rad) which 
was pre-equilibrated with H2O. The boric acid generated was removed by repeated 
co-evaporation with methanol under N2 stream, followed by lyophilisation. The 
products of PSM were reconstituted in H2O for further analysis and fractionation. The 
products of crude ovarian cystadenoma materials (such as Cyst 756) were taken up 
with 0.05 M NH4OAc and were further purified by size fractionation. The products 
were applied to a Bio-Gel P6 column (1.6 × 30 cm, Bio-Rad) equilibrated by 0.05 M 
NH4OAc. Elution was with the same buffer so as to separate the oligosaccharide-
enriched fraction in the included volume from residual glycoproteins or large 
glycopeptides eluted at void volume and salts eluted in the total volume. The 
oligosaccharide-enriched fraction was pooled, lyophilised, and reconstituted in 0.05 
M NH4OAc for further analysis. 
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2.4 Release of O-glycans in reducing form from mucins 
 
Two non-reductive methods were applied in this study to release the 
oligosaccharides in reducing form.  
 
Hydrazinolysis was performed by our collaborator Radoslaw Kozak at Ludger (Oxford) 
to release O-glycans from PSM as described (352). In brief, 50 mg (dry weight) PSM 
were dissolved in 10 ml of H2O and divided into 1 ml aliquots. To each aliquot 1 ml 
hydrazine was added. Incubation was at 60 °C for 6 h. The products were re-N-
acetylated and desalted by passing over LudgerClean CEX cartridges (cation 
exchange cartridge). One percent of the released products was labelled with 2-
aminobenzamide (2-AB) using a Ludger 2-AB Glycan Labelling Kit as described (352) 
and analysed by HPLC and MALDI-MS. The rest were lyophilised and sent to us for 
further analysis. 
 
Ethylamine was used to release the oligosaccharides in reducing form from ovarian 
cystadenoma material as described previously (308). Typically, ovarian Cyst 756 
(250 mg, dry weight) was dissolved in 10 ml 70% (w/v) aqueous ethylamine and kept 
in the dark at either 22°C for 48 h or at 65°C for 6 h. These two conditions are 
referred to as E22 and E65, respectively. The bulk of ethylamine was evaporated 
under a stream of N2 at 20°C and 60°C for the two reaction conditions, respectively, 
and the viscous yellow syrup was diluted with a small volume of H2O before 
acidification to pH 4-5 by addition of AcOH/H2O (1:1, v/v). The mixture was left at 4°C 
overnight and then passed through a cation-exchange column (AG50W-X8, H+ form, 
10 ml gel) equilibrated with H2O. The column was washed with three bed-volumes of 
H2O. The combined fall-through and washes were further purified using Bio-Gel P6 
as described in Section 2.3, and the oligosaccharide-enriched fraction was freeze-
dried and reconstituted in 0.05 M NH4OAc for further analysis and fractionation. 
  
 87 
 
2.5 Fractionation and purification of the oligosaccharides 
from reaction mixtures 
 
2.5.1 Fractionation of O-glycans by charge 
 
Two anion-exchange methods were used to fractionate the oligosaccharide mixtures 
released from PSM or ovarian cyst material. 
 
For the reducing oligosaccharides released from PSM by hydrazinolosis and the 
reduced oligosaccharide alditols released from Cyst 756 by Carlson degradation, 
fractionation was performed with a column of DEAE-Sephadex A25 (OH form, GE). 
The oligosaccharide-enriched fraction was applied onto the column prewashed with 2 
M NaCl, 500 mM NH4OAc buffer (pH 5.0) and 10 mM NH4OAc buffer (pH 5.0). The 
column was washed stepwise with 10 mM. 100 mM, 300 mM, and 500 mM NH4OAc 
buffer (pH 5.0). After removal of the NH4OAc by repeated co-evaporation with H2O by 
lyophilisation, the fractions were ready for analysis or size fractionation. For the 
fractions of reducing O-glycans of PSM released by hydrazinolysis, further 
purification was performed. Each fraction was passed through a C18 Sep-Pak 
cartridge (Waters) and applied to a graphitised carbon SPE cartridge (Grace Davison 
Discovery Sciences) equilibrated with H2O containing 0.1% (v/v) TFA. Elution was by 
25% CH3CN containing 0.1% (v/v) TFA. The purified fractions were lyophilised 
repeatedly and re-dissolved in H2O for analysis and conjugation.  
 
For the reducing oligosaccharides non-reductively released from Cyst 756 by 
ethylamine (E65), charge fractionation was performed using a column of AG1-X8 
(acetate form, Bio-Rad). The column was washed with 300 mM pyridine/AcOH and 
equilibrated by 2 mM pyridine/AcOH. The reaction products were reconstituted in 2 
mM pyridine/AcOH (pH 5.0) and applied on the column. Three fractions were eluted 
by 2 mM pyridine/AcOH (pH 5.0), 100 mM pyridine/AcOH (pH 5.0) and 300 mM 
Na2SO4, respectively. The former two fractions were repeatedly lyophilised to remove 
the pyridine/AcOH. The Na2SO4 eluent was desalted by Superdex peptide column (1 
x 30cm, GE) with 0.05 M NH4OAc as the solvent. All the fractions were lyophilised 
and reconstituted in H2O for analysis and conjugation.  
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2.5.2 Fractionation of O-glycans by size 
 
The oligosaccharide fractions obtained above and the O-glyan products from Carlson 
degradation of PSM were further fractionated by gel filtration chromatography on a 
Bio-Gel P4 column (1.6 × 90 cm, Bio-Rad). Samples containing mainly neutral 
oligosaccharides were dissolved in H2O and were applied onto the column pre-
equilibrated with H2O. Samples with both neutral and acidic oligosaccharides were 
dissolved in 0.05 M NH4OAc and were applied onto the column pre-equilibrated with 
0.05 M NH4OAc. Elution was at a flow rate of 15 ml/h with H2O or 0.05 M NH4OAc for 
the former or latter situations. Detection was by refractive index detector. The column 
was pre-calibrated using dextran and dextran hydrolysate under the same condition. 
Fractions were pooled according elution position. For refractionation of a pool of 
subfractions in the F77 study, a Bio-Gel P6 column (1.6 × 90 cm, Bio-Rad) was used 
and the conditions were the same as those used for Bio-Gel P4. Subfractions were 
combined and lyophilised. NH4OAc was removed by repeated co-evaporation with 
H2O. The dried fractions were re-dissolved in H2O for further analysis or conjugation 
reaction. 
 
2.5.3 Affinity chromatography for enrichment of antigen-positive O-
glycans 
 
Affinity chromatography was carried out using both UEA-I column and F77 antibody 
column for the purpose of enriching F77 antigen-positive O-glycan alditols. 
 
The UEA-I absorbent (10 ml, Vector Labs) was packed in a syringe (1.6 × 5 cm) and 
prewashed with 10 mM PBS (pH 7.4). An O-glycan fraction, F3, obtained from size 
fractionation of the O-glycans released from PSM was dissolved in PBS and applied 
on top of the column. This was followed by washing with the same buffer until no 
materials appears in the effluent monitored by a refractive index detector. The bound 
material was then eluted by 40 ml of 10 mM, 30 mM and 50 mM Fuc in PBS. Fall-
through and eluents were collected and combined according to the elution profile. 
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The obtained subfractions were purified by graphitised carbon SPE cartridge as 
described in Section 2.5.1 to remove the Fuc and salts.  
 
The F77 affinity column was prepared by conjugating the F77 antibody to NHS-
activated agarose (Thermo) in a spin column by our collaborators in Mark Greene 
Laboratory of University of Pennsylvania. An O-glycan fraction, F3, obtained from 
size fractionation of the O-glycans released from PSM was dissolved in PBS and 
applied onto the F77 affinity column equilibrated with the same buffer. The fall-
through was collected and designated A1F. After a two-hour incubation at room 
temperature, the column was centrifuged (1000 × g) and washed with PBS three 
times. The washes were combined as A1W. Elution was with 100 mM glycine HCl 
(pH 2.5-3) and the eluents were neutralized by 1 M (NH4)2CO3 and designated as 
A1E. The fraction A1F was then reapplied onto the column. The procedure was 
repeated and A2F, A2W and A2E were similarly obtained. All the five fractions were 
desalted by graphitised carbon SPE cartridge as mentioned in Section 2.5.1. 
 
All the fractions obtained by affinity chromatographies were lyophilised and dissolved 
in H2O for analysis and conjugation. 
  
 90 
 
2.6 Preparation of NGLs 
 
2.6.1 Lipid conjugation 
 
2.6.1.1 Reducing oligosaccharides 
 
Oligosaccharides listed in Table 2.8 and those O-glycans in reducing form in each 
fraction were converted into NGLs by reductive amination (for DH- and AD-NGLs) 
(353) or oxime ligation (for AO-NGLs) (310). Typically, 100 nmol of oligosaccharide 
was lyophilised and 80 μl DHPE, ADHP or AOPE solution (10 nmol/μl) in 
CHCl3/MeOH, 1:1 (v/v) was added. For DH- and AD-NGL generation, 20 μl freshly 
prepared tetrabutylammonium cyanoborohydride (20 μg/μl in MeOH) were added to 
the mixture. Incubation of the reaction mixture was at 60 ˚C for 16 h. For AO-NGL 
generation, the solution was directly incubated at 60 ˚C for 16 h. When 
oligosaccharides larger than hexasacharides were used in both cases, a small 
amount of H2O (~5%, w/v) was included at the beginning and the incubation time was 
prolonged to 72 h. After incubation, the solvent was evaporated and the residue was 
reconstituted in CHCl3/MeOH/H2O 25:25:8 for TLC analysis. 
 
2.6.1.2 Reduced oligosaccharide alditols 
 
Reductively released oligosaccharide alditols were conjugated to ADHP after mild 
periodate oxidation (303). Oligosaccharides in each fraction (~100 nmol) were 
lyophilised, followed by addition of 70 μl freshly prepared NaIO4 (1.25 mg/ml) in 
imidazole buffer (40mM, pH 6.5). The mixture was incubated on ice in the dark for 5 
min. Butane-2,3-diol (8 µl, 9 mg/ml in MeOH) was added and the mixture was 
incubated on ice for a further 40 min. Thereafter 200 μl ADHP solution (10 nmol/μl in 
CHCl3/MeOH, 1:1) and 145 μl freshly prepared tetrabutylammonium 
cyanoborohydride solution (20 μg/μl in MeOH) was added followed by further 
incubation at 60 °C for 16 h. The solvent was evaporated and the mixture was 
dissolved in CHCl3/MeOH/H2O 25:25:8 for TLC analysis. 
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2.6.1.3 Glycoamino acid 
 
The amino-terminating glyco-amino acid Galβ-3GalNAcα-Ser (Table 2.8) was 
converted to NGL using a novel lipid reagent (designated DHPA) with an aldehyde 
functionality linked to DHPE (unpublished) developed by Pengtao Zhang, Chunxia Li 
(Ocean University of China, Qingdao) and Wengang Chai (Glycosciences 
Laboratory). The details of preparation of the DHPA conjugate will be described 
elsewhere. 
 
2.6.2 HPTLC analysis of conjugation products 
 
Aliquots of the reaction mixtures (~1 nmol starting sugar) were analysed by HPTLC 
as described (353). The reaction product was applied onto aluminium-backed HPTLC 
plates (Merck) and developed in suitable solvents listed in Table 2.1. After 
development, the fluorescent NGLs and excess lipids were directly visualized under 
long-wave UV light. The non-fluorescent DH- and AO- NGLs were stained with 
primulin reagent (Table 2.2) before visualization under long-wave UV light. The same 
plate can be sprayed with orcinol reagent (Table 2.2) further and heated at 105 ˚C for 
detection of hexose. 
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2.7 Separation and purification of NGLs or glycolipids 
 
For the purpose of removing excess lipid and isolating and purifying antigen-positive 
NGLs or glycolipids, silica cartridge, semi-prep HPTLC and HPLC were performed. 
 
For normal-phase chromatography on silica cartridge, the reaction mixture was dried 
under N2 stream, reconstituted in CHCl3/MeOH/H2O, 130:50:9 and applied onto a 
silica Sep-Pak cartridge containing 100 mg or 200 mg sorbents (Waters) 
preconditioned by CHCl3. The column was then washed sequentially with 
CHCl3/MeOH/H2O, 130:50:9 (×3), 60:35:8 (×3), and 25:25:8 (×3). An aliquot of each 
fraction was analysed by HPTLC to monitor the separation as mentioned in Section 
2.6.2. According to the mobility profile, washes were pooled into one or several 
fractions according to activity and interest and dried under N2 stream for further 
investigation.  
 
Alternatively, semi-prep HPTLC was performed to remove excess lipid and to purify 
the NGLs and glycolipids. The dried samples were reconstituted in CHCl3/MeOH/H2O, 
25:25:8 and applied as long straits on HPTLC plates. The plates were then 
developed in a suitable solvent (Table 2.1). For fluorescent NGL fractions, after 
visualization under UV light, the TLC bands of interest were cut out and the silica 
gels were scraped off the plates. The NGLs were extracted from the silica gels with 
CHCl3/MeOH/H2O 25:25:8; alternatively a mini-column was packed with the scraped 
slilica gels and the NGLs were eluted off by the same solvent. Non-fluorescent NGLs 
and glycolipids can also be purified in the same way but they were localized by 
primulin staining of the two vertical edges (a few mm) cut from the plate. 
 
Fluorescent NGLs can be fractionated and separated by HPLC (Gilson system) with 
a fluorescence detector at λex 255 nm and λem 405 nm or a UV  detector at λmax 255 
nm as described (304). An APS-2 column (5 μm Hypersil, 4.6 × 250 mm) was used 
with a gradient of CHCl3/MeOH/H2O 130:70:9 (solvent A) to 10:20:8 (solvent B) in 60 
min at a flow rate of 0.5 ml/min. Fractions were pooled according to the 
chromatogram and were dried under N2 stream for further investigation.  
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The NGL fractions obtained in silica cartridge, semi-prep TLC and HPLC were 
desalted by reverse-phase chromatography using C18 cartridge. Samples were 
reconstituted in a minimal amount of CHCl3/MeOH/H2O, 15:70:30 and applied onto a 
C18 Sep-Pak cartridge (100 mg or 200 mg sorbents, Waters) prewashed by 
CHCl3/MeOH/H2O, 15:70:30. After washing with MeOH/H2O, 1:1, the NGLs were 
eluted by CHCl3/MeOH/H2O, 60:35:8, dried under N2 stream and stored at -20 ˚C for 
further analysis. 
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2.8 Quantitation 
 
2.8.1 Quantitation of oligosaccharides 
 
Quantification of hexose in samples was carried out by dot orcinol-sulphuric acid 
method on TLC plates, using galactose as standard. Oligosaccharide fractions and 
serially diluted standard galactose were dotted on HPTLC plates. After spraying with 
orcinol reagent, the colour developed was measured by densitometry on a Shimadzu 
CS-9000 flying-spot scanner at 550 nm. Hexose content in samples was determined 
against the calibration curve recorded by the standard galactose samples. The molar 
quantities of the oligosaccharides in each fraction were estimated based on hexose 
content and molecular mass determined by MS analysis.   
 
Quantification of sialic acid was carried out by resorcinol assay, using Neu5Ac as 
standard. The oligosaccharide fractions and standard Neu5Ac were dotted on 
HPTLC plates and sprayed with resorcinol reagent (Table 2.2). The silica surface of 
the plates was immediately sealed by clamping with two glass plates and heated at 
140 ˚C for 10 min. Measurement was by densitometer at 580 nm. Content of sialic 
acid in samples was determined against the calibration curve recorded by the 
standard Neu5Ac samples. 
 
2.8.2 Quantitation of NGLs 
 
NGLs were generally quantified on HPTLC plates. The purified NGLs were dissolved 
in CHCl3/MeOH/H2O, 25:25:8 and applied on the HPTLC plate together with DH- or 
AD-NGL standards. After development the plate was sequentially immerged in PBS 
buffer, primulin solution, and PBS buffer for 10, 20 and 10 min, respectively, and air-
dried. The fluorescence was measured by densitometer in linear reflectance 
fluorescence mode with excitation at 370 nm and detection through a filter with cut-
off at 460 nm. The quantities of the NGLs in each fraction were then calculated by 
the calibration curve with the standard DH-NGLs. The NGLs were then adjusted to 
50-100 pmol/μl as stock solution and stored at -20 ˚C. 
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2.9 Mass spectrometry of oligosaccharides, glycolipids and 
NGLs 
 
MALDI-MS of the oligosaccharides and the derived NGLs was carried out on a TOF 
Spec-2E (Waters) or an AXIMA Assurance instrument (Shimadzu). Negative-ion 
MALDI-MS/MS was performed on an AXIMA Resonance instrument (Shimadzu). The 
oligosaccharides were dissolved in H2O and the NGLs in CHCl3/MeOH/H2O, 25:25:8. 
The sample was deposited on the sample target together with ~1 μl of matrix of 
2‘,4‘,6‘-trihydroxyacetophenon. Laser energy was set at 20% (coarse) and 60% (fine) 
for TOF Spec-2E and at attenuation scale 80 for the AXIMA Assurance. For MS/MS, 
a collision gas Ar (2 bar) and collision energy set at 80-140 depending on specific 
samples were used for oligosaccharides and NGLs.  
 
ES-MS and ES-CID-MS/MS of oligosaccharides were carried out on a Synapt G2-S 
instrument (Waters). Cone voltage was at 80 eV for the oligosaccharides while 
capillary voltage was maintained at 2.7 kV for conventional scale electrospray. The 
source temperature was at 120 °C and the desolvation temperature at 150 °C. 
Product-ion spectra were obtained using argon as the collision gas at a pressure of 
1.7 bar. The collision energy was adjusted between 12 and 20 eV for optimal 
fragmentation of reducing oligosaccharides. A scan rate of 1.0 s/scan was used for 
both ES-MS and MS/MS experiments and the acquired spectra were summed for 
presentation. For analysis, oligosaccharides were dissolved in H2O at a concentration 
of 10−20 pmol/μl, of which 1 μl was injected via HPLC injector. Solvent (ACN/H2O 1:1) 
was delivered by a HPLC pump (Waters) at a flow rate of 10 μl/min.     
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2.10 Glycosidase treatment of oligosaccharides and NGLs 
 
The synthetic nanosaccharide GSC-915 was treated sequentially with 
exoglycosidases, β1,4-galactosidase, β-N-acetylglucosaminidase, α1,2-fucosidase 
and β1,4-galactosidase  to prepare a series of oligosaccharides GSC-915-2 to GSC-
915-5 as shown in Table 2.8. The conditions were indicated in Table 2.6. 
Oligosaccharide substrates were lyophilised before reaction and dissolved in the 
reaction buffer to make 1 nmol/μl solution. The enzymes (3-20 U/nmol sugar) were 
added in the solution and incubated at 37 °C for 48 h. Thereafter, the reaction 
mixtures in each step were separated by HPLC on a Click-Mal column (5 μm, 
4.6×150 mm) with a solvent system of A (ACN/H2O, 80/20) and B (ACN/H2O, 20/80). 
The gradient was from 20 to 45% B in 30 min at a flow rate of 1 ml/min and detection 
was by UV at 196 nm. The products were analysed by MALDI-MS, reconstituted in 
H2O, quantified by dot-orcinol before converting to NGLs. 
 
The NGLs and glycolipids were also treated with α1,2-fucosidase to remove minor 
component or to verify the carbohydrate sequences. Typically, 2 nmol of the NGL or 
glycolipids were taken up with 70 μl 50 mM sodium citrate buffer (pH 6.0), containing 
100 mM NaCl, 1 μg/ml BSA and 0.5 mg/ml sodium cholate. The reaction mixture was 
sonicated briefly before addition of 200 U of 1-2 fucosidase, followed by incubation 
at 37 °C for 48 h. A standard LnNFPI AD-NGL was treated and analysed in parallel. 
The reaction process was monitored by MALDI-MS. After the reaction, the products 
were purified on a Sep-Pak C18 cartridge, reconstituted in CHCl3/MeOH/H2O, 
25:25:8 and stored at -20 ˚C for further analysis. 
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2.11 Assays of antigen activities of glycoproteins, 
glycolipids, NGLs and oligosaccharides 
 
Binding of mAb F77 was found to be temperature-dependent. Thus temperature of 
the binding experiments involving F77 was specified in the Chapter 3. Unless 
otherwise specified, the binding and inhibition experiments described below were 
performed at ambient temperature. The buffers and solutions used in the binding 
assays are listed in Table 2.3. The antibodies and lectins are listed in Table 2.4 and 
Table 2.5, respectively. 
 
2.11.1 Chromatogram-binding and dot-blot assays 
 
Mixtures of NGLs (~1 nmol of starting oligosaccharides) derived from 
oligosaccharides released from mucins, together with NGL standards (50-150 pmol) 
were applied onto a HPTLC plate. The plate was then developed in a suitable solvent 
(Table 2.1) and air-dried. The fluorescent AD-NGLs were visualized directly under UV 
light. If glycolipids or non-fluorescent DH- and AO-NGLs were included in the 
analysis, a duplicate plate was prepared for visualization by UV light after primulin 
staining of lipids. Thereafter, the plate was cut to a desired size (e.g. 3 × 3 cm) and 
immerged in plexigum solution for 1 min and air-dried. The plate was then soaked in 
3% BSA or casein blocking solution for 1 h followed by overlay with antibodies or 
biotinylated lectins for 2 h. For antibody binding, appropriate, biotinylated secondary 
antibodies (typically at 3 μg/ml) were used. The incubation time was 1 h. This was 
followed by incubation of streptavidin-peroxidase at 5 μg/ml. Plates for probing with 
biotinylated lectins were overlaid with streptavidin-peroxidase directly after the lectin 
binding. The binding signals were detected by 3,3‘-diaminobenzidine (DAB) liquid 
substrate system.  
 
For dot-blot assays, dilutions of glycoproteins (1 μl) were spotted directly onto a 
nitrocellulose membrane using an Eppendorf pipette. Purified glycolipids or NGLs 
(50-150 pmol) were applied as a mini-band using a Linomat IV TLC applicator 
(CAMAG). The nitrocellulose sheet was blocked with 3% BSA and the remaining 
procedures for detection binding were similar to these mentioned above.  
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2.11.2 Microwell-binding and inhibition assays 
 
PC3 cells were grown in 96-well microplates (Nunc MaxiSorp, Thermo Fisher 
Scientific). Thereafter the cells were fixed with 4% (w/v) paraformaldehyde in PBS 
and treated with MeOH containing 0.3% H2O2 overnight at 4 ˚C. Alternatively, the 
microwell plates were coated with PSM solution (0.5 μg/well) in PBS buffer by 
incubating overnight at 4 ˚C. After removal of the coating solutions, 3% BSA was 
added to each well and incubated for 1 h. This was followed by the addition of serial 
dilutions of mAb F77 or biotinylated lectins and further incubation for 2 h. To the wells 
with mAb F77, anti-mouse IgG (Fc specific) (1:2000) was added, followed by 
streptavidin-peroxidase polymer (2 μg/ml). To the wells with biotinylated lectins, 
streptavidin-peroxidase polymer was added directly. Colour development was using 
FAST OPD substrate (200 μl/well) and absorbance was read at 492 nm by plate 
reader. 
 
Inhibition of F77 binding was performed similarly. PC3 cells or PSM were in the 
microwells as described above. The F77 antibody at the indicated dilution was pre-
incubated with serially diluted oligosaccharides and the mixtures were added to each 
well after blocking with 3% BSA. The remaining procedures were the same as in the 
binding assays mentioned above. The results were expressed as percentage 
inhibition according to: 
[OD(without inhibitor) – OD(with inhibitor) / OD(without inhibitor) ] x 100 
 
2.11.3 Microarray analysis 
 
Four microarrays were used in this thesis. Three of them were prepared previously. A 
microarray of 492 sequence-defined oligosaccharide probes (319), designated 
Glycosciences Array Set 32-39 (Appendix S1) was used for screening analysis of 
mAbs F77 and AE3. The probes included were from the collection assembled in the 
course of research in Glycosciences Laboratory. These include a variety of 
mammalian type sequences, representative of N-glycans (high-mannose-type and 
neutral and sialylated complex-type), peripheral regions of O-glycans; blood group 
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antigen-related sequences (A, B, H, Lea, Leb, Lex, and Ley) on linear or branched 
backbones and their sialylated and/or sulphated analogues; linear and branched 
poly-N-acetyllactosamine sequences; gangliosides, oligosaccharide fragments of 
GAGs and polysialic acid. They also include microbial and plant-derived homo-
oligomers of glucose and of other monosaccharides. Two glycoprotein microarrays 
designated Mucin Array Set 1 and Mucin Array Set 2, (Table 3.1 and Table 4.2, 
respectively) were used for screening of mAb F77 and AE3 for binding. All the 
glycoproteins included are listed in Table 2.7 and the details of treatment are in 
Section 2.2.3. These glycoproteins were arrayed in duplicate at 30 and 150 pg per 
spot on nitrocellulose-coated glass slides (Grace Bio-Labs) using a noncontact 
robotic Piezorray arrayer (PerkinElmer LAS). Cy3 was included in each probe for 
spot localization and monitoring the arrayed spots. A new microarray (designated 
F77/Ii focused array) containing 54 lipid-linked oligosaccharide probes (Table 3.7) 
was generated during the studies of the F77 antigen. The probes were arrayed as 
described previously (354) at 2 and 5 fmol per spot in duplicate, with Cy3 included for 
localization and monitoring of arrayed spots. 
 
Microarray analyses were performed essentially as described (354). The arrayed 
slides were placed in a 16 pad silicon gasket and inserted into a FAST frame. To 
each pad of the slide, 3% BSA or casein was added and blocking was for 1 h. 
Thereafter the blocking reagents were removed and each pad was overlaid with 
antibodies of interest for 2 h. Antibody binding was detected using biotinylated 
secondary antibodies (typically at 3 μg/ml) followed by an Alexa Fluor-647-labelled 
streptavidin (Molecular Probes, 1 μg/ml). Binding by plant lectins was detected 
directly by Alexa Fluor-647-labelled streptavidin. The slides were thereafter scanned 
at 633 nm using a ProScanArray scanner (PerkinElmer LAS). Signals quantified with 
the scanner software. Microarray data were stored, analysed and presented using 
dedicated glycan array software developed by Mark Stoll of the Glycosciences 
Laboratory (325). Binding signals were related to dose of probe spotted; results 
presented are at 150 pg per spot for glycoproteins and 5 fmol per spot for lipid-linked 
probes. 
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Chapter 3  
CHARACTERIZATION OF THE PROSTATE 
CANCER-ASSOCIATED CARBOHYDRATE 
ANTIGEN F77 
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3.1 Introduction 
 
Prostate cancer is the second most common cancer and the fifth leading cause of 
death from cancer in males worldwide. It is estimated that 1.1 million men were 
diagnosed with prostate cancer and more than 0.3 million died of prostate cancer in 
2012 (355). In the UK, it is the most common cancer in men in 2011, accounting for 
25% cases of cancer in males (356). Prostate cancer incidence has increased in the 
UK and worldwide (355,356). This is partially due to the introduction and increasing 
usage of prostate-specific antigen (PSA) test. The crude 5-year survival rate of 
prostate cancer is 84.1%, but the 5-year survival rate for metastatic prostate cancer 
is only around 30% (356,357).  
 
As an existing serum biomarker, PSA has made great contributions to prostate 
cancer diagnosis and significantly reduced prostate cancer mortality because of 
better diagnosis (358). However, it has been found that the PSA test may give false-
positive and false-negative results. On the one hand, serum PSA level is elevated in 
some benign diseases such as prostatic hyperplasia and subclinical prostatic 
inflammation (359). On the other hand, although PSA level of 4 ng/ml or less is 
considered normal, many ‗normal‘ cases can still be determined as prostate cancer 
by biopsy detection (360). Reliable biomarkers for prostate cancer are therefore 
urgently needed for both diagnostic and prognostic purposes. 
 
Originally generated in 1984, mAb F77 (IgG3) was raised against the human prostate 
cancer cell line PC3 in the laboratory of Mark Greene (361). Recently the F77 
antigen was considered as a potential biomarker for human prostate cancer (341). It 
was detected on both androgen-independent (PC3-MM2, PC3 and Du145) and 
androgen-dependent (LNCap) human prostate cancer cell lines, with little or no 
detection on non-prostatic cell lines from lung, kidney or skin. The mAb F77 was 
found to label 112 of 116 primary and 29 of 34 metastatic cancer specimens but with 
only limited focal staining in benign prostate tissues. Minimal staining to a small 
fraction of small blood vessels in human brain was observed. No specific staining 
was detected on normal or tumour tissues of human colon, kidney, cervix, pancreas, 
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lung and skin (341). Thus it was concluded that the F77 antigen is highly restricted to 
the prostate and overexpressed in prostate cancer. 
 
In a nontumourigenic human prostate epithelial cell line RWPE-1, F77 antigen 
expression was associated with a small malignant subpopulation which led to 
tumours after being transplanted in nude mice. Transfection of the oncogene K-ras to 
RWPE-1 cells resulted in a more tumourigenic cell line RWPE-2, which had a higher 
F77 antigen level, grew faster and displayed enhanced colony-forming activity. 
 
In vitro studies showed that mAb F77 could directly promote PC3 cell death by 
apoptosis/necrosis process and it also mediated complement-dependent and 
antibody-dependent cell death of PC3 and Du145 cells. In vivo, treatment of mice 
bearing established prostate cancer xenografts with mAb F77 significantly inhibited 
the tumour growth, with no activity against an F77-negative xenograft. Altogether, 
these findings suggest that the F77 antigen is a novel, biologically important, 
clinically relevant prostate cancer-associated molecule. 
 
Efforts have been made to identify the nature of the antigenic determinant of mAb 
F77. Immuno-precipitation of PC3 cell extracts with mAb F77 followed by gradient 
SDS/ polyacrylamide gel electrophoresis (4-16%) revealed a significant band with 
MW <5 KD, which was not stained by Coomassie blue but only by carbohydrate 
staining (Figure 3.1A). A dose-dependent decrease of F77 antigen expression was 
observed on surface of PC3 and Du145 cells after treatment with the glycolipid 
synthase inhibitor 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol, but not with 
the protein N- and O-glycosylation inhibitors, tunicamycin and benzyl--GalNAc, 
respectively (Figure 3.1B). Indeed, the lipid extracts of PC3 and Du145 cells were 
bound by mAb F77, whereas lipid extracts from A431 and HEK293 cells lacked the 
activity (Figure 3.1C). Taken together, these data indicated that glycolipids were the 
main carriers of F77 antigen in PC3 cells, but the carbohydrate structure was not 
determined. 
 
This chapter is concerned with the characterization of the carbohydrate structure of 
the F77 antigen using a multifaceted approach. 
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Figure 3.1 F77 binds to a glycolipid antigen. (A) F77 Immunoprecipitation. Lane 1: PC3 + F77. Lane 2: A431 + 
F77. Lane 3: PC3 + control IgG.  Samples were separated by Tris SDS-PAGE (4-16%). Gel was first stained with 
Pro-Q Emerald 300 carbohydrate staining (left panel), and then stained with Coomassie blue (right panel). H and 
L indicate the position of heavy and light chains of mAb F77. (B) PPMP treatment. Anti-CD147 mAb 3B3 was 
used as a control. (C) Specific binding of mAb F77 to glycolipids extracted from PC3 and DU 145 but not from 
A431 or 293T cells. Glycolipids extracted by chloroform/methanol/water (5.4/10.8/6.5, v/v/v) were examined in 
ELISA assay with F77 antibody or a control antibody at 1 μg/ml. Taken from Zhang et al reference (341). 
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3.2 Microarray screening analysis of mAb F77 with 
sequence-defined oligosaccharide probes 
 
Here in the Glycosciences Laboratory, my colleague Dr. Yan Liu explored the 
carbohydrate sequence of the F77 antigen in microarray screening analysis of mAb 
F77 using an existing array of 492 sequence-defined oligosaccharide probes 
(Glycosciences Array Set 32-39, Appendix S1). Only two branched, poly-N-
acetyllactosamine-based, blood group B-related glycolipids BIII 
(dodecaglycosylceramide, probe 226) and BIV (tetradecaglycosylceramide, probe 
227) were revealed, in a strikingly selective manner (Figure 3.2). These two probes 
were also strongly bound by anti-blood group B, which proved their identity. In 
contrast, the unbranched blood group B-related hexaglycosylceramide (probe 147), 
although bound by anti-blood group B, gave no detectable binding signal with mAb 
F77, nor were binding signals detected with the branched B-like analogues lacking 
α1,2-fucose (probe 209) and the polyLacNAc based I-octaosylceramide (probe 205) 
lacking both α1,2-fucose and α1,3-galactose. Though at that stage the possibility 
could not be excluded that a minor component exists in these two glycolipids which 
was bound very strongly by mAb F77, the microarray results suggested the α1,2-
fucose present on the 6-branch is involved in the recognition of the antibody. As the 
branched blood group H and A analogues were not readily available for inclusion in 
the existing microarray, it was not possible to assign the epitope to a particular 
domain on the BIII and BIV glycolipids.  
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Figure 3.2 Microarray analyses of mAbs F77 and anti-B (89-F) with lipid-linked sequence-defined 
oligosaccharide probes. The results are the means of fluorescence intensities of duplicate spots, printed at 5 
fmol with error bars representing half of the difference between the two values. These 492 lipid linked probes 
(Glycosciences Laboratory Array Set 32-39) are arranged according to their backbone sequences as annotated in 
the coloured panels below the figure. The binding intensities are listed together with the probe sequences in 
Appendix S1. 
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3.3 Initial mAb F77 binding studies with a glycolipid extract 
from PC3 cells 
 
Initially, I analysed the antigenic activity of a glycolipid extract from PC3 cells (5×108). 
An aliquot of the extract was desalted using C18 cartridge, resolved by HPTLC and 
stained with primulin to detect the lipid moieties. Numerous primulin stained 
components were revealed (Figure 3.3). However, when mAb F77 was overlaid onto 
the PC3 glycolipid extract, only multiple minor components were detected and they 
did not correspond to the migration positions of any clearly primulin-stained 
components.  
 
These results suggest that the F77 antigen is strongly expressed on a series of 
glycolipids that are extremely minor cellular components. As glycolipids from PC3 cell 
extracts are limited in amount and not readily amenable to detailed characterization, 
these were not investigated further. Rather, I searched for abundant sources of F77 
antigen.  
 
 
Figure 3.3 Binding of mAb F77 to PC3 glycolipid extract resolved by HPTLC. The PC3 glycolipid extract was 
chromatographed on a silica gel HPTLC plate using the solvent CHCl3/MeOH/0.5M sodium acetate, 25:25:8 (v/v) 
and visualized with lipid stain primulin (left panel). Duplicate lanes were overlaid with mAb F77 (middle panel) or 
with the secondary antibody alone (right panel). Binding was visualized by colour development using the 
streptavidin-peroxidase followed by DAB liquid substrate system. O indicates the origin. 
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3.4 O-glycome designer array to detect and characterize 
the F77 antigen 
 
3.4.1 Identification of porcine stomach mucin (PSM) as a F77 
antigen-positive glycoprotein 
 
Given that O-glycans and glycolipids have glycan sequences in common, I performed 
an exploratory microarray analysis of mAb F77 (Section 2.11.3) using an array of 30 
preparations of mucin type glycoproteins (Mucin array Set 1, Table 3.1) in order to 
identify abundantly available F77 antigen-positive sources from which to isolate the 
antigen. Among the 30 mucin type glycoprotein preparations, blood group A, B or H 
antigen activities were detected by microarray analysis using anti-A, anti-B antibodies 
and the plant lectin UEA-I, respectively (Figure 3.4).  
 
The strongest F77 binding activity was with PSM (glycoprotein 29). Little or no 
binding of mAb F77 was detected to the other human glycoproteins included in the 
array. As predicted from the classical work with PSM (362), strong binding signals 
were elicited with PSM using anti-A and UEA-I, corresponding to blood group A and 
H antigen activities, respectively. Blood group B activity was not detected on PSM. 
Four strongly B-active glycoproteins (glycoproteins 18, 22, 23 and 27) were only very 
weakly bound by mAb F77, indicating that the blood group B trisaccharide 
determinant per se is not an essential part of the F77 antigen. Two glycoproteins (10 
and 21), which were strongly A-active and relatively weakly H-active compared with 
PSM, gave no binding signals with mAb F77. Collectively, these results suggested 
that mAb F77 bound to a blood group H-related structural motif present on PSM. 
Therefore, PSM was selected for further investigation by the glycome designer array 
approach. 
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Table 3.1 Mucin-type epithelial glycoproteins arrayed in Mucin array Set 1. 
Position Designation 
Donor red cell 
blood-group  
Secretor status 
 Enriched cystadenoma glycoproteins 
1 Cys 350 (Trp)* A1 Non-secretor 
2 Cys 444 (Trp) Unknown Non-secretor 
3 Cys 444 (Pro) Unknown Non-secretor 
4 Cys 446 (Pro) B Non-secretor 
5 Cys 461 (Trp) Unknown Non-secretor 
6 Cys 461 (Pro) Unknown Non-secretor 
7 Cys 654 (Pro) B Non-secretor 
8 Cys 705 (Pro) Unknown Non-secretor 
9 Cys 717 (Pro) A1 Non-secretor 
10 Cys 733 (Pro) A1 Secretor 
11  Cys 745 (Pro) A Non-secretor 
12 Cys 754 (Pro) Unknown Non-secretor 
13 Cys 756 (Trp) A Non-secretor 
14 Cys 756 (Pro) A Non-secretor 
15 Cys 762 (Trp) O Non-secretor 
16 Cys 762 (Pro) O Non-secretor 
17 Cys 765 (Pro) O Non-secretor 
    
 Meconia   
18 Meconium B (Pro) B Unknown  
19 Meconium Mo (Pro) Unknown Unknown 
20 Meconium Wo (Pro) Unknown Unknown 
21 Meconium He (Pro) Unknown Unknown 
22 Meconium Pa (Pro) Unknown Unknown 
    
 Purified cystadenoma glycoproteins 
23 B substance (Pro) B Secretor 
24 Og 10% 2x (Pep) Unknown Non-secretor 
25 Og 10% from 20% (Pep) Unknown Non-secretor 
26 N1 20% (Pep) Unknown Non-secretor 
27 Tij 10% 2x (Pep) B Secretor 
    
 Other glycoproteins    
28 HCA Unknown  Unknown 
29 Porcine gastric mucin  A+H (Sigma) 
30 Bovine submaxillary mucin Unknown (Sigma) 
Details for the enrichment procedures for the mucin preparations 1-27 from the lyophilised powders and of sample 
28 are given in Section 2.2.3. Samples 29 to 30 were commercial samples. 
 *Trp, Pro and Pep refer to proteases, pronase, trypsin or pepsin, used in the process of solubilizing the mucins.  
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Figure 3.4 Microarray analyses of mAbs F77, anti-B (89-F), anti-A (T36), and UEA-I lectin with mucin type 
glycoproteins. The descriptions of the glycoproteins are in Table 3.1. Results are the means of fluorescence 
intensities of duplicate spots printed at 150 pg glycoprotein per spot. The error bars represent half of the 
difference between the two values. 
 
3.4.2 Detection of F77 antigen activity among non-reductively 
released O-glycans from PSM 
 
In order to investigate the F77 antigen sequence expressed on PSM, I performed 
antigenic analysis with the reducing O-glycans released from PSM. With the help of 
our collaborators at Ludger (Oxford), PSM (50 mg) was subjected to non-reductive O-
glycan release by hydrazinolosis (Section 2.4).  
 
With the products obtained from hydrazinolosis of PSM, I first performed anion-
exchange chromatography to separate the neutral oligosaccharides from the acidic 
as described in Section 2.5.1. As the results of microarray screening analysis with 
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sequence-defined glycans suggested that the F77 antigen is expressed on neutral 
oligosaccharides, the neutral fraction was investigated further. 
 
Fluorescent AD-NGLs were prepared with the neutral reducing O-glycans using 
ADHP as the lipid reagent (Section 2.6.1.1). After removal of excess lipid, the NGLs 
were analysed by MALDI-MS (Table 3.2). The monosaccharide compositions (in 
terms of dHex, Hex and HexNAc) of the major components were deduced based on 
their molecular ions. The results indicated that there are in total 25 glycan species 
corresponding to O-glycans ranging from di- to nona-saccharide. Three of these 
glycans (labelled p) in Table 3.2 are most likely products of alkaline catalysed 
degradation (peeling).   
 
Table 3.2 MALDI-MS of the NGLs of O-glycans non-reductively released from PSM. Monosaccharide 
compositions of were deduced from MALDI-MS analysis. P refers to possible peeled O-glycan. 
 [M-H]
-
 Monosaccharide Compositions 
1219 dHex1.Hex1
p
 
1276 Hex1.HexNAc1 
1318 HexNAc2 
1479 Hex1.HexNAc2 
1422 dHex1.Hex1.HexNAc1 
1439 Hex2.HexNAc1
p
 
1585 dHex1.Hex2.HexNAc1 
1627 dHex1.Hex1.HexNAc2 
1642 Hex2.HexNAc2 
1682 Hex1.HexNAc3 
1723 HexNAc4
p
 
1787 dHex1.Hex2.HexNAc2 
1828 dHex1.Hex1.HexNAc3 
1845 Hex2.HexNAc3 
1950 dHex1.Hex3.HexNAc2 
1991 dHex1.Hex2.HexNAc3 
2007 Hex3.HexNAc3 
2048 Hex2.HexNAc4 
2096 dHex2.Hex3.HexNAc2 
2153 dHex1.Hex3.HexNAc3 
2194 dHex1.Hex2.HexNAc4 
2221 Hex3.HexNAc4 
2299 dHex2.Hex3.HexNAc3 
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2356 dHex1.Hex3.HexNAc4 
2502 dHex2.Hex3.HexNAc4 
Abbreviations: dHex, deoxyhexose; Hex, hexose; HexNAc, N-acetylhexosamine 
 
F77 antigenic analysis was carried out on HPTLC with mAb F77 using 1 nmol of the 
starting O-glycans. Although multiple fluorescent NGL bands were resolved on the 
plate and revealed by UV light (Figure 3.5A), no antigen-positive band was detected 
(not shown). The total NGL products were thereafter fractionated into four 
subfractions a-d (Figure 3.5A) by preparative HPTLC so that larger amounts of NGLs 
could be applied to detect any very minor antigen-positive components. Higher 
amounts of subfractions c and d, 10 and 20 nmols, respectively, were subjected to 
chromatogram binding assay with mAb F77 (Figure 3.5B). A smear of weak 
immunostaining was detected in faction d, in a slow migrating region. Similar to the 
glycolipid extracts of PC3 cells, the F77 antigen-positive oligosaccharides were 
extremely minor and heterogeneous. 
 
 
Figure 3.5 F77 antigenic analyses with NGLs derived from O-glycans non-reductively released from PSM. 
(A). HPTLC analysis of the total NGLs derived from O-glycans non-reductively released from PSM. a to d indicate 
the four subfractions collected from prep-TLC. (B). Binding analysis with mAb F77 of the NGLs in subfractions c 
and d. The TLC plates were developed using CHCl3/MeOH/H2O, 60:35:8 (v/v), as solvent. The fluorescent NGLs 
were visualized under UV light and binding by mAb F77 was detected as in the legend to Figure 3.3. O indicates 
the origin. 
 
It would be extremely difficult to isolate the F77 antigen-positive components from 
this minor, and highly heterogeneous population of O-glycans. Therefore an 
alternative approach was made to identifying the F77 antigenic components as 
described in the sections that follow. 
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3.4.3 Detection of F77 antigen activity among reductively released 
O-glycans from PSM 
 
O-glycans were released by reductive alkaline borohydride degradation from 800 mg 
PSM. The reduced oligosaccharides (alditols) were enriched from the reaction 
mixture as described in Section 2.3. These were quantified by hexose assay: total 
hexose content was 15 mg. The products were thereafter fractionated by size using 
Bio-Gel P4 (Figure 3.6A). Six fractions a to f were collected based on the elution 
profile. MALDI-MS analysis indicated the major components of fractions b to d were 
small oligosaccharides mono- to tri-saccharides. Orcinol assay showed fractions e to 
f did not contain oligosaccharides (not shown). 
 
 
Figure 3.6 Gel filtration chromatography of the products of reductive alkaline hydrolysis from PSM. (A) 
Initial chromatography profile using a Bio-Gel P4 column (1.6×90cm) eluted with H2O. (B) Rechromatogrph of 
fraction a in panel (A) using a Bio-Gel P6 column (1.6×90cm) eluted with H2O. V0 is the void volume of the column; 
Vt is the total volume; glucose units 1-11 indicate positions of elution of oligosaccharides with degrees of 
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polymerization 1-11 in an acid hydrolysate of dextran. a to f and F1 to F7 designate the pooled fractions in each 
preparation. 
 
Elutions between 4.5-8 h on the Bio-Gel P4 column were pooled as fraction a. The 
major components in a ranged from tetra- to tridecasccharide. This fraction was 
subjected to further Bio-Gel P6 fractionation. Seven fractions (F1 to F7) were 
harvested from Bio-Gel P6 (Figure 3.6B) and analysed by MALDI-MS. The 
monosaccharide compositions of the major components in each fraction are deduced 
and listed in Table 3.3. There are in total 43 glycan species with various 
compositions. The two peaks to the left of F1 gave no detectable orcinol but strong 
ninhydrin staining signals, suggesting these peaks were dominated by peptides. F1 
contained a small amount of oligosaccharides larger than undecasaccharides; 
fractions 2-5 contained hepta- to nona-saccharides; fractions 6-7 contained penta- to 
hexa-saccharides, as indicated by MALDI-MS profiling. 
 
Table 3.3 Compositions of the reductively released O-glycan alditols in the Bio-Gel P6 fractions 1-7, 
deduced from MALDI-MS analysis. 
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Abbreviations: dHex, deoxyhexose; Hex, hexose; HexNAc, N-acetylhexosamine, HexNAcol, N-
acetylhexosaminitol. 
 
Fluorescent NGLs were prepared from fractions 1 to 7 after mild periodate oxidation 
using ADHP as the lipid reagent as in Section 2.6.1.2. The periodate oxidation results 
in the splitting of  each O-glycan alditol at the core GalNAcol into two fragments and 
each is converted into an NGL (Figure 3.7). The NGLs derived from the 3-linked 
branches are designated –OX (OX: -OCH2-CH(NHAc)-CH2OH-CH2-ADHP). Those 
derived from the 6-linked branches are designated –OY (OY: -OCH2-CH2-ADHP). 
Monosaccharide compositions of the resulting NGLs were deduced by MALDI-MS 
(Table 3.4). In total 29 NGL species with different compositions were detected in 
these seven fractions. Clearly a substantial number of species were shared in many 
fractions as different parent oligosaccharides can have the same 3- or 6-fragment 
after periodate oxidation. 
 
As a result of the cleavage of the core GalNAcol, the glycans in the NGLs 
represented branches of the parent oligosaccharide. For example, the major 
components of fraction 4 among the parent oligosaccharides were hepta- to octa-
saccharide alditols (Table 3.3), whereas the NGL components were di- to hepta-
saccharides derived from the 3-linked branches (-OX) and mono- to tetra-
saccharides from the 6-linked branches (-OY) as shown in Table 3.4.  
 
 115 
 
 
Figure 3.7 Reaction scheme of periodate oxidation cleavage and conjugation to the ADHP lipid (363). The 
sugar ring splits between C4 and C5 of the core GalNAc, yielding 3- and 6-linked fragments. The NGL that 
derives from the 3-linked fragment is designated 3-OX. The other, which derives from the 6-linked fragment, is 
designated 6-OY.  
 
Table 3.4 Compositions of the NGLs derived from the O-glycan alditols in Bio-Gel P6 fractions 1-7, 
deduced from MALDI-MS analysis. 
 
Abbreviations: dHex, deoxyhexose; Hex, hexose; HexNAc, N-acetylhexosamine, HexNAcol, N-
acetylhexosaminitol. –OX and –OY are the 3- and 6- linked fragments of core GalNAc after periodate oxidation as 
further explained in Figure 3.7. 
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The NGLs in each fraction were first resolved by HPTLC, visualized by UV light, and 
then probed for binding by mAb F77 (Figure 3.8). In each fraction, UV detection 
revealed numerous fluorescent bands. Many discrete F77-positive bands were 
detected in the middle migrating area in fractions 1, 3, 4 and 5. F77 binding was also 
detected to the slow migrating area in fractions 1-3. None of these were bound by 
IgG3 control, which revealed binding to the fast migrating region. The F77 antigen-
positive bands did not correspond with the major fluorescent components, suggesting 
that mAb F77 binding was to minor components among the large number of 
heterogeneous components. 
 
 
Figure 3.8 Chromatogram binding of mAb F77 to NGLs derived from the O-glycan alditols in fractions 1–7. 
The NGLs derived from the O-glycan alditols in fractions 1–7 were chromatographed on HPTLC plates, using 
CHCl3/MeOH/H2O, 60:35:8 (v/v), as solvent. The fluorescent NGLs were visualized under UV light (left panel). 
The same plate and a duplicate plate were incubated with mAb F77 (middle panel) and the isotype IgG3 control, 
MG3-35 (right panel), followed by biotinylated anti-mouse immunoglobulins. Binding was detected as in Figure 3.3. 
O indicates the origin. 
 
3.4.4 Attempts to enrich the F77 antigen-positive O-glycan alditols 
by affinity chromatography 
 
As results so far indicated that the F77 antigen is expressed only on minor 
components among O-glycans released from PSM, an attempt was made to enrich 
the F77 antigen-positive O-glycans in fraction 3 (PSMF3) by affinity chromatography 
using an anti-H specific lectin UEA-I and the F77 antibody as absorbents. Below I 
summarize the results. 
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UEA-I affinity chromatography was initially investigated. This is because the F77 
antigen-positive motif on O-glycans of PSM was proposed to be a blood group H 
sequence from the results of the initial screening analysis with oligosaccharide 
microarray (Figure 3.2) and glycoprotein array (Figure 3.4). After application of the O-
glycan alditols of fraction 3 (Figure 3.6) onto the column, a retarded peak was 
observed by refractive index detection (Figure 3.9A). Two fall-through fractions (a 
and b) and three retarded fractions (c to e) were obtained. Elution was with 10 mM, 
30 mM and 50 mM Fuc stepwise and three fractions f to h, were collected. The two 
fall-through fractions were later combined; the oligosaccharides in these seven 
fractions (a+b, c to h) were converted to NGLs for probing with mAb F77.  
 
By UV detection multiple fluorescent bands were revealed in fractions a+b and c to f, 
indicating the presence of heterogeneous NGLs in these NGL subfractions (Figure 
3.9B). Very weak fluorescent bands were detected in the NGLs derived from 
fractions g and h, indicating that the amounts of oligosaccharides tightly bound and 
eluted from the UEA-I column were limited. F77 antigen activity was restricted mainly 
to the middle- and slow-migrating area of fractions e-g (Figure 3.9D) and correlated 
with blood group H type 2 activities, as shown by binding of UEA-I (Figure 3.9E). 
Clearly the column had a relatively low capacity as the H type 2 activity was also 
detected in the fall-through fraction a+b and the retarded fractions c and d. In addition, 
the separation of the retarded fractions from the fall-through was not complete. 
Therefore this approach was not pursued further. 
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Figure 3.9 Affinity chromatography to enrich F77 antigen-positive O-glycan alditols from PSMF3 using 
UEA-I column. (A) Refractive index detection of the affinity chromatography using an UEA-I column (1.6×5cm). a 
to h are the fractions collected. Arrows indicate the time points changing the elution buffer. (B) TLC analysis of the 
NGLs derived from O-glycan alditols of the seven subfractions, a+b and c to h, revealed by UV light. (C-E) 
Chromatogram binding analysis of the IgG3 control, MG3-35 (C), mAb F77 (D), and UEA-I (E) on replicate TLC 
plates to panel (B). The fluorescent NGLs derived from the O-glycans in the seven subfractions of PSMF3 and 
the unfractionated F3 were chromatographed using CHCl3/MeOH/H2O, 60:35:8 (v/v), as solvent, visualized by UV 
light. Binding was detected as described in Figure 3.8. O indicates the origin. 
 
Enrichment of F77 antigen-positive O-glycans was then attempted using the F77 
affinity column. The procedures are described in Section 2.5.3 and the workflow is in 
Figure 3.10A. In total, five fractions were obtained and NGLs were generated (Figure 
3.10B) with the O-glycans in these fractions. Surprisingly, except for the second 
eluent A2E, the fractions all contained F77 antigen-positive components (Figure 
3.10C) and the binding patterns of these fractions were very similar to that observed 
with the starting material F3. These binding data indicated that the F77 affinity 
column had a very small capacity and could not be exploited for antigen enrichment.  
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Figure 3.10 Affinity chromatography to enrich the F77 antigen-positive O-glycan alditols from PSMF3 
using F77 antibody column. (A) Workflow of the F77 affinity chromatography. In total, five fractions were 
obtained, A1W, A1E, A2F, A2W and A2E. (B) TLC analysis of the NGLs derived from O-glycan alditols of the five 
subfractions in (A), revealed by UV light. (C-D) Chromatogram bindings of mAb F77 (C) and the IgG3 control (D) 
on replicate TLC plates to panel (B). The fluorescent NGLs derived from the O-glycan alditols in the five 
subfractions of F3 and the unfractionated F3 were chromatographed, visualized and detected as described in 
Figure 3.8. O indicates the origin. 
 
In summary, although affinity chromatography of the O-glycans in fraction 3 with 
UEA-I or F77 showed fractionation to some extent, the limited capacities of the UEA-I 
and F77 columns precluded their application to the F77 antigen enrichment. 
Therefore other avenues were explored. 
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3.4.5 Separation of a F77 antigen-positive NGL by preparative TLC 
and HPLC 
 
Separation of the F77 antigen-positive NGL component was then attempted by 
combined preparative TLC and HPLC (Section 2.7). For this, the NGLs in fraction 4 
were resolved by semi-preparative TLC (Figure 3.11A) and the region designated 4M 
which includes the F77 antigen-positive component was harvested. The NGLs in 4M 
were resolved by HPLC (Figure 3.11B). Eight subfractions 4M-a to -h were obtained. 
F77 activity in each fraction was monitored using chromatogram-binding assays.  
One of the subfractions 4M-f was found to be F77-positive. The F77 antigen activity 
was detected in the top (4M-f1) of the triplex bands resolved by HPTLC (inset Figure 
3.11B). The other HPLC fractions were F77 antigen-negative (not shown). Attempts 
to isolate the F77 antigen-positive component in subfraction 4M-f by a repeated 
HPLC were unsuccessful (data not shown). However, 4M-f could be well resolved 
into three bands by semi-preparative HPTLC (Figure 3.11C); and subfractions 4M-f1 
to -f3 were harvested. 
 
 
Figure 3.11 Isolation of a F77 antigen-positive component in fraction 4 of PSM O-glycans. (A). 
Chromatography of NGLs prepared from fraction 4 (Figure 3.8) on HPTLC plates. Three fractions (upper 4U, 
middle 4M and lower 4L) were harvested. O indicates origin. (B). Separation of fraction 4M into eight subfractions 
(a-h) by HPLC. Inset shows binding of mAb F77 to the upper band in subfraction 4M-f (designated 4M-f1). (C). 
Resolution of subfraction 4M-f by HPTLC. Three bands 4M-f1 to 4M-f3 were harvested. O indicates origin. All the 
HPTLC plates were chromatographed, visualized and detected as described in Figure 3.8. 
 
3.4.6 Assignment of the sequence of the F77 antigen-positive NGL 
 
NGL subfractions 4M-f1 to -f3 were analysed by negative-ion MALDI-MS (Figure 
3.12). Subfraction 4M-f1 gave a [M-H]- at m/z 2033, corresponding to the NGL of a 6-
linked branch with a composition dHex1Hex2HexNAc3-OY (Figure 3.12A). Subfraction 
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4M-f2 contained two components, which gave [M-H]- at m/z 2240 and m/z 2297, 
corresponding to NGLs of 3-linked branches with compositions dHex2Hex3HexNAc2-
OX and dHex1Hex3HexNAc3-OX, respectively (Figure 3.12B). The components in 
subfraction 4M-f3 gave [M-H]- ions at m/z 2094 and 2297 corresponding to 
dHex1Hex3HexNAc2-OX and dHex1Hex3HexNAc3-OX, respectively (Figure 3.12C).  
 
In order to assign the oligosaccharide sequence of the F77 antigen-positive 4M-f1, 
MALDI-CID-MS/MS was performed (Section 2.9). The fragmentation pattern is shown 
in Figure 3.13. The oligosaccharide sequence was deduced based on the 
fragmentation pattern. Neutral loss of 146 Da from [M-H]- (m/z 2033) corresponded to 
the loss of dHex (-dHex). Similarly, loss of 162 Da from the fragment m/z 1887 and 
203 from m/z 1725 correlated with the loss of Hex (-Hex) and HexNAc (-HexNAc), 
respectively. The large gap (365 Da) between m/z 1522 and 1157 corresponded to 
the loss of Hex.HexNAc, indicating the branching point as shown in the structure. 
After further loss of HexNAc (-HexNAc from m/z 1157), the fragment ion at m/z 954 
was assigned to 6-linked fragment linked to ADHP (-OY). From information above, a 
dHex-Hex-HexNAc-Hex-HexNAc-OY sequence can be deduced. The fragment at 
m/z 1830 with a neutral loss of 203 Da from [M-H]- indicated the presence of a 
HexNAc branch. Taken together, the deduced sequence is clearly identified as an 
NGL derived from the 6-linked branch of the GalNAcol core with the hexasaccharide 
sequence shown in Figure 3.13. 
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Figure 3.12 Negative-ion MALDI-MS analysis of the fraction 4M-f1 (A), 4M-f2 (B) and 4M-f3 (C). The 
deduced monosaccharide compositions were shown in each spectrum. dHex, deoxyhexose; Hex, hexose; 
HexNAc, N-acetetylhexosamine; OY and OX, 6- and 3-linked fragment of core GalNAc after periodate oxidation 
as described in Figure 3.8. OY: -OCH2-CH2-ADHP. OX: -OCH2-CH(NHAc)-CH2OH-CH2-ADHP (304). 
 
 
Figure 3.13 MALDI-CID-MS/MS analysis and the proposed sequence of the F77-positive 4M-f1. 
Abbreviations are as in legend to Figure 3.12. 
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Considering the origin of 4M-f1 is blood group H and A-active PSM, it is reasonable 
to predict that the component is a branched blood group H related structure. Indeed, 
when 4M-f1 was treated with α1-2 fucosidase as shown in Section 2.10, the [M+H]+ 
shifted from m/z at 2035 to 1889 (Figure 3.14). The 146 Da loss from the parent NGL 
4M-f1 confirms the presence of a α1,2-linked, blood group fucose. 
 
 
Figure 3.14 MALDI-MS analysis of NGL 4M-f1 before (A) and after (B) treatment with α1-2 fucosidase. The 
change in molecular ion [MH]
+
 from m/z 2035 (A) to 1889 (B) indicated the capping sequence Fucα1-2Gal in 4M-
f1. Abbreviations are as in legend to Figure 3.12. 
 
In separate experiments (microarray analyses) described in Section 3.6, 4M-f1 was 
shown to be bound by UEA-I, but not anti-H type 1. Taking into account the F77 
antigen activity of the branched blood group B glycolipid (BIII), the proposed 
oligosaccharide sequence of 4M-f1 is that of a blood group H on a branched, poly-
LacNAc backbone (289), originating from the 6-branch of the core GalNAcol as 
depicted below. 
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Thus we can deduce that the parent O-glycan alditol before periodate oxidation is at 
least the octasaccharide as shown below. 
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3.5 Investigation of F77 antigen expression on blood group 
H-, A- and B-active sequences 
 
Having identified the red cell-derived branched blood group B glycolipids BIII and BIV， 
and the mucin-derived branched blood group H-related O-glycan sequence (Section 
3.4.6) as being bound by mAb F77, the question arose as to whether a branched 
blood group A analogue would also be bound by the antibody. If they were, it would 
be desirable to compare the antigenic activities of blood group H, A and B sequences. 
 
To address this, I performed antigenic analyses with some linear and the branched 
blood group A and H glycolipids, also inhibition assays using the free 
oligosaccharides.  
 
3.5.1 Chromatogram-binding analyses with linear and branched 
blood group H and A glycolipids 
 
As the branched blood group H and A glycolipids were not present in the initial 
screening array (Appendix S1), we requested some preparations of the desired 
glycolipids from Dr. Michiko Fukuda at Sanford-Burnham Medical Research Institute. 
HPTLC and primulin analysis showed that each of these preparations from Dr 
Fukuda‘s archival collection contained multiple components (data not shown). To 
isolate the targeted glycolipids, I performed extensive purifications by HPTLC with 
monitoring by help of MALDI-MS analysis. Finally four human red cell-derived 
glycolipids were isolate: linear and branched blood group H, designated H2 and H3, 
respectively and linear and branched blood group A, designated Ab and Ad, 
respectively (Table 3.5). 
 
The four glycolipid preparations Ab, Ad, H2 and H3 were resolved on an HPTLC plate 
and visualized by primulin (Figure 3.15A). Duplicate plates were probed for binding 
by mAb F77 (Figure 3.15B) and anti-H type 2 (Figure 3.15C). The branched H3 and 
Ad but not the linear H2 or Ab were bound by mAb F77. The anti-H type 2 antibody 
bound to both H2 and H3 but not to Ab and Ad, thus ruling out the presence of minor 
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H contaminants in the preparations of Ab and Ad. Collectively the results above 
showed that the mAb F77 recognizes the blood group H sequence on a 6-branched 
backbone but can also accommodate an additional α1,3-linked GalNAc or Gal, which 
constitute the blood group A or B analogues, respectively. These results, together 
with those obtained from the initial microarray analyses, were summarized in Table 
3.5. 
 
 
Figure 3.15 Chromatogram binding with mAbs F77 and anti-H type 2 to the four human blood group H- 
and A-derived glycolipids H2, H3, Ab, and Ad. (A). The four blood group H and A glycolipids were resolved by 
HPTLC and revealed by primulin staining for lipid. (B). Binding analysis of mAb F77 on a replicate TLC plate to 
(A). (C). Binding analysis of mAb anti-H type 2 on a replicate TLC plate to A. Solvent used for development was 
CHCl3/MeOH/H2O, 60:35:8 (v/v). O indicates the origin. Binding was detected as described in the legends to 
Figure 3.3.  
 
Table 3.5 Blood group H-, A- and B-active and B-like glycosylceramides and their binding activities with 
mAb F77. 
Designation Carbohydrate sequence 
mAb F77 
binding 
H
2
* 
                                                                        Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                                                        │  
                                             Galβ-4GlcNAcβ-3  
                                             │ 
                                   Fucα-2 
 
H
3
ǂ
 
                                              Galβ-4GlcNAcβ-6  
                                              │                         │ 
                                    Fucα-2                         Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                                                         │  
                                              Galβ-4GlcNAcβ-3  
                                              │ 
                                    Fucα-2 
+ 
Ab* 
                                                                        Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                                                        │  
                           GalNAcα-3Galβ-4GlcNAcβ-3  
                                              │ 
                                    Fucα-2 
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Ad 
                             GalNAcα-3Galβ-4GlcNAcβ-6  
                                              │                         │ 
                                    Fucα-2                         Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                                                         │  
GalNAcα-3Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3  
                   │ 
         Fucα-2 
+ 
B-hexa- 
                                                                         Galβ-4Glc-Cer 
                                                                         │  
                                   Galα-3Galβ-4GlcNAcβ-3  
                                               │ 
                                     Fucα-2 
 § 
BIII 
                                   Galα-3Galβ-4GlcNAcβ-6  
                                               │                        │ 
                                     Fucα-2                        Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                                                         │  
                                   Galα-3Galβ-4GlcNAcβ-3  
                                               │ 
                                     Fucα-2 
+§ 
BIV 
                                   Galα-3Galβ-4GlcNAcβ-6  
                                              │                        │ 
                                     Fucα-2                       Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                                                        │  
      Galα-3Galβ-4GlcNAcβ-3Galβ-4GlcNAcβ-3  
                  │ 
        Fucα-2 
+§ 
B-like deca- 
                                  Galα-3Galβ-4GlcNAcβ-6  
                                                                        │ 
                                                                       Galβ-4GlcNAcβ-3Galβ-4Glc-Cer 
                                                                        │  
                                  Galα-3Galβ-4GlcNAcβ-3  
 § 
*The asterisked glycolipid preparations contain a minor component with an additional fucose residue detected by 
MALDI-MS; most likely part of di-fucosylated Le
y 
sequence. 
ǂ 
The glycolipid H3 contains a minor component lacking one fucose residue detected by MALDI-MS.   
§
These results were from the screening array analysis in Figure 3.2. 
 
3.5.2 Inhibition assays with synthetic linear blood group A, B and O 
(H) oligosaccharides 
 
It is desirable to corroborate the mAb F77 binding by other methods, e.g. inhibition 
assays. Unfortunately, only short and unbranched blood group-containing analogues 
were available in sufficient amounts. These were type 2-based blood group H, A, B, 
Lex and Ley-containing tetra- or pentasaccharides (Table 3.6). Although in direct 
binding assays, such as microarray analysis, the NGL derivatives of these short and 
unbranched oligosaccharides gave no binding signals (Appendix S1), it was 
considered possible that they could inhibit mAb F77 binding at high concentrations. 
Their inhibitory activities were tested in binding assays using PC3 cells and PSM as 
the reference immobilized substrates (Section 2.11.2).  
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When a monolayer of PC3 cells was immobilized on a microwell plate as substrate, 
mAb F77 showed good binding signals at concentrations between 3×10-3 and 3 μg/ml 
(Figure 3.16A). A concentration of 0.03 μg/ml of the antibody was selected for 
inhibition assays. At millimolar concentrations of oligosaccharide inhibitors, partial 
inhibitory activity (~50% inhibition) was recorded with blood group H sequence, H-
tetra-T2, but not with the blood group A, B, Lex and Ley analogues (Figure 3.16B).  
 
Table 3.6 Oligosaccharides included in the inhibition assays. 
Designation Carbohydrate sequence 
H-tetra-T2 
                           Galβ-4GlcNAcβ-3Gal 
                           │ 
                  Fucα-2 
A-penta-T2 
         GalNAcα-3Galβ-4GlcNAcβ-3Gal 
                           │ 
                  Fucα-2 
B-penta-T2 
                Galα-3Galβ-4GlcNAcβ-3Gal 
                           │ 
                  Fucα-2 
Le
X
-tetra 
                           Galβ-4GlcNAcβ-3Gal 
                                        │ 
                               Fucα-3 
Le
Y
-penta 
                           Galβ-4GlcNAcβ-3Gal 
                           │           │ 
                  Fucα-2 Fucα-3 
 
 
Figure 3.16 ELISA binding assays of mAb F77 to PC3 cells and inhibition of binding by short unbranched 
blood group oligosaccharides. (A). ELISA binding analysis of mAb F77 to PC3 cells. Arrow indicates the 
concentration of antibody used for inhibition assays. (B). Inhibition of mAb F77 binding to PC3 cells by the five 
oligosaccharides H-tetra-T2, A-penta-T2, B-penta-T2, Le
x
-tetra and Le
y
-penta. PC3 cells were grown in 96-well 
plates and reacted with mAb F77, with/without the presence of oligosaccharides between 3-10 mM, followed by 
incubation of biotinylated anti-mIgG and streptavidin-peroxidase polymer. Binding was detected using FAST OPD 
substrate. 
 
When the A+H-active PSM was used as the immobilized substrate, mAb F77 binding 
was detected from 1×10-3 to 0.1 μg/ml (Figure 3.17A). A concentration of 0.01 μg/ml 
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was selected for inhibition assays. H, A and B oligosaccharides were almost equal 
potent in inhibiting binding of mAb F77 at high millimolar levels of inhibitors (Figure 
3.17B).  
 
 
Figure 3.17 ELISA binding assays of mAb F77 to A+H antigen-positive PSM and inhibition of binding by 
short unbranched blood group oligosaccharides. (A). ELISA binding analysis of mAb F77 to PSM. Arrow 
indicates the concentration of antibody used for inhibition assays. (B). Inhibition of mAb F77 binding to PSM by 
the five oligosaccharides H-tetra-T2, A-penta-T2, B-penta-T2, Le
x
-tetra and Le
y
-penta. PSM was added in 96-well 
plates and reacted with mAb F77, with/without the presence of oligosaccharides between 3-10 mM. Binding was 
detected as described in the legend to Figure 3.16. 
 
Thus when A+H active PSM was immobilized, H, A and B oligosaccharides were 
equally active as inhibitors, whereas when PC3 cells were used, the inhibitory activity 
of H oligosaccharide was stronger than the A and B analogues. In subsequent ELISA 
binding analysis, we found that the PC3 cells only express H antigen but lack of A 
and B antigens (Figure 3.18). It is likely that the abundant H antigen expression on 
PC3 cells made the H sequence a better inhibitor than the A and B analogues. 
Collectively, these results corroborate the ability of mAb F77 to accommodate the 
three blood group antigens but with a preference for the H analogue. 
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Figure 3.18 ELISA binding assays of UEA-I, anti-A and anti-B to PC3 cells. The PC3 cells were incubated 
with mAbs anti-A (dilutions between 1:10
6
 and 1:100) or anti-B (10
-3
-10 μg/ml), or biotinylated UEA-I (0.05-50 
μg/ml), followed biotinylated secondary antibody and streptavidin-peroxidase polymer (for mAbs), or streptavidin-
peroxidase polymer alone (for UEA-I). Binding was detected using FAST OPD substrate.  
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3.6 Further investigation of mAb F77 specificity using a 
focused glycan array 
 
In order to complement the initial screening microarray analyses, a focused 
microarray (F77/Ii focused array) was assembled (Table 3.7). This included the 
aforementioned glycan probes with blood group A, B and H activities based on linear 
and branched poly-LacNAc sequences: H2, H3, Ab, Ad, BIII and BIV, and PSM-4M-f1 
(probes 3, 7, 10, 12, 16, 17 and 18). The microarray also included twelve additional 
probes of the blood group H, A, B and Ley series with type 1 and/or type 2 backbones 
(probes 1, 2, 4-6, 8-9, 11, 13-15 and 26). Other probes including selected Lewis 
antigen-containing sequences (probes 19-25), and linear and branched type 1 and/or 
type 2 backbone sequences (probes 27-54) were arrayed as well to further 
investigate the F77 binding specificity.  
 
The mAb F77, together with UEA-I and mAbs anti-A, anti-B and anti-H type 1 were 
used to probe with the focused microarray (Figure 3.19). F77 binding was clearly 
restricted to the blood group H-, A- and B-active sequences with branched type 2 
backbones. These included H3 (probe 7), Ad (probe 12), BIII and BIV (probes 16 and 
17) and the O-glycan-derived NGL PSM-4M-f1 (probe 18). Signals elicited by BIII 
and BIV were lower than with the two blood group H sequences H3 and PSM-4M-f1, 
and the signal with Ad was even lower. The unbranched blood group H (probes 1-3), 
A (probes 8-10) and B (probes 13-14), A-Lea (probe 11) and B-Ley (probe 15) 
sequences were not bound. There was also no binding to probes with type 1 blood 
group H (probes 4, 5 and 6). Binding was also not detected to the Lewis antigen-
containing sequences (probes 19-26), and to the non-fucosylated LacNAc and poly-
LacNAc backbone sequences (probes 27-54). The binding of UEA-I, anti-A, anti-B 
and anti-H type 1 were in accord with their known specificities to blood group H type 
2, A, B and H type 1 sequences, respectively. In particular, the binding of UEA-I to 
the purified PSM-4M-f1 (probe 18) and the lack of binding of anti-H type 1 
corroborated the assignment of a type 2 H sequence. 
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Table 3.7 Oligosaccharide probes included in the F77/Ii focused array. 
Pos
a Probeb Sequence 
1 LNFP-I Fucα-2Galß-3GlcNAcß-3Galß-4Glc-DH 
2 LnNFPI Fucα-2Galß-4GlcNAcß-3Galß-4Glc-DH 
3 H2 (& H2+Fuc) Fucα-2Galß-4GlcNAcß-3Galß-4GlcNAcß-3Galß-4GlcNAcß-Cer 
4 MFLNH-I 
     Galß-4GlcNAcß-6  
                   │  
                   Galß-4Glc-DH 
                   │  
     Galß-3GlcNAcß-3 
     │ 
Fucα-2 
5 DFiLNO(1-2,-,-3) 
     Galß-3GlcNAcß-3Galß-4GlcNAcß-6 
                          │       │ 
                     Fucα-3       Galß-4Glc-DH 
                                  │ 
                    Galß-3GlcNAcß-3 
                    │ 
               Fucα-2 
6 TFiLNO(1-2,-2,-3) 
     Galß-3GlcNAcß-3Galß-4GlcNAcß-6 
     │                    │       │ 
Fucα-2               Fucα-3       Galß-4Glc-DH 
                                  │ 
                    Galß-3GlcNAcß-3 
                    │ 
               Fucα-2 
7 H3 (& H3-Fuc) 
     Galß-4GlcNAcß-6  
     │             │  
Fucα-2             Galß-4GlcNAcß-3Galß-4Glc-Cer 
                   │  
     Galß-4GlcNAcß-3  
     │ 
Fucα-2 
8 A-Hexa-T1 
GalNAcα-3Galß-3GlcNAcß-3Galß-4Glc-DH 
         │ 
    Fucα-2 
9 A-Hexa-T2 
GalNAcα-3Galß-4GlcNAcß-3Galß-4Glc-DH 
         │ 
    Fucα-2 
10 Ab (& Ab+Fuc) 
GalNAcα-3Galß-4GlcNAcß-3Galß-4GlcNAcß-3Galß-4Glcß-Cer 
         │ 
    Fucα-2 
11 A-Hepta 
GalNAcα-3Galß-3GlcNAcß-3Galß-4Glc-DH 
         │       │ 
    Fucα-2  Fucα-4 
12 Ad (& Ad+Fuc) 
               GalNAcα-3Galß-4GlcNAcß-6 
                        │             │ 
                   Fucα-2             Galß-4GlcNAcß-3Galß-4Glcß-Cer 
                                      │ 
GalNAcα-3Galß-4GlcNAcß-3Galß-4GlcNAcß-3 
         │   
    Fucα-2 
13 B-Hexa-T1 
Galα-3Galß-3GlcNAcß-3Galß-4Glc-DH 
      │ 
 Fucα-2 
14 B-Hexa-T2 
Galα-3Galß-4GlcNAcß-3Galß-4Glc-DH 
       │ 
  Fucα-2 
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15 B penta-AO 
Galα-3Galß-4Glc-AO 
      │      │ 
 Fucα-2 Fucα-3 
16 B-III dodeca 
Galα-3Galß-4GlcNAcß-6 
      │             │ 
 Fucα-2             Galß-4GlcNAcß-3Galß-4Glcß-Cer 
                    │ 
Galα-3Galß-4GlcNAcß-3 
      │ 
 Fucα-2 
17 B-IV tetradeca 
               Galα-3Galß-4GlcNAcß-6 
                     │             │ 
                Fucα-2             Galß-4GlcNAcß-3Galß-4Glcß-Cer 
                                   │ 
Galα-3Galß-4GlcNAcß-3Galß-4GlcNAcß-3 
      │ 
 Fucα-2 
18 PSM-4M-f1 
     Galß-4GlcNAcß-6  
     │             │  
Fucα-2             Galß-4GlcNAcß-OY   
                   │  
           GlcNAcß-3 
19 LNFP-II 
Galß-3GlcNAcß-3Galß-4Glc-DH 
      │ 
 Fucα-4 
20 
Leb-
hexaosylceramide 
Fucα-2Galß-3GlcNAcß-3Galß-4Glcß-Cer 
            │ 
       Fucα-4 
21 LNFP-III 
Galß-4GlcNAcß-3Galß-4Glc-DH 
      │ 
 Fucα-3 
22 LNnDFH-I 
Fucα-2Galß-4GlcNAcß-3Galß-4Glc-DH 
            │ 
       Fucα-3 
23 DFLNH(b) 
Galß-4GlcNAcß-6 
      │       │ 
 Fucα-3       Galß-4Glc-DH 
              │ 
Galß-3GlcNAcß-3 
      │ 
 Fucα-4 
24 TFLNH 
      Galß-4GlcNAcß-6  
            │       │  
       Fucα-3       Galß-4Glc-DH 
                    │  
Fucα-2Galß-3GlcNAcß-3  
            │  
       Fucα-4 
25 DFLNnH 
Galß-4GlcNAcß-6 
      │       │ 
 Fucα-3       Galß-4Glc-DH 
              │ 
Galß-4GlcNAcß-3 
      │ 
 Fucα-3 
26 MSDFLNnH 
        Galß-4GlcNAcß-6  
        │      │      │ 
   Fucα-2 Fucα-3      Galß-4Glc-AO 
                      │  
NeuAcα-6Galß-4GlcNAcß-3 
27 Orsay-1 Galß-4GlcNAcß-6Gal-AO 
28 Orsay-2 Galß-4GlcNAcß-3Gal-AO 
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29 Orsay-3 Galß-3GlcNAcß-6Gal-AO 
30 Orsay-4 Galß-3GlcNAcß-3Gal-AO 
31 LNT Galß-3GlcNAcß-3Galß-4Glc-DH 
32 LNnT Galß-4GlcNAcß-3Galß-4Glc-DH 
33 LSTa NeuAcα-3Galß-3GlcNAcß-3Galß-4Glc-DH 
34 LSTc NeuAcα-6Galβ-4GlcNAcβ-3Galβ-4Glc-DH 
35 LSTd NeuAcα-3Galß-4GlcNAcß-3Galß-4Glc-DH 
36 pLNH Galß-3GlcNAcß-3Galß-4GlcNAcß-3Galß-4Glc-DH 
37 pLNnH Galß-4GlcNAcß-3Galß-4GlcNAcß-3Galß-4Glc-DH 
38 LNnO Galß-4GlcNAcß-3Galß-4GlcNAcß-3Galß-4GlcNAcß-3Galß-4Glc-DH 
39 O1.AO 
GlcNAcß-3 
        │ 
        Gal-AO 
        │ 
GlcNAcß-6 
40 Orsay-5 
      GlcNAcß-6 
              │ 
              Gal-AO 
              │ 
Galß-3GlcNAcß-3 
41 Orsay-6 
Galß-4GlcNAcß-6 
              │ 
              Gal-AO 
              │ 
Galß-3GlcNAcß-3 
42 Orsay-7 
Galß-4GlcNAcß-6 
              │ 
              Gal-AO 
              │ 
Galß-4GlcNAcß-3 
43 LNH 
Galß-4GlcNAcß-6 
              │ 
              Galß-4Glc-DH 
              │ 
Galß-3GlcNAcß-3 
44 LNnH 
Galß-4GlcNAcß-6 
              │ 
              Galß-4Glc-DH 
              │ 
Galß-4GlcNAcß-3 
45 MSLNH 
NeuAcα-6Galß-4GlcNAcß-6 
                      │ 
                      Galß-4Glc-DH 
                      │ 
        Galß-3GlcNAcß-3 
46 MSLNnH-I 
        Galß-4GlcNAcß-6 
                      │ 
                      Galß-4Glc-DH 
                      │ 
NeuAcα-6Galß-3GlcNAcß-3 
47 DSLNnH 
NeuAcα-6Galß-4GlcNAcß-6 
                      │ 
                      Galß-4Glc-DH 
                      │ 
NeuAcα-6Galß-4GlcNAcß-3 
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48 iLNO 
Galß-3GlcNAcß-3Galß-4GlcNAcß-6 
                             │ 
                             Galß-4Glc-DH 
                             │ 
               Galß-3GlcNAcß-3 
49 LND 
Galß-4GlcNAcß-6 
              │ 
              Galß-4GlcNAcß-6 
              │             │ 
Galß-3GlcNAcß-3             Galß-4Glc-DH 
                            │ 
              Galß-3GlcNAcß-3 
50 Nonaosylceramide 
              GlcNAcß-6 
                      │ 
GlcNAcß-6             Galß-4GlcNAcß-3Galß-4Glcß-Cer 
        │             │ 
        Galß-4GlcNAcß-3 
        │ 
GlcNAcß-3 
51 I-octaosylceramide 
Galß-4GlcNAcß-6 
              │ 
              Galß-4GlcNAcß-3Galß-4Glcß-Cer 
              │ 
Galß-4GlcNAcß-3 
52 
I-
dodecaosylceramid
e 
              Galß-4GlcNAcß-6 
                            │ 
Galß-4GlcNAcß-6             Galß-4GlcNAcß-3Galß-4Glcß-Cer 
              │             │ 
              Galß-4GlcNAcß-3 
              │ 
Galß-4GlcNAcß-3 
53 
B-like 
decaosylceramide 
Galα-3Galß-4GlcNAcß-6 
                    │ 
                    Galß-4GlcNAcß-3Galß-4Glcß-Cer 
                    │ 
Galα-3Galß-4GlcNAcß-3 
54 
B-like 
pentadecaosylcera
mide 
              Galα-3Galß-4GlcNAcß-6 
                                  │ 
Galα-3Galß-4GlcNAcß-6             Galß-4GlcNAcß-3Galß-4Glcß-Cer 
                    │             │ 
                    Galß-4GlcNAcß-3 
                    │ 
Galα-3Galß-4GlcNAcß-3 
a
Pos, Probe position in the screening microarray. 
b
The oligosaccharide probes are all lipid-linked, neoglycolipids (NGLs) or glycosylceramides. Unless 
otherwise specified the NGLs are prepared from reducing oligosaccharides by reductive amination with 
the amino lipid, 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine (DHPE) (353); AO, NGL prepared 
from reducing oligosaccharides by oxime ligation with an aminooxy (AO) functionalized DHPE (310); 
Cer, natural glycolipids with various ceramide moieties; –OY is the 6-linked fragment of core GalNAc 
after periodate oxidation as further explained in Figure 3.7. 
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Figure 3.19 Microarray analysis of mAbs F77, anti-A, anti-B and anti-H type 1, and lectin UEA-I with 
oligosaccharide probes in F77/Ii focused array. The results are the means of fluorescence intensities of 
duplicate spots, printed at 5 fmol with error bars representing half of the difference between the two values. These 
54 lipid linked probes (F77/Ii focused array) are arranged according to their epitopes and backbone sequences as 
annotated in the coloured panels below the figure. The probe sequences are in Table 3.7. 
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3.7 Haemagglutination properties and temperature-
dependent binding of mAb F77 
 
The results above have shown that mAb F77 binds specifically to blood group H, A 
and B sequences on branched poly-LacNAc backbones. The linear and branched 
poly-LacNAc-based blood group sequences are highly expressed on human red cells, 
with the linear (i-antigen type) being predominantly on cord cells and the branched (I-
antigen type) on adult cells, respectively (30). We therefore tested if mAb F77 
agglutinates human red cells (Table 3.8). The haemagglutination assays were done 
by our collaborator Dr. Don Siegel at Univerisity of Pennsylvania. Indeed, at ambient 
temperature, when dilutions of mAb F77 were tested with blood group O (H) adult 
cells and cord blood cells, there was, as predicted, agglutination of both cell types, 
but to a higher titre with the adult cells: haemagglutination of the adult and cord cells 
giving 4+ were at 625 and 5,000 ng/ml, respectively. Haemagglutination activity of 
mAb F77 at 37 ˚C was lower than at ambient temperature; the 4+ score with group O 
adult red cells was 1,250 ng/ml. Thus mAb F77 had features resembling those of 
anti-I cold-agglutinins (30). 
 
Blood group B and A adult red cells were also agglutinated by mAb F77, but to lower 
titres with 4+ score at concentration of 1,250 ng/ml at ambient temperature. There is 
a resemblance here also to the so-called anti-HI in normal human sera that have 
been detected serologically in blood transfusion laboratories; these behave as low 
titre cold-agglutinins, with the hierarchy of titres: adult group O > adult groups A , B 
and AB, and >> cord blood (31). 
 
Table 3.8 Haemagglutination assay of mAb F77 with adult and cord red blood cells at 20 and 37 ˚C. Data 
from Don Peehl. 
Blood 
Group/Temp 
mAb F77 concentrations (ng/ml) 
5000  2500  1250  625 313  156  78  39 
Adult O/20 ˚C 4+ 4+ 4+ 4+ 3+  3+ 2+ 0 
Adult A/20 ˚C 4+ 4+ 4+ 3+ 2+ 1+ 0 0 
Adult B/20 ˚C 4+ 4+ 4+ 3+  3+ 2+ 1+ 0 
Cord O/20 ˚C 4+ 3+  3+ 2+ 0 0 0 0 
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Adult O/37 ˚C 4+ 4+ 4+ 3+  3+ 2+ 1+ 0 
 
To further investigate the temperature-dependent property of mAb F77, I performed 
microarray analysis of mAb F77 at three temperatures, 4, 20 and 37 ˚C, together with 
a typical anti-I cold-agglutinin, anti-I Ma. This latter antibody recognizes the β1-6-
linked backbone branch Galβ-4GlcNAcβ-6Gal (19) which is present in the probes 
designated Orsay-1, -6, -7 and B-like deca (Table 3.7). The binding intensities of 
mAb F77 were indeed the highest at 4 ˚C and lower at 20 ˚C, and even lower at 37 
˚C (Figure 3.20A and B). The temperature effect was most prominent at 0.1 μg/ml 
(Figure 3.20B). The temperature-dependence of ligand binding was very similar to 
that of anti-I Ma (Figure 3.20C), whose binding was abolished at 37 ˚C. 
 
 
Figure 3.20 Temperature dependence of the binding intensities of mAb F77 and anti-I Ma. (A and B). 
Binding intensities elicited in microarray analyses of mAb F77, 1.0 (panel A) and 0.1 μg/ml (panel B), at 4 ˚C, 20 
˚C and 37 ˚C with the four branched human blood group H, A and B glycolipids, H3, Ad, BIII and BIV. (C). Binding 
intensities elicited in microarray analyses of anti-I Ma (1:100) at 4 ˚C, 20 ˚C and 37 ˚C with NGLs of the 
chemically synthesized oligosaccharides designated Orsay-1, -6, -7 and the B-like decaosylglyceramide. The 
experiments were performed using the F77/Ii focused array and only probes relevant were shown. The 
carbohydrate sequences of the probes are listed in Table 3.7.   
 
  
 139 
 
3.8 Corroboration of the specificity of mAb F77 with a 
chemically synthesized glycan 
 
The assignment of the F77 antigen described in Section 3.4.5 was made using 
naturally occurring glycolipids and O-glycan. It was desirable to corroborate this 
finding with a chemically synthesized glycan and to gain insights into the size of the 
F77 antigen.  
 
A nonasaccharide GSC-915 was synthesized in Laboratory of Makoto Kiso of Gifu 
University (Table 3.9). I performed treatments with specific glycosidases (Section 
2.10) to sequentially remove Gal and GlcNAc on the 3-linked branch, to obtain 
oligosaccharides designated GSC-915-2 and GSC-915-3, respectively (Table 3.9). 
The Fuc and Gal on the 6-linked branch were sequentially removed from GSC-915-3 
to obtain GSC-915-4 and GSC-915-5, respectively (Table 3.9). The oligosaccharide 
products were purified by HPLC and analysed by ES-CID-MS and ES-CID-MS/MS to 
corroborate their sequences (not shown).  
 
Table 3.9 Sequences of the chemically synthesized nonasaccharide and its four enzymatic treatment 
products 
Designation Sequences 
GSC-915 
Galβ-4GlcNAcβ-6 
          |                         | 
Fucα-2                        Galβ-4GlcNAcβ-3Galβ-4Glc 
                                    | 
         Galβ-4GlcNAcβ-3 
GSC-915-2 
Galβ-4GlcNAcβ-6 
          |                         | 
Fucα-2                        Galβ-4GlcNAcβ-3Galβ-4Glc 
                                    | 
                    GlcNAcβ-3 
GSC-915-3 
Galβ-4GlcNAcβ-6 
          |                         | 
Fucα-2                        Galβ-4GlcNAcβ-3Galβ-4Glc 
GSC-915-4        Galβ-4GlcNAcβ-6Galβ-4GlcNAcβ-3Galβ-4Glc  
GSC-915-5                   GlcNAcβ-6Galβ-4GlcNAcβ-3Galβ-4Glc 
 
NGLs were generated from these five oligosaccharides. MALDI-MS (Figure 3.21) 
analysis confirmed the high purity of each NGL product. [M-H]- of each NGL was 
consistent with the predicted molecular mass of each NGL product. The mass 
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differences between the products and the starting oligosaccharide, GSC-915, clearly 
indicated the successful removal of Gal, GlcNAc, Fuc and Gal, respectively.  
 
Antigenic analyses were performed using NGLs of GSC-915 and the glycosidase 
digestion products (Figure 3.22). Clearly, F77 antigen-activity was retained after 
removal of the Gal and GlcNAc from the 3-linked branch. Defucosylation of the 6-
linked branch markedly reduced mAb F77 binding but it was not until the 6-linked Gal 
was removed that the F77 antigen activity was abolished. The complete 
defucosylation of GSC-915-3 was confirmed by the lack of binding of GSC-915-4 by 
UEA-I and AAL. These results highlighted the importance of LacNAc on the 6-linked 
branch in the F77 antigen. The minimal sequence that elicited the strongest F77 
binding signal was the unbranched blood group H sequence with the β1,6-linked 
LacNAc backbone. This contrasts with the lack of mAb F77 binding to the 
unbranched H with the β1,3-linked LacNAc backbone discussed in Section 3.6. 
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Figure 3.21 Negative-ion MALDI-MS analysis of the NGLs derived from the synthetic nonasaccharide, 
GSC-915, and its four glycosidase treated products GSC-915-2, -3, -4 and -5.  
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Figure 3.22 Microarray analysis of mAb F77, UEA-I and AAL with NGLs derived from the synthetic 
oligosaccharide GSC-915 and its four glycosidase treated products GSC-915-2, -3, -4 and -5. The results 
are the means of fluorescence intensities of duplicate spots, printed at 5 fmol with error bars representing half of 
the difference between the two values. The glycan sequences of the five NGLs are depicted on the top of the 
figure and listed in Table 3.9.  
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3.9 Discussion 
 
This study illustrates the value of microarrays of sequence-defined glycans in 
conjunction with glycome-scale designer arrays for the elucidation of novel 
carbohydrate antigenic determinants. The initial microarray analysis of mAb F77 with 
existing glycan probes clearly pointed to the presence of the F77 antigen on the two 
blood group B sequences (BIII and BIV) based on branched poly-N-
acetyllactosamine backbones. This was quite unpredicted as F77 antigen is known to 
be widely expressed in prostate cancer tissues (341) whereas the prevalence of 
blood group B in Caucasians is only 9% (364). The branched blood group H and A 
equivalents of BIII and BIV glycolipids were not available in the microarray initially. 
However, the lack of F77 antigen activity on the unbranched analogue, the blood 
group B hexaglycosylceramide, and on an analogue of the branched blood group B 
glycolipids lacking the terminal α1,2-linked blood group H fucose (so called B-like), 
was an important clue indicating the presence of the F77 antigen on the branched 
blood group H, and this was indeed corroborated by the studies that followed.  
 
The F77-active glycolipids of PC3 cells were found to be very minor components 
within an extremely heterogeneous population. Therefore, the discovery of F77 
antigen on an abundantly available mucin, PSM, opened up an alternative route to 
isolating the antigen, namely, by generating designer arrays from the PSM O-
glycome. Antigenic analyses of the O-glycan population released from PSM and 
arrayed as NGLs led to the isolation and characterization of a F77 antigen-positive 
component, 4M-f1, as being a blood group H sequence on a 6-linked branch of a di-
lactosamine backbone. This assignment is supported by the lack of F77 antigen 
activity of the two unbranched H-active sequences LnNFPI and H2 (probes 2 and 3 in 
Figure 3.19). 
 
It was essential thereafter to evaluate directly the F77 antigen expression on a 
branched blood group A analogue. This was achieved by analysis of the glycolipid Ad, 
the blood group A analogue of BIV, isolated from a glycolipid extract of human red 
cells. Ad was included in conventional chromatogram-binding analyses and 
compared with the red cell-derived branched blood group H glycolipid H3. In addition 
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microarray analyses were performed using a newly generated set of probes among 
which Ad and H3 glycolipids were included, also their respective analogues BIV and 
BIII, their unbranched analogues, the Lewis antigen-related probes and the linear 
and branched nonfucosylated backbones. It was thus shown that mAb F77 binds to 
the branched rather than the linear blood group A in addition to the branched blood 
group B and H on poly-N-acetyllactosamine backbones. The agglutination of red cells 
of A, B and O types, and more strongly those of adults than of cord blood, were also 
in accord with the conclusions above that mAb F77 can bind each of the branched A, 
B and H antigens. The specificity was clinched using a synthetic oligosaccharide 
GSC-915 and the products obtained by serial enzymatic treatments. The minimum 
sequence that mAb F77 recognizes was shown to be a type 2 blood group H (Fucα-
2Galβ-4GlcNAc) linked to poly-LacNAc backbone through β-6 linkage; and the 3-
linked branch was not required. 
 
The approach of generating designer probes (NGLs) from O-glycans, following 
alkaline reductive release from PSM and mild periodate-oxidation, has three 
advantages: first, there is a higher yield of glycans than by non-reductive release 
(308); second, there are diagnostic MS features with respect to their origins from 3-
linked (OX) or 6-linked (OY) branches at the core GalNAcol residues (363); and third, 
the cleavage at the core GalNAcol residues gives rise to a population of NGLs with 
reduced heterogeneity as there arise branches of the same size and sequence from 
different cores. Thus the antigen-positive components among the NGLs were 
resolved into discrete bands on HPTLC (Figure 3.8) unlike those derived from non-
reductively released glycans which were not only larger but also more heterogeneous 
(Figure 3.5), and would be difficult to purify in sufficient amounts for detailed analyses. 
The patterns of binding of F77 to the NGLs from the reductively released O-glycans 
together with the fluorescence labelling of the NGLs facilitated both the visualization 
and isolation of the main antigen-positive component, 4M-f1.  
 
In the previous study (341), there was a lack of a perceptible effect on F77 antigen 
expression on PC3 and DU 145 cells after treatment with the O-glycosylation inhibitor 
benzyl-α-GalNAc, contrasting with diminished antigen expression after treatment with 
the glycolipid synthase inhibitor 1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. 
The authors concluded that the F77 antigen was expressed on glycolipids rather than 
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O-glycosylated proteins. However, in our study, we identified PSM [which has O-
glycan sequences that resemble those of humans (365)] to express strongly the F77 
antigen and we isolated an antigen-positive O-glycan fragment. Thus our studies 
established the F77 antigen can be expressed not only on glycolipids, but also on O-
glycans of glycoproteins. This conclusion is supported by the finding in our 
collaborator, Minoru Fukuda‘s lab that benzyl-α-GalNAc treatment abolished F77 
antigen activity in another cell line human prostate epithelial 267B1 that had been co-
transfected with FUT1 and GCNT3 (366). Collectively these results indicate that there 
is a predominance of glycolipids with F77 antigen activity in PC3 and DU 145 cells 
and a low content of O-glycosylated proteins relative to those on the transfected 
267B1 cells such that the inhibition of O-glycan biosynthesis would not have a 
perceptible effect on expression of the F77 antigen. Recent more sensitive analyses 
using immunoprecipitation followed by Western blotting have revealed a glycoprotein 
that is bound by mAb F77 (Mark Greene lab, unpublished). The entity of the carrier 
protein is under investigation.  
 
The marked differences in carbohydrate antigen expression on cancer cells 
compared with normal counterparts have been discussed and reviewed in Section 
1.2. These changes reflect the altered activities of the corresponding 
glycosyltransferases. Highly relevant to F77 antigen expression are α1,2-
fucosyltransferase encoded by FUT1, which adds α1,2-linked blood group H fucose 
(367) and, β1,6-N-acetylglucosaminyltransferase branching enzymes encoded by 
GCNTs 1-4, which synthesize the 6-linked GlcNAc for cores 2, core 4 and I-antigen 
type backbones (289,368), as depicted in Scheme 3.1. 
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Scheme 3.1 Key glycosyltransferases responsible for the biosynthesis of F77 antigen 
 
With the exception of GCNT3, the expression of which was found to be down-
regulated in colorectal cancer (369), the above-mentioned branching enzyme genes 
have been observed to be increased in epithelial cancers. Notably, over-expression 
of GCNT1 has been reported to be associated with progression of prostate cancer 
(370,371). Indeed upregulation of GCNT1 has been reported to be associated with 
invasiveness and high metastasis in many cancer types, including endometrial 
carcinoma (372), breast cancer (373), bladder cancer (374), testicular germ cell 
tumour (375), colorectal cancer and pulmonary carcinoma (376,377). Recently, 
GCNT2 has been reported to be involved in metastasis of breast cancer through 
TGF-β signalling, and blocking the expression of GCNT2 was shown to abrogate the 
tumour cell migration and invasion (378). 
 
The question then arises as to why F77 antigen that includes a branched backbone 
sequence is strongly expressed in prostate cancer rather than in other cancers. We 
propose that the answers lie in the finding that the type 2 blood group H antigen, 
which is expressed in the normal prostate irrespective of the ABO blood group status, 
is increased in prostate cancer tissues (379-382). This contrasts with many other 
cancers in which the branching enzyme genes are overexpressed, but the type 2 H 
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antigen expression is decreased due to α1,3-fucosylation and the formation of Ley 
antigen sequence, which we have shown not to be bound by mAb F77 (probe 26 in 
Figure 3.19). Alternatively, there may occur competition by sialylation on the terminal 
galactose instead of α1,2-fucosylation (156). Results of glycosyltransferase gene 
transfections in the Fukuda lab (366) are in complete accord both with our findings 
and our hypothesis. These include first, expression of F77 antigen was induced in 
267B1 cells lacking the antigen by co-transfection of the gene for α1,2-
fucosyltransferase and those for the branching enzymes GCNT1, GCNT2 or GCNT3; 
second, the antigen activity persisted when A or B enzyme was transferred into the 
cells but binding was less strong; third, RT-PCR analysis revealed the expression of 
the genes for FUT1 and GCNT2, and those for FUT1 and GCNT3 in F77 antigen-
positive cells PC3 and LNCaP, respectively; and fourth, siRNA targeting these 
enzyme genes in antigen-positive cells resulted in significantly reduced levels of the 
antigen. 
 
With knowledge of the structure, prevalence and potential biological function of F77 
antigen in prostate cancer, the way is open to explore rationally its applications as a 
biomarker. Whereas direct use of mAb F77 in cancer sero-diagnosis and tumour 
imaging would be precluded because of the expression of the antigen on red cells. 
One possibility under current investigation is the detection of the antigen on 
circulating tumour cells. We are also exploring F77-antigen-positive prostatic 
glycoproteins as potential serum biomarkers of prostate cancer. Possible new 
approaches to immunotherapy of prostate cancer using the single chain variable 
region (scFv) of F77 antibody in are discussed in Chapter 5. 
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Chapter 4  
STUDIES OF AN EPITHELIAL CANCER-
ASSOCIATED CARBOHYDRATE ANTIGEN AE3 
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4.1 Introduction 
 
Monoclonal antibody AE3 (IgM) was raised against sialidase treated (asialo)  murine 
epiglycanin (383), which is a large (~500 kDa) sialylated mucin produced by murine 
mammary adenocarcinoma TA3-Ha cells (384). The mAb bound to high molecular 
weight (>1,000 kDa) human cancer-associated epithelial glycoproteins that are 
collectively designated HCA (human carcinoma antigen) (385). Among more than 40 
mAbs raised against epiglycanin, mAb AE3 was considered the ‗most carcinoma-
specific‘ (386). Using mAb AE3, the HCA could be immunochemically detected in 
ascites fluid of patients with ovarian cancer (385) and in sera of patients with breast 
cancer (386). The AE3 antibody strongly stained human cancer tissues such as 
those of breast (386), prostate (387), bladder (388) and oesophagus (389). 
 
The molecular identities of the murine epiglycanin and HCA have been investigated. 
By differential analyses of the murine mammary carcinoma cell variants that express 
or lack epiglycanin (designated TA3-Ha and TA3-St, respectively), a mouse 
epiglycanin cDNA fragment was first identified. Using homology searching, the 
human orthologue was cloned, expressed and designated MUC21 (390). This was 
followed by the clone of the mouse complete epiglycanin gene which was designated 
as Muc21 (391). The two human and murine orthogogues have been shown to be 
highly glycosylated transmembrane mucins with 28 and 98 tandem repeat domains, 
respectively, rich in serine and threonine residues (390,391).  
 
In earlier studies, the binding of epiglycanin by most of the 40 mAbs was reduced 
after incubation of the glycoprotein with trypsin or pronase, suggesting a high 
molecular weight dependency for binding by the antibodies (392). The binding of 
these antibodies to epiglycanin was also attenuated by periodate treatment, and 
inhibited by peanut agglutinin (PNA) or high concentrations of the T disaccharide, 
Galβ-3GalNAc. Another plant lectin, Ricinus communis agglutinin I (RCA120), could 
also inhibit the binding of one of these 40 antibodies (392). Treatment of the AE3 
antigen-positive cells with endo-α-N-acetyl-D-galactosaminidase abolished binding of 
mAb AE3 (383). This enzyme removes the T disaccharide from the reducing terminal 
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on O-glycans. Collectively, these results suggested the involvement of carbohydrate, 
and specifically the Galβ-3GalNAc in the antigenic determinant. 
 
The authors investigated the specificity of mAb AE3 by performing inhibition assays 
(inhibition of binding to epiglycanin) using T disaccharide and synthetic glycopeptides 
carrying this disaccharide sequence (393). The results are summarized in Table 4.1. 
Binding of mAb AE3 to epiglycanin was inhibited by the glycoproteins epiglycanin 
(number 1) or asialoglycophorin (number 2) at very low concentration (~0.7 μg/ml). 
Seven glycopeptides with various combinations of T disaccharide and Tn (GalNAc) 
monosaccharide (numbers 3 to 9, listed in Table 4.1) also inhibited AE3 binding, but 
at a higher concentration with IC50 between 150 and 5,000 μg/ml. The glycopeptides 
with triple Tn (number 10) did not show inhibitory activity. The free T disaccharide 
(number 11) could inhibit mAb AE3 binding although the inhibitory activity was 
relatively low (IC50 at 5000 μg/ml). These results suggested that mAb AE3 resembles 
PNA which recognizes the T antigen disaccharide Galβ-3GlcNAc. However, mAb 
AE3 differed from PNA in that the concentration of the T disaccharide required for 
inhibition was 104 times greater than for PNA, suggesting that the T disaccharide 
sequence forms part of a larger antigenic determinant recognized by mAb AE3 (393). 
In addition, among the glycopeptides, the one that had the strongest inhibitory activity 
was a glycopeptide with one Tn monosaccharide (GalNAc) on the first threonine 
residue and two T disaccharides on the second and third threonine residues (number 
3). This was followed by the glycopeptide with one T on the middle threonine 
(number 4) and by the one with trivalent T on all three threonines (number 5). This 
was suggestive of the requirement for clustered presentation of T disaccharide, but 
not conclusive. The structure of AE3 antigen has remained an open question over 
the ensuing years. The molecular basis of ordering of the clustered mucin-type O-
glycosylation has been investigated in detail. Recent results have shown that this is 
dependent on the specificities and catalytic activities of the UDP-GalNAc:polypeptide 
α-N-acetylgalactosaminyltransferases (ppGalNAc Ts), which initiate O-glycosylation, 
these, are influenced by the amino acid sequence and pre-existing GalNAc on the 
substrate (394,395). 
 
Palma et al in the Glycosciences Laboratory (319) carried out microarray analysis of 
mAb AE3 using almost 500 glycan probes (Glycosciences Lab Array Sets 32-39). 
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The binding profile for mAb AE3 partially overlapped with that of PNA but was clearly 
distinct from that of RCA120 (Figure 4.1A). There was an unpredicted finding that the 
strongest binding of mAb AE3 was to a sulphoglycolipid SM1a, an analogue of the 
sialoglycolipid GM1 (Figure 4.1B). The AE3 antibody bound relatively weakly to the 
three structurally-related sequences asialo-GM1, GM1 and GM1 (Gc) (probes 301, 
306 and 308, respectively in Figure 4.1A and B). Additional sulphation on the 
terminal Gal impeded the AE3 binding as evidenced by the lack of binding to SB1a 
(probe 304, Figure 4.1A and B). This was the first report of a glycolipid carrier of 
human HCA. 
 
Table 4.1 Inhibition of mAb AE3 binding to epiglycanin by glycoproteins, synthetic 
glycopeptides and T disaccharide. Data were taken from  reference (393). 
Number Inhibitor IC50 (μg/ml) 
Glycoprotein 
1 Asialoglycophorin ~0.7 
2 Epiglycanin ~0.7 
Synthetic glycopeptides 
3 
             Tn    T    T 
Ac---P----T----T----T----P----I----S----T---NH2 
~150 
4 
             Tn    T    Tn 
Ac---P----T----T----T----P----I----S----T---NH2 
~300 
5 
              T     T    T 
Ac---P----T----T----T----P----I----S----T---NH2 
~1200  
6 
              T    Tn    T 
Ac---P----T----T----T----P----I----S----T---NH2 
~2100 
7 
              T    T    Tn 
Ac---P----T----T----T----P----I----S----T---NH2 
~2100 
8 
              T    Tn   Tn 
Ac---P----T----T----T----P----I----S----T---NH2 
~3000 
9 
              Tn   Tn   T 
Ac---P----T----T----T----P----I----S----T---NH2 
>5000 
10 
             Tn   Tn   Tn 
Ac---P----T----T----T----P----I----S----T---NH2 
not inhibited 
T disaccharide 
11 Galβ1-3GalNAc ~5000 
 
The carbohydrate sequence of SM1a has not been reported on mucin-type 
glycoproteins so far. Sequences related to SM1a have been described (348) among 
O-glycans of glycoproteins in normal descending colon (Figure 4.1C): These are 
structures a, with sulphate on Gal but lacking terminal Galβ1-3GalNAc and structure 
b, a Sda/Cad sequence (Figure 1.6 and Section 1.1.2.2) lacking a terminal Gal but 
with sialic acid instead of sulphate on Gal. Taken together, these findings led to a 
proposal that an O-glycan analogue of SM1a with a non-reducing terminal Galβ1-
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3GalNAc, a sulphate on an inner galactose and the core 3 sequence at the reducing 
end (Figure 4.1C) may be present on mucin-type glycoproteins bound by mAb AE3. 
 
 
Figure 4.1 Microarray screening analyses of mAb AE3 and the plant lectins peanut agglutinin (PNA) and 
Ricinus communis agglutinin I (RCA120). (A) The results with 492 lipid-linked probes (>370 mammalian type) 
printed at 5 fmol in the arrays (means of fluorescence intensities of duplicate spots with error bars). The probes 
are grouped according to their backbone sequences as annotated by the coloured panels. (B) Relative intensities 
of binding of AE3 and PNA to five glycolipids sharing the asialo-GM1 backbone sequence in the microarray 
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screening analyses. (C) Schematic presentation of oligosaccharide sequences, structures a and b, related to that 
of SM1a and based on the O-glycan core 3 that have been described among O-glycans of glycoproteins in 
descending colon; also shown is a possible O-glycan analogue of SM1a. Taken from (319) with permission. 
 
This chapter has been to investigate whether the AE3 determinant among O-glycans 
indeed occurs as an SM1a analogue or if it is a sequence with which SM1a cross 
reacts. It is important to determine which glycan sequence constitutes the cancer-
associated antigen and thereby to have an indication of which glycosyltransferases 
are involved. 
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4.2 Antigenic analysis of an AE3 antigen-positive glycolipid 
SM1a 
 
The sulphoglycolipid SM1a that was unexpectedly bound by mAb AE3 in the 
microarray screening analysis was from a natural source. It could not be ruled out 
that a minor component existed in the preparation and could not be detected by MS. 
In order to corroborate the mAb AE3 binding to SM1a, two glycolipids, 
monosulphated SM1a and disulphated SB1a, were chemically synthesized in the 
Laboratory of Makato Kiso of Gifu University for this project. 
 
Purity of the two synthetic glycolipids was corroborated by HPTLC and MS analyses. 
They were then arrayed for probing with mAb AE3 (Figure 4.2). The result showed 
that the synthetic and the naturally occurring SM1a were equally well bound by mAb 
AE3, whereas the disulphated glycolipid SB1a was completely AE3 antigen-negative. 
This corroborated the finding in the screening array analysis that AE3 binding was 
restricted to the monosulphated glycolipid SM1a. Sulphation on the terminal Gal 
masked the AE3 binding epitope. 
 
 
Figure 4.2 Microarray analyses of mAb AE3 with naturally occurring and chemically synthesized SM1a 
and synthetic SB1a. The results shown are binding intensities with the three glycolipids printed at 5 fmol in the 
arrays (means of fluorescence intensities of duplicate spots with error bars). 
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4.3 Identification of an AE3 antigen-positive ovarian cyst 
mucin, Cyst 756 
 
In the hope of finding a source of the proposed O-glycan analogue of SM1a (Figure 
4.1C), microarray analysis of mAb AE3 was performed using an array of 46 
preparations of mucin-type glycoproteins (Mucin Array Set 2, Table 4.2). These 
included most of the 30 glycoproteins in Mucin Array Set 1 used in the F77 study 
(Table 3.1) and some additional glycoproteins: 11 enriched cystadenoma 
glycoprotein preparations being pepsin treated, 4 glycoprotein preparations of human 
milk and sheep stomach and 2 glycoproteins transferrin and invertase. A preparation 
of HCA served as the positive control. Two lectins PNA and RCA120 were tested in 
parallel to compare their binding profiles with that of mAb AE3.  
 
Twenty eight of the mucin preparations gave binding signals with mAb AE3 (Figure 
4.3). Glycoproteins giving moderate or high binding signals were those purified from 
cystadenomas (probes 29 to 32, Figure 4.3), preparations from meconia (probes 34 
to 37), transferrin (probe 45) and the positive control, HCA (probe 42). The AE3 
antibody bound only moderately or weakly to the enriched (but not purified) 
cystadenoma glycoproteins (probes 1, 5 to 12, 15, 16 and 23 to 26). Among them, 
three preparations of cystadenoma 756 (Cyst 756), probes 23 to 25, elicited relatively 
strong mAb AE3 binding. These samples had been enriched for high molecular mass 
glycoproteins (mucins) by trypsin, pronase or pepsin treatment, respectively, followed 
by ethanol precipitation (Section 2.2.3). The plant lectins PNA and RCA120 showed 
similar binding profiles which also overlapped with that of mAb AE3. In this sense, 
mAb AE3 indeed resembled the two plant lectins, albeit binding with a lower intensity. 
These results were in accord with the inhibition of binding of mAb AE3 and related 
mAbs raised against epiglycanin in the presence of RCA120 and PNA (392). However, 
mAb AE3 differed from the two plant lectins clearly in its lack of bindings to the two 
sheep stomach glycoproteins (probes 40 and 41). These findings suggested that the 
epitope of this antibody may partially overlap with those of the lectins but it is clearly 
not identical as indicated in the glycan array data in Figure 4.1A.  
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One of the samples most strongly bound by AE3, samples 29 to 32 and 35 to 36, 
would have been desirable sources of antigen-positive O-glycans for investigation. 
But these glycoproteins are available only in limited amounts. Thus an abundantly 
available ovarian cystadenoma glycoprotein preparation (Cyst 756) was selected for 
the studies described in this Chapter.  
 
Table 4.2 Mucin-type epithelial glycoproteins arrayed as Mucin Array Set 2 for screening for mAb AE3 
binding.  
Position Designation 
Donor red cell 
blood-group  
Secretor status 
 Enriched cystadenoma glycoproteins 
1 Cys 301 (Pro)* 
2 Cys 301 (Pep) 
3 Cys 379 (Pro) A1 Non-secretor 
4 Cys 379 (Pep)   
5 Cys 444 (Trp) Unknown Non-secretor 
6 Cys 444 (Pro) Unknown Non-secretor 
7 Cys 444 (Pep) Unknown Non-secretor 
8 Cys 446 (Pro) B Non-secretor 
9 Cys 446 (Pep) B Non-secretor 
10 Cys 461 (Try) Unknown Non-secretor 
11 Cys 461 (Pro) Unknown Non-secretor 
12 Cys 461 (Pep) Unknown Non-secretor 
13 Cys 654 (Pro) B Non-secretor 
 14 Cys 654 (Pep) B Non-secretor 
 15 Cys 705 (Pro) Unknown Non-secretor 
16 Cys 717 (Pro) A1 Non-secretor 
17 Cys 717 (Pep) A1 Non-secretor 
18 Cys 733 (Pro) A1 Secretor 
19  Cys 745 (Pro) A Non-secretor 
20 Cys 745 (Pep) A Non-secretor 
21 Cys 754 (Pro) Unknown Non-secretor 
22 Cys 754 (Pep) Unknown Non-secretor 
23 Cys 756 (Trp) A Non-secretor 
24 Cys 756 (Pro) A Non-secretor 
25 Cys 756 (Pep) A Non-secretor 
26 Cys 762 (Pro) O Non-secretor 
27 Cys 762 (Pep) O Non-secretor 
28 Cys 765 (Pro) O Non-secretor 
    
 Purified cystadenoma glycoproteins 
29 Og 10% from 20% (Pep) Unknown Non-secretor 
30 Og 10% 2x (Pep) Unknown Non-secretor 
31 N1 20% (Pep) Unknown Non-secretor 
32 Tij 10% 2x (Pep) B Secretor 
33 OC2 Unknown Unknown 
    
 Meconia   
34 Meconium B (Pro) B Unknown  
35 Meconium Mo (Pro) Unknown Unknown 
36 Meconium Wo (Pro) Unknown Unknown 
37 Meconium He (Pro) Unknown Unknown 
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 Milk glycoproteins 
38 Milk batch #3 Unknown Unknown 
39 Milk batch #6 Unknown Unknown 
    
 Sheep stomach glycoproteins 
40 Sheep (S1+S10) (pep)   
41 New sheep pool (pep)   
    
 Other glycoproteins    
42 HCA Unknown  Unknown 
43 Porcine gastric mucin  A+H (Sigma) 
44 Bovine submaxillary mucin Unknown (Sigma) 
45 Transferrin Unknown (Sigma) 
46 Invertase Unknown (Sigma) 
Details for the enrichment procedures for the mucin preparations 1-37, 40-41 and of 42 are given in Section 2.2.3. 
Samples 43 to 46 were from commercial sources. 
 *Trp, Pro and Pep refer to proteases, pronase, trypsin or pepsin, used in the process of solubilizing the mucins. 
 
 
Figure 4.3 Microarray analyses of mAb AE3-containing culture supernatant, PNA and RCA120 with mucin-
type glycoproteins. The mucin-type epithelial glycoproteins are from enriched and purified ovarian 
cystadenomas, meconia, human milk, sheep stomach and commercial glycoproteins such as porcine gastric 
mucin, bovine submaxillary mucin, transferrin and invertase. They are arranged according to their sources as 
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annotated in the coloured panels below the figure. Results are the means of fluorescence intensities of duplicate 
spots printed at 150 pg glycoprotein per spot. The error bars represent half of the difference between the 
duplicate values. In brackets are the three preparations of cystadenoma 756 selected for further investigation of 
the AE3 antigen. 
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4.4 Antigenic analyses of O-glycans reductively released 
from Cyst 756 
 
Following the success in the F77 study, reductive release was initially attempted. The 
workflow is summarized in Scheme 4.1. Five hundred milligrams of the crude Cyst 
756 lyophilised powder was used to release the O-glycans by reductive alkaline 
borohydride degradation. Total hexose content of the products was 12.4 mg 
determined by dot-orcinol assay. The products were initially fractionated by charge 
using DEAE-Sephadex A25 column (Section 2.5.1). Four fractions were successively 
eluted using 10, 100, 300 and 500 mM NH4OAc buffer, and they were designated 
Cyst 756-C-N, Cyst 756-C-A1, Cyst 756-C-A2 and Cyst 756-C-A3, respectively 
(Scheme 4.1). The four subfractions were analysed by ES-MS and the 
monosaccharide compositions of each component in these fractions were deduced 
and listed in Table 4.3. One molecular ion may correspond to multiple possible 
monosaccharide compositions. Sometimes both with and without sialic acid (SA) or 
sulphate (SU) is possible. There were in total 72 molecular species based on the m/z 
values observed as singly, doubly and triply charged ions, corresponding to 
oligosaccharides ranging from disaccharide to hexadecasaccharide. The major 
components in Cyst 756-C-N were neutral oligosaccharides, ranging from 
disaccharide to heptasaccharide, whereas in Cyst 756-C-A1, Cyst 756-C-A2 and 
Cyst 756-C-A3 the major components were acidic and ranged from disaccharide to 
hexadecasaccharide. The ion corresponding to the predicted AE3 antigen-positive O-
glycan (Figure 4.1C), SU1.Hex2.HexNAc2.HexNAcol, was not observed, however, 
suggesting that the sought-after antigen may be a minor component  as was the case 
with F77 antigen in PSM or that it was absent. 
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Scheme 4.1. Workflow of the reductive O-glycan release, fractionation and conjugation to lipid to 
generate NGLs. 
 
Table 4.3 Compositions of the reductively released O-glycans in fractions Cyst 756-C-N (N), Cyst 756-C-
A1 (A1), Cyst 756-C-A2 (A2) and Cyst 756-C-A3 (A3) deduced from ES-MS analysis (tick indicates the 
corresponding ion is found in this fraction). 
m/z 
Monosaccharide composition 
Fractions 
[M-H]
-
 [M-2H]
2-
 [M-3H]
3-
 N A1 A2 A3 
384.1   Hex1, HexNAcol1 √    
 478.6  SA1, SU1-Hex1, HexNAc1, HexNAcol1    √ 
 482.6  SA2-Hex1, HexNAcol1   √ √ 
513.2   SA1-HexNAcol1  √ √  
530.2   dHex1, Hex1, HexNAcol1    √ 
 553.3  SU1-dHex2, Hex1   √  
 559.6  SA1, SU1-Hex2, HexNAc1, HexNAcol1   √ √ 
 584.2  SA2-Hex1, HexNAc1, HexNAcol1   √  
587.2   Hex1, HexNAc1, HexNAcol1 √    
623.2   SU3-Hex1, HexNAcol1    √ 
 632.7  SA1, SU1-dHex1, Hex2, HexNAc1, HexNAcol1    √ 
  640.2 
SA1, SU1-dHex3, Hex3, HexNAc2, HexNAcol1 
SU2-Hex7, HexNAc2, HexNAcol1 
SA2, SU1-dHex1, Hex3, HexNAc2, HexNAcol1 
   √ 
 657.2  
SU2-Hex2, HexNAc3, HexNAcol1 
SU1-Hex5, HexNAc1, HexNAcol1 
SA2-dHex1, Hex1, HexNAc1, HexNAcol1 
  √  
 665.2  SA2-Hex2, HexNAc1, HexNAcol1   √  
667.2   SU1-Hex1, HexNAc1, HexNAcol1   √ √ 
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675.2   SA1-Hex1, HexNAcol1 √ √ √ √ 
 702.2  SA1-Hex3, HexNAc2, HexNAcol1 √    
733.2   dHex1, Hex1, HexNAc1, HexNAcol1 √    
 734.2  
SA1, SU1-dHex1, Hex2, HexNAc2, HexNAcol1 
SA1-dHex1, Hex5, HexNAcol1 
  √  
 742.2  
SA1SU1-Hex3, HexNAc2, HexNAcol1 
SA1-Hex6, HexNAcol1 
SU1-dHex2, Hex3, HexNAc2, HexNAcol1 
  √ √ 
749.3   Hex2, HexNAc1, HexNAcol1 √    
755.2   SA1, SU1-Hex1, HexNAcol1    √ 
785.2   SU3-Hex2, HexNAcol1    √ 
793.2   SU3-dHex3, Hex3, HexNAc1, HexNAcol1  √   
812.3   SU1-dHex1, Hex1, HexNAc1, HexNAcol1 √    
 815.2  
SU1-dHex3, Hex3, HexNAc2, HexNAcol1 
SA1, SU1-dHex1, Hex3, HexNAc2, HexNAcol1 
SA1-dHex1, Hex6, HexNAcol1 
dHex3, Hex6, HexNAcol1 
  √ √ 
829.2   SU1-Hex2, HexNAc1, HexNAcol1   √ √ 
878.3   SA1-Hex1, HexNAc1, HexNAcol1 √ √ √ √ 
 887.7  SA1, SU1-dHex2, Hex3, HexNAc2, HexNAcol1    √ 
 892.2  
SU2-dHex1, Hex4, HexNAc3, HexNAcol1 
SA2-dHex2, Hex3, HexNAc1, HexNAcol1 
SA3-Hex3, HexNAc1, HexNAcol1 
   √ 
 898.7  SA2, SU2-dHex1, Hex3, HexNAc1, HexNAcol1    √ 
895.3   dHex1, Hex2, HexNAc1, HexNAcol1 √    
931.3   SU3-dHex1, Hex2, HexNAcol1    √ 
 920.8  
SA1-dHex3, Hex3, HexNAc2, HexNAcol1 
SA2-dHex1, Hex3, HexNAc2, HexNAcol1 
SU2-Hex4, HexNAc4, HexNAcol1 
SA1, SU1-dHex3, Hex5, HexNAcol1 
SU1-Hex7, HexNAc2, HexNAcol1 
  √  
952.3   Hex2, HexNAc2, HexNAcol1 √    
958.2   SA1, SU1-Hex1, HexNAc1, HexNAcol1    √ 
  958.0 
SA2, SU1-dHex2, Hex5, HexNAc4, HexNAcol1 
dHex4, Hex4, HexNAc7, HexNAcol1 
SA1-dHex2, Hex4, HexNAc7, HexNAcol1 
  √  
 960.8  
SA1, SU1-dHex3, Hex3, HexNAc2, HexNAcol1 
SU2-Hex7, HexNAc2, HexNAcol1 
SA2, SU1-dHex1, Hex3, HexNAc2, HexNAcol1 
   √ 
966.3   
SA1-dHex2, Hex1, HexNAcol1 
SA2-Hex1, HexNAcol1 
  √ √ 
 971.8  
SA2, SU2-dHex2, Hex3, HexNAc1, HexNAcol1 
SU1-dHex2, Hex6, HexNAc1, HexNAcol1 
   √ 
980.2   SA1, SU2-dHex1, Hex1, HexNAcol1    √ 
988.3   SU3-Hex2, HexNAc1, HexNAcol1    √ 
 997.8  
SA1, SU1-dHex1, Hex4, HexNAc3, HexNAcol1 
SU1-dHex3, Hex4, HexNAc3, HexNAcol1 
SA1-dHex1, Hex7, HexNAc1, HexNAcol1 
  √  
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  1008.0 
SA1, SU1-dHex5, Hex8, HexNAc2, HexNAcol1 
SA1, SU2-dHex5, Hex5, HexNAc4, HexNAcol1 
SA1, SU2-Hex7, HexNAc6, HexNAcol1 
SU2-dHex2, Hex7, HexNAc6, HexNAcol1 
SA2-dHex3, Hex6, HexNAc4, HexNAcol1 
  √  
1024.3   SA1-dHex1, Hex1, HexNAc1, HexNAcol1 √ √   
1040.4   SA1-Hex2, HexNAc1, HexNAcol1 √ √ √ √ 
 1070.8  
SA1, SU1-dHex2, Hex4, HexNAc3, HexNAcol1 
SA1-dHex2, Hex7, HexNAc1, HexNAcol1 
SA2, SU1-Hex4, HexNAc3, HexNAcol1 
SU2-dHex4, Hex6, HexNAc1, HexNAcol1 
SU1-dHex4, Hex4, HexNAc3, HexNAcol1 
dHex4, Hex7, HexNAc1, HexNAcol1 
  √  
 1110.9  
SA1, SU1-dHex2, Hex7, HexNAc1, HexNAcol1 
SU1-dHex4, Hex7, HexNAc1, HexNAcol1 
√    
 1111.3  
SU2-dHex4, Hex4, HexNAc3, HexNAcol1 
SU1-dHex4, Hex7, HexNAc1, HexNAcol1 
SA2-Hex5, HexNAc3, HexNAcol1 
SA2-dHex5, Hex3, HexNAc1, HexNAcol1 
SA1, SU1-dHex2, Hex7, HexNAc1, HexNAcol1 
 √ √  
1114.4   Hex3, HexNAc2, HexNAcol1 √    
1120.3   SA1, SU1-Hex2, HexNAc1, HexNAcol1    √ 
1142.3   SA1, SU2-dHex1, Hex2, HexNAcol1    √ 
1160.4   
SU2-dHex2, Hex3, HexNAcol1 
SA1, SU1-Hex1, HexNAc2, HexNAcol1 
√    
1178.3   SA1-dHex1, Hex2, HexNAc2, HexNAcol1  √   
  1178.4 
SA2, SU2-dHex4, Hex6, HexNAc5, HexNAcol1 
SA1, SU2-dHex1, Hex8, HexNAc7, HexNAcol1 
SA1, SU2-dHex6, Hex6, HexNAc5, HexNAcol1 
  √  
1186.4   SA1-dHex1, Hex2, HexNAc1, HexNAcol1 √ √   
1194.4   
SU1-Hex3, HexNAc2, HexNAcol1 
Hex6, HexNAcol1 
  √  
 1216.4  
SA2, SU1-dHex2, Hex4, HexNAc3, HexNAcol1 
SA2-dHex2, Hex7, HexNAc1, HexNAcol1 
  √  
  1226.7 
SA2, SU2-Hex8, HexNAc7, HexNAcol1 
SA2, SU2-dHex5, Hex6, HexNAc5, HexNAcol1 
SA1, SU2-dHex2, Hex8, HexNAc7, HexNAcol1 
  √  
1243.4   SA1-Hex2, HexNAc2, HexNAcol1  √   
 1253.4  SA1, SU1-dHex2, Hex5, HexNAc4, HexNAcol1   √  
1260.4   dHex1, Hex3, HexNAc2, HexNAcol1 √    
1296.4   SU3-dHex1, Hex3, HexNAc1, HexNAcol1    √ 
1306.4   SU2-dHex3, Hex3, HexNAcol1 √    
 1326.4  SA1, SU1-dHex3, Hex5, HexNAc4, HexNAcol1   √  
1340.4   SU1-dHex1, Hex3, HexNAc2, HexNAcol1  √ √  
1405.4   SA1-Hex3, HexNAc2, HexNAcol1 √ √   
 1439.4  
SA2, SU1-dHex2, Hex8, HexNAc2, HexNAcol1 
SA1, SU2-dHex4, Hex5, HexNAc4, HexNAcol1 
SA1, SU1-dHex4, Hex8, HexNAc2, HexNAcol1 
  √  
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 1450.4  SA2, SU2-dHex3, Hex8, HexNAc1, HexNAcol1   √  
1485.4   SA1, SU1-Hex3, HexNAc2, HexNAcol1    √ 
1551.5   SA1-dHex1, Hex3, HexNAc2, HexNAcol1 √ √   
1587.4   SU3-dHex3, Hex3, HexNAc1, HexNAcol1  √   
Abbreviations: SA, NeuAc; SU, sulphate; dHex, deoxyhexose; Hex, hexose; HexNAc, N-acetylhexosamine; 
HexNAcol, N-acetylhexosaminitol. 
 
The fractions Cyst 756-C-N, Cyst 756-C-A1 and Cyst 756-C-A2 were further 
fractionated by size using Bio-Gel P4 and the elution profiles are in Figure 4.4. Seven 
pooled subfractions were obtained in each of the fractions. These were N-1 to N-7 in 
Figure 4.4A, A1-1 to A1-7 in Figure 4.4B and A2-1 to A2-7 in Figure 4.4 C. As the 
material in Cyst 756-C-A3 was very limited, it was not further fractionated. Twenty-
one subfractions of Cyst756-C-N, -A1 and -A2, together with the unfractionated 
Cyst756-C-A3, were quantified by hexose assay (Table 4.4). The subfractions N-1 to 
N-7 were the most abundant, with hexose content ranging from 300-2,300 μg. The 
hexose content was less in subfractions in Cyst 756-C-A1 and -A2 (10 to 340 μg and 
7 to 260 μg, respectively) and even less (140 μg) in Cyst756-C-A3.  
 
Table 4.4 Quantitation of hexose in the subfractions N-1 to -7, A1-1 to -7 and A2-1 to -7 obtained from size 
fractionation and A3. 
Fractions 
Total Hex 
(μg) 
Fractions 
Total Hex 
(μg) 
Fractions 
Total Hex 
(μg) 
Fractions 
Total Hex 
(μg) 
N-1 2314.6 A1-1 337.8 A2-1 258.5 A3 140.0 
N-2 1867.9 A1-2 233.9 A2-2 99.2   
N-3 1835.8 A1-3 212.1 A2-3 75.5   
N-4 1351.3 A1-4 323.4 A2-4 24.9   
N-5 1147.5 A1-5 112.3 A2-5 82.3   
N-6 1280.9 A1-6 34.7 A2-6 35.6   
N-7 300.0 A1-7 10.8 A2-7 7.3   
Total 10098.0 Total 1265.1 Total 583.2 Total 140.0 
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Figure 4.4 Size fractionation of the three subfractions, Cyst756-C-N (A), Cyst756-C-A1 (B) and Cyst756-C-
A2 (C). The chromatography was on a Bio-Gel P4 column (1.6×90cm) eluted with 0.05 M NH4OAc. V0 is the void 
volume of the column; numbers 2-12 indicate the positions of elution of oligosaccharides with degrees of 
polymerization 2-12 in an acid hydrolysate of dextran glucose units. N-1 to N-7, A1-1 to A1-7 and A2-1 to A2-7 
designate the pooled fractions in each preparation. 
 
Fluorescent NGLs of these 22 subfractions were prepared using ADHP after mild 
periodate oxidation. The reaction mixture in each fraction was resolved by HPTLC 
together with the positive control SM1a (Figure 4.5). Numerous fluorescent bands 
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were detected in each fraction under UV light. The same plates were then probed for 
binding with mAb AE3 (Figure 4.5). The SM1a control was clearly bound by mAb 
AE3 on each of the plates. Immunostained bands were detected in subfractions 5 
and 6 of Cyst 756-C-N, subfractions 2 to 5 of Cyst 756-C-A1, subfractions 2 to 5 of 
Cyst 756-C-A2, and Cyst 756-A3 (Figure 4.5). However the intensities of these 
immunostained bands seemed to correlate with the amounts of NGLs visualized by 
fluorescence. This raised the possibility that the immunostained bands were non-
specific. 
 
The reaction mixtures of the two fractions Cyst 756-C-A1-3 and Cyst 756-C-A2-2 
(squared in Figure 4.5) were then selected for further fractionation on a silica column 
(Section 2.7) followed by binding analysis (Figure 4.6). The reaction mixture A1-3 
yielded four subfractions a to d (Figure 4.6A); the other, A2-2, yielded five 
subfractions a to e (Figure 4.6B). In both cases, subfraction a contained mainly 
excess lipid (not shown) and was not studied further. The remaining subfractions 
were chromatographed on two HPTLC plates with lactose AD-NGL (Lac.AD) and 
SM1a in the control lane. The plates were visualized by UV light and probed for 
binding by mAb AE3 (panel C and D, Figure 4.6). Clearly, numerous fluorescent 
bands with differing mobilities were observed in subfractions b to d in A1-3 and b to e 
in A2-2. In the control lane, only the fluorescent Lac.AD was visualized by UV. The 
position of the non-fluorescent glycolipid SM1a was marked. Immunostaining was 
observed only with SM1a by mAb AE3 on these two plates (panel C and D, Figure 
4.6). 
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Figure 4.5 Chromatogram binding analysis of mAb AE3 to NGLs in subfractions of Cyst 756-C-N, Cyst 
756-C-A1 and Cyst 756-C-A2, and of fraction Cyst 756-C-A3. The NGLs in the fractions were 
chromatographed together with the glycolipid SM1a on HPTLC plates, using CHCl3/MeOH/H2O, 60:35:8 (v/v), as 
solvent. The fluorescent NGLs were visualized under UV light (left panel). The same plate was incubated with 
mAb AE3 (right panel), followed by biotinylated anti-mouse IgM (μ-chain specific). Binding was visualized by 
colour development using the streptavidin-peroxidase followed by DAB liquid substrate system. O indicates the 
origin. Arrow indicates the position of SM1a, which was revealed by immunostaining with mAb AE3. Squares 
highlight the two subfractions Cyst 756-C-A1-3 and Cyst 756-C-A2-2 which were selected for further fractionation. 
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Figure 4.6 TLC analysis and mAb AE3 binding analyses of the NGLs in fractions Cyst 756-C-A1-3 and 
Cyst 756-C-A2-2. (A). TLC analysis of NGLs in Cyst 756-C-A1-3 (A1-3). (B). TLC analysis of NGLs in Cyst 756-
C-A2-2 (A2-2). b to e indicate subfractions obtained in in the prep-TLC of A1-3 and A2-2. The subfractions a 
which contained excess lipid in the two preparations was not shown. (C). Binding analysis of mAb AE3 using the 
NGLs in subfractions b to d of A1-3. (D). Binding analysis of mAb AE3 using the NGLs in subfractions b to e of 
A2-2. The NGLs were chromatographed together with the glycolipid SM1a and Lac.AD (Lane controls) on HPTLC 
plates, using CHCl3/MeOH/H2O, 60:35:8 (v/v), as solvent. The fluorescent NGLs were visualized under UV light 
(left panel). The same plate was incubated with mAb AE3 (right panel), followed by biotinylated anti-mouse IgM 
(μ-chain specific). Binding was visualized as in the legend to Figure 4.5. Arrows indicate the positions of Lac.AD 
and SM1a. O indicates the origin.  
 
The NGLs in subfractions N-1 to N-7, A1-1 to A1-7, and A2-1 to A2-7 as well as 
fraction A3 (Scheme 4.1) were analysed by MALDI-MS; the results are listed in three 
tables. Table 4.5 contained MS data of the seven subfractions in Cyst 756-C-N, 
Table 4.6 for the nine subfractions in Cyst 756-C-A1 and Table 4.7 for the ten 
subfractions in Cyst 756-C-A2 and the unfractionated Cyst 756-C-A3. In total, thirty-
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six molecular species were identified in NGL subfractions of N-1 to N-7, fifty in A1-1 
to A1-7 and fifty-one in A2-1 to A2-7. There were fourteen molecular species 
detected in the unfractionated A3 NGL fraction. Note that only major components are 
observed in the MALDI-MS spectra, very minor components cannot be seen. The 
same molecular ion may arise from different NGL components. In the absence of 
additional data (such as MS/MS), it is difficult to assign unambiguously the 
compositions of each component and to draw conclusions as to the number of 
sialylated or sulphated species in each subfraction. Therefore only the possible 
monosaccharide compositions corresponding to individual ions are listed in the three 
tables. The major components deduced to be present in N-1 to N-7 ranged from 
monosaccharide to nonasaccharide and most of these were neutral (Table 4.5). The 
deduced major components in subfractions A1-1 to A1-7 contained acidic moieties 
such as sialic acid and sulphate. In addition, there were neutral components as in N-
1 to N-7. Among subfractions of Cyst 756-C-A2 components with multiple negatively 
charged moieties, sulphate and sialic acid were deduced to be present. However, 
none of the molecular ions deduced corresponded to that of the putative AE3 
antigen-positive O-glycan (Figure 4.1C), SU1.Hex2.HexNAc2-OX. 
 
Thus from the results of antigenic analysis and MS we concluded that O-glycans 
reductively released from Cyst 756 contained little if any of the proposed AE3 
antigen-positive O-glycan.  
 
Table 4.5 Compositions of the NGLs in the seven subfractions of Cyst 756-C-N (tick indicates the 
corresponding ion is found in this fraction). 
m/z Monosaccharide composition 
Subfractions of Cyst 756-C-N 
1 2 3 4 5 6 7 
954.3 -OY 
   
√ √ 
 
√ 
1055.3 -OX 
   
√ √ √ √ 
1157.3 HexNAc1-OY 
   
√ √ √ 
 
1217.3 Hex1-OX √ √ √ √ √ √ √ 
1258.4 HexNAc1-OX 
     
√ √ 
1319.3 Hex1, HexNAc1-OY √ √ √ √ √ √ √ 
1363.4 dHex1, Hex1-OX 
      
√ 
1379.3 Hex2-OX 
      
√ 
1420.3 Hex1, HexNAc1-OX √ √ √ √ √ √ √ 
1465.0 dHex1, Hex1, HexNAc1-OY 
   
√ √ √ 
 
1522.3 Hex1, HexNAc2-OY 
  
√ √ √ √ 
 
1525.4 dHex1, Hex2-OX 
      
√ 
1538.3 SU2-Hex2-OX 
    
√ √ 
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1566.4 dHex1, Hex1, HexNAc1-OX 
   
√ √ √ √ 
1582.3 Hex2, HexNAc1-OX 
 
√ √ √ √ √ √ 
1640.3 SU2-Hex2, HexNAc1-OY 
  
√ √ 
   
1684.3 Hex2, HexNAc2-OY 
  
√ √ √ 
 
√ 
1728.3 dHex1, Hex2, HexNAc1-OX 
 
√ √ √ √ √ 
 
1785.3 Hex2, HexNAc2-OX 
   
√ √ 
  
1830.3 dHex1, Hex2, HexNAc2-OY 
 
√ √ √ √ 
  
1887.3 
Hex2, HexNAc3-OY 
SU2-dHex1, Hex2, HexNAc1-OX    
√ 
   
1932.2 dHex1, Hex2, HexNAc2-OX 
  
√ √ √ 
  
1947.2 
Hex3, HexNAc2-OX 
SU1-HexNAc4-OX    
√ √ 
  
1976.2 
dHex2, Hex2, HexNAc2-OY 
SA1, SU2-dHex1, Hex2-OX   
√ √ 
   
2033.2 dHex1, Hex2, HexNAc3-OY 
  
√ √ 
   
2049.2 Hex3, HexNAc3-OY 
  
√ √ 
   
2077.3 dHex2, Hex2, HexNAc2-OX 
  
√ 
 
√ 
  
2093.4 dHex1, Hex3, HexNAc2-OX 
  
√ √ √ 
  
2151.1 Hex3, HexNAc3-OX 
  
√ √ 
   
2195.2 dHex1, Hex3, HexNAc3-OY 
  
√ √ 
   
2239.2 dHex2, Hex3, HexNAc2-OX 
  
√ √ √ 
  
2297.1 dHex1, Hex3, HexNAc3-OX 
  
√ √ 
   
2341.2 
dHex2, Hex3, HexNAc3-OY 
SA1, SU2-dHex1, Hex3, HexNAc1-OX  
√ √ √ 
   
2444.1 dHex2, Hex3, HexNAc3-OX 
  
√ 
    
2458.3 
dHex1, Hex4, HexNAc3-OX 
SA2, SU2-dHex3, Hex2-OY 
SU1-dHex1, Hex1, HexNAc5-OX 
   
√ 
   
2604.1 
SA2, SU2-dHex4, Hex2-OY 
dHex2, Hex4, HexNAc3-OX 
SU1-dHex2, Hex1, HexNAc5-OX 
 
√ √ √ 
   
Abbreviations:  –OX and –OY are the 3- and 6- linked fragments of core GalNAc after periodate oxidation; -OX: -
OCH2-CH(NHAc)-CH2OH-CH2-ADHP; OY: -OCH2-CH2-ADHP; the rest abbreviations are in legends to Table 4.3. 
 
Table 4.6 Compositions of the NGLs in the nine subfractions of Cyst 756-C-A1 (tick indicates the 
corresponding ion is found in this fraction). 
m/z Monosaccharide composition 
Subfractions of Cyst 756-C-A1 
1 2 3b 3c 3d 4 5 6 7 
954.3 -OY 
  
√ √ √ √ √ √  
1055.3 -OX 
  
√ √ 
 
√ √ √  
1157.3 HexNAc1-OY 
   
√ √ √ 
  
 
1217.3 Hex1-OX √ √ √ 
 
√ √ √ √ √ 
1319.3 Hex1, HexNAc1-OY √ √ √ √ √ √ √ √  
1420.3 Hex1, HexHexNAc1-OX √ √ √ √ 
 
√ √ √ √ 
1465.0 dHex1, Hex1, HexNAc1-OY 
   
√ √ √ √ √  
1508.3 SA1-Hex1-OX 
   
√ 
  
√ 
 
 
1522.3 Hex1, HexNAc2-OY 
   
√ 
   
√  
1564.4 SU2-dHex1, HexNAc1-OX 
      
√ 
 
 
1566.4 dHex1, Hex1, HexNAc1-OX 
   
√ 
 
√ 
 
√  
1582.3 Hex2, HexNAc1-OX √ √ √ √ 
 
√ 
 
√  
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1640.3 SU2-Hex2, HexNAc1-OY 
   
√ √ 
  
√  
1654.9 SA1-dHex1, Hex1-OX 
    
√ 
   
 
1668.3 SU2-dHex2, Hex1-OX 
   
√ 
    
 
1684.3 Hex2, HexNAc2-OY 
 
√ 
 
√ 
 
√ √ √  
1698.4 Hex1, HexNAc2-OY 
   
√ 
    
 
1728.3 dHex1, Hex2, HexNAc1-OX √ √ 
 
√ √ √ √ √  
1749.5 SA1, SU1-Hex2-OX 
      
√ 
 
 
1785.3 Hex2, HexNAc2-OX 
   
√ 
 
√ √ 
 
 
1830.3 dHex1, Hex2, HexNAc2-OY √ √ 
 
√ √ √ 
  
 
1844.3 
SU2-Hex2, HexNAc2-OY 
SA2-dHex1, Hex1-OY    
√ √ 
   
 
1854.0 SA1-HexNAc3-OY 
 
√ 
      
 
1873.0 SA1-Hex2, HexNAc1-OX 
 
√ 
      
 
1887.3 Hex2, HexNAc3-OY 
   
√ 
 
√ √ √  
1932.2 dHex1, Hex2, HexNAc2-OX 
 
√ 
 
√ √ √ 
  
 
1947.3 
Hex3, HexNAc2-OX 
SU1-HexNAc4-OX    
√ 
    
 
1976.4 
dHex2, Hex2, HexNAc2-OY 
SA1, SU2-dHex1, Hex2-OX 
√ 
  
√ √ 
   
 
2005.0 SA2, SU2-dHex1, Hex1-OY 
    
√ 
   
 
2033.2 dHex1, Hex2, HexNAc3-OY 
   
√ √ √ 
  
 
2049.3 Hex3, HexNAc3-OY 
   
√ √ 
   
 
2077.3 dHex2, Hex2, HexNAc2-OX 
   
√ 
    
 
2093.4 dHex1, Hex3, HexNAc2-OX √ √ 
 
√ √ 
   
 
2142.0 SU1-dHex3, Hex1, HexNAc2-OX 
 
√ 
      
 
2151.1 Hex3, HexNAc3-OX 
    
√ 
   
 
2195.2 dHex1, Hex3, HexNAc3-OY √ √ 
 
√ √ 
   
 
2204.5 
SA1, SU2-dHex2, HexNAc2-OX 
SA1, SU1-dHex2, Hex3-OX   
√ 
     
 
2239.2 dHex2, Hex3, HexNAc2-OX √ √ 
  
√ 
   
 
2297.1 dHex1, Hex3, HexNAc3-OX 
    
√ 
   
 
2341.2 
dHex2, Hex3, HexNAc3-OY 
SA1, SU2-dHex1, Hex3, HexNAc1-OX 
√ √ √ 
 
√ 
   
 
2376.3 SU1-dHex1, Hex3, HexNAc3-OX 
  
√ 
     
 
2378.5 
dHex1, Hex1, HexNAc5-OX 
SA1, SU1-Hex4, HexNAc2-OY 
SA1, SU2-Hex1, HexNAc4-OY 
  
√ 
     
 
2394.3 
SU2-dHex1, Hex7-OY 
SA2, SU1-dHex2, Hex3-OY 
SA2, SU2-dHex2, HexNAc2-OY 
dHex2, HexNAc5-OX 
  
√ 
     
 
2444.1 dHex2, Hex3, HexNAc3-OX 
 
√ 
  
√ 
   
 
2458.3 
dHex1, Hex4, HexNAc3-OX 
SA2, SU2-dHex3, Hex2-OY 
SU1-dHex1, Hex1, HexNAc5-OX 
    
√ 
   
 
2549.2 
SU2-dHex4, Hex4, HexNAc1-OY 
SA2, SU1-Hex2, HexNAc3-OY 
SA2-Hex5, HexNAc1-OY 
√ 
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2560.1 dHex1, Hex4, HexNAc4-OY 
 
√ 
      
 
2604.1 
dHex2, Hex4, HexNAc3-OX 
SU1-dHex2, Hex1, HexNAc5-OX 
√ √ 
  
√ 
   
 
2706.0 dHex2, Hex4, HexNAc4-OY 
 
√ 
      
 
2809.0 
SA1, SU2-dHex1, Hex4, HexNAc3-OY 
SU2-dHex3, Hex4, HexNAc3-OY 
SA2-dHex4, Hex3, HexNAc1-OY 
 
√ 
      
 
Abbreviations are in the legends to Table 4.5. 
 
Table 4.7 Compositions of the NGLs in the ten subfractions of Cyst 756-C-A2 and the unfractionated A3 
(tick indicates the corresponding ion is found in this fraction). 
m/z Monosaccharide composition 
Subfractions of Cyst 756-C-A2 
A3 
1 2b 2c 2d 2e 3 4 5 6 7 
954.3 -OY 
  
√ 
    
√ 
  
√ 
1055.3 -OX 
  
√ 
    
√ 
  
√ 
1157.3 HexNAc1-OY 
 
√ √ √ 
      
√ 
1217.3 Hex1-OX √ √ √ √ 
 
√ √ √ 
  
√ 
1319.3 Hex1, HexNAc1-OY 
 
√ √ √ √ √ √ √ 
  
√ 
1409.0 dHex2, Hex1-OY 
     
√ 
    
 
1420.3 Hex1, HexNAc1-OX 
 
√ √ √ 
 
√ √ √ √ √ √ 
1464.9 dHex1, Hex1, HexNAc1-OY 
  
√ √ √ √ √ √ 
  
√ 
1504.4  SU1-dHex1, Hex2-OY 
      
√ 
   
 
1508.3 SA1-Hex1-OX 
  
√ 
       
 
1522.3 Hex1, HexNAc2-OY 
      
√ √ 
  
 
1564.4 SU2-dHex1, HexNAc1-OX 
     
√ √ 
   
 
1566.4 dHex1, Hex1, HexNAc1-OX 
       
√ 
  
√ 
1582.3 Hex2, HexNAc1-OX 
 
√ √ √ √ √ √ √ 
  
√ 
1625.2 SU2-dHex1, Hex1, HexNAc1-OY 
          
√ 
1640.3 SU2-Hex2, HexNAc1-OY 
  
√ √ 
  
√ √ 
  
√ 
1654.9 
SA1-dHex1, Hex1-OX 
dHex3, Hex1-OX   
√ √ √ 
     
 
1668.3 dHex1, Hex1, HexNAc2-OY 
  
√ √ 
      
 
1684.3 Hex2, HexNAc2-OY 
  
√ √ √ √ √ 
   
√ 
1694.4 SA1-dHex1, HexNAc1-OX 
      
√ 
   
 
1705.9 SU3-dHex1, Hex1, HexNAc1-OY 
    
√ 
     
 
1721.9 Su3-Hex2, HexNAc1-OY 
    
√ 
     
 
1728.3 dHex1, Hex2, HexNAc1-OX √ 
 
√ √ 
 
√ √ 
   
√ 
1749.5 SA1, SU1-Hex2-OX 
     
√ 
    
 
1785.3 Hex2, HexNAc2-OX 
   
√ 
      
 
1794.4 SA1, SU1-dHex1, Hex2-OY 
      
√ 
   
 
1800.9 dHex2, Hex1, HexNAc1-OX 
   
√ √ 
     
 
1830.3 dHex1, Hex2, HexNAc2-OY 
  
√ √ √ √ 
    
√ 
1844.3 
SU2-Hex2, HexNAc2-OY 
SA2-dHex1, Hex1-OY    
√ 
      
 
1851.9 SA1, SU1-Hex2, HexNAc1-OY 
    
√ 
     
 
1887.2 
Hex2, HexNAc3-OY 
SU2-dHex1, Hex2, HexNAc1-OX    
√ 
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1932.2 
dHex1, Hex2, HexNAc2-OX 
SA1, SU2-Hex2, HexNAc1-OY   
√ √ √ √ 
    
 
1947.2 
Hex3, HexNAc2-OX 
SU1-HexNAc4-OX    
√ 
      
 
1977.2 
dHex2, Hex2, HexNAc2-OY 
SA1, SU1-dHex1, HexNAc2-OX 
SA1-dHex1, Hex3-OX 
   
√ 
      
 
1995.1 
SU1-dHex2, Hex1, HexNAc2-OX 
dHex2, Hex4-OX      
√ 
    
 
2005.0 SA2, SU2-dHex1, Hex1-OY 
     
√ 
    
 
2033.2 dHex1, Hex2, HexNAc3-OY 
   
√ 
      
 
2050.2 
Hex3, HexNAc3-OY 
SU2-dHex1, Hex3, HexNAc1-OX    
√ √ 
     
 
2094.2 
dHex1, Hex3, HexNAc2-OX 
SA1, SU2-Hex3, HexNAc1-OY    
√ √ √ 
    
 
2151.1 
Hex3, HexNAc3-OX 
SA3-Hex2-OY    
√ 
 
√ 
    
 
2195.2 
dHex1, Hex3, HexNAc3-OY 
SU1-dHex1, HexNAc5-OY 
SA1, SU2-Hex3, HexNAc1-OX 
   
√ √ 
     
 
2275.1 SU1-dHex1, Hex3, HexNAc3-OY 
    
√ 
     
 
2297.1 dHex1, Hex3, HexNAc3-OX 
   
√ √ 
     
 
2342.2 
dHex2, Hex3, HexNAc3-OY 
SU2-dHex3, Hex3, HexNAc1-OX 
SA1, SU2-dHex1, Hex3, HexNAc1-OX 
   
√ √ 
     
 
2376.3 SU1-dHex1, Hex3, HexNAc3-OX 
 
√ 
        
 
2394.3 
SU2-dHex1, Hex7-OY 
SA2, SU1-dHex2, Hex3-OY 
SA2, SU2-dHex2, HexNAc2-OY 
dHex2, HexNAc5-OX 
 
√ 
        
 
2421.1 SU1-dHex2, Hex3, HexNAc3-OY 
    
√ 
     
 
2443.1 
SA1, SU2-dHex1, Hex3, HexNAc2-OY 
dHex2, Hex3, HexNAc3-OX    
√ √ 
     
 
2560.1 
dHex1, Hex4, HexNAc4-OY 
SA1-dHex4,Hex2, HexNAc2-OY 
SA1, SU3-Hex1, HexNAc4-OX 
SA1, SU2-Hex4, HexNAc2-OX 
    
√ 
     
 
2706.0 dHex2, Hex4, HexNAc4-OY 
    
√ 
     
 
2787.0 
SA1-dHex2, HexNAc6-OY 
SA2-dHex3, HexNAc4-OY 
dHex2, Hex7, HexNAc2-OY 
SU1-dHex2, Hex4, HexNAc4-OY 
SU3-dHex3, Hex4, HexNAc2-OX 
SA1, SU3-dHex1, Hex4, HexNAc2-OX 
    
√ 
     
 
Abbreviations are in the legends to Table 4.5. 
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4.5 Antigenic analyses of O-glycans non-reductively 
released from Cyst 756 
 
As discussed in Section 3.4.3, reductively released O-glycans need to be oxidized by 
periodate before conjugation to obtain reactive aldehydes at their reducing ends. The 
periodate oxidation causes cleavage of the core GalNAcol. However, as the core 
GalNAc may be a part of the AE3 antigenic determinant on the possible O-glycan 
structure (Figure 4.1C), non-reductive release of O-glycans was carried out. The 
resulting reducing oligosaccharides would be conjugated without periodate oxidation. 
 
Cyst 756 was subjected to preparative-scale (500 mg) non-reductive degradation 
using ethylamine at 22 °C or 65 °C as described in Section 2.4. This procedure lends 
itself better to large-scale degradation in a biochemical laboratory, rather than the 
use of hydrazine which is highly flammable and toxic and unsuitable for large scale 
use in a basic biosafety level 2 (risk group 2) laboratory environment. The two 
ethylamine conditions were referred to as E22 or E65. Hexose content of the 
products, as determined by dot-orcinol assay, was 3.2 for E22 and 6.6 mg for E65. It 
is well known that the yield of non-reductive was less than reductive release. The 
products from E22 were not investigated further.  
 
The workflow of non-reductive release under condition of E65 is summarized in 
Scheme 4.2. The products of E65 were fractionated by anion exchange 
chromatography using AG1-X8 as described in Section 2.5.1. Three fractions were 
successively eluted using 2 mM and 100 mM pyridine/AcOH (pH 5.0), and 300 mM 
Na2SO4. The first fraction was designated E65-N and the latter two were combined 
and designated E65-A (Scheme 4.2). Size fractionation of the E65-N and the E65-A 
fractions was carried out using a Bio-Gel-P4 (Figure 4.7). Twelve subfractions were 
obtained in the E65-N and the E65-A fractions (N-1 to N-6, and A-1 to A-6) based on 
the individual elution profile. These twelve subfractions were quantified by hexose 
assay (Table 4.8). Hexose content of the subfractions of N-1 to N-6 and A-1 to A-6 
ranged from 380-2,000 μg and 100-520 μg, respectively.   
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Scheme 4.2 Workflow of the non-reductive O-glycan release, fractionation and conjugation. 
 
 
Table 4.8 Quantitation of hexose in the subfractions N-1 to -6, and A-1 to -6 obtained from size 
fractionation. 
Fractions 
Total Hex 
(μg) 
Fractions 
Total Hex 
(μg) 
N-1 2020.0 A-1 538.8 
N-2 1159.2 A-2 264.0 
N-3 528.4 A-3 146.4 
N-4 372.4 A-4 184.8 
N-5 591.8 A-5 376.8 
N-6 386.2 A-6 105.6 
Total 5058.0 Total 1616.4 
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Figure 4.7 Size fractionation of the two subfractions, E65-N (A) and E65-A (B). The chromatography was on 
a Bio-Gel P4 column (1.6×90cm) eluted with 0.05 M NH4OAc. V0 is the void volume of the column; numbers 1 to 9 
indicate the positions of elution of oligosaccharides with degrees of polymerization 1 to 9 in an acid hydrolysate of 
dextran glucose units. N-1 to N-6, and A-1 to A1-6 designate the pooled fractions in each preparation. 
 
Fluorescent NGLs of these 12 subfractions were prepared using ADHP. The reaction 
mixture in each fraction was resolved by HPTLC together with the positive and 
negative controls, SM1a and Lactose-AD (Figure 4.8). Numerous fluorescent bands 
were detected in the NGL fractions N-1 to N-6 and A-1 to A-6 by UV light. The 
mobilities of the NGLs generated gradually increased from N-1 to N-6 and from A-1 
to A-6. This was in accord with the decreased size of the O-glycans in the 
corresponding fractions. Faint or no fluorescent bands were detected in N-1 and A-1, 
suggesting the limited amounts of NGLs in these two fractions. When the same 
plates were probed for binding with mAb AE3, only the positive control SM1a 
glycolipid gave immunostaining. No binding was detected to the NGLs in the twelve 
subfractions of E65-N and E65-A (Figure 4.8). 
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Figure 4.8 Chromatogram binding analysis with mAb AE3 of NGLs in subfractions of Cyst 756-E65-N (A), 
and Cyst 756-E65-A (B). The NGLs in the fractions were chromatographed together with the glycolipid SM1a and 
Lac-AD (lane controls) on HPTLC plates, using CHCl3/MeOH/H2O, 60:35:8 (v/v), as solvent. The fluorescent 
NGLs were visualized under UV light (left panel in A and B). The same plate was incubated with mAb AE3 (right 
panel), followed by biotinylated anti-mouse IgM (μ-chain specific). Binding was detected as in the legend to Figure 
4.5. O indicates the origin. 
 
Thus, although innumerable fluorescent NGLs were obtained from O-glycans non-
reductively released from Cyst 756, no AE3 antigen-positive bands were detected 
among them. This approach was not pursued further. Rather, we plan to 
chemoenzymatically synthesize the proposed core-3-based O-glycan sequence 
(below) and examine its AE3 antigen activity. This will be discussed in Section 4.7. 
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4.6 AE3 binding to a T antigen-containing glyco-amino acid 
 
I next revisited the T disaccharide sequence, Galβ-3GalNAcα-, as a recognition motif 
for mAb AE3 using a novel approach. The starting material was a commercially 
available glyco-amino acid Galβ-3GalNAcα-O-Ser, in which the core GalNAc is intact 
and is linked to the hydroxyl group of the Ser in α-configuration as in mucin-type 
glycoproteins. 
 
The glyco-amino acid was converted into an NGL by using an aldehyde-
functionalized DHPE developed by Dr Wengang Chai (to be described elsewhere). 
This lipid designated DHPA can be conjugated to the amine-terminating Ser by a 
peptide-type bond. In this NGL (Galβ-3GalNAcα-O-Ser-DHPA), designated T-Ser-
DHPA (Figure 4.9A), the ring-closed α form of the GalNAc is preserved as the 
conjugation reaction involves the amino group of the amino acid moiety. The AE3 
antigenicity of the T-Ser-DHPA was compared with that of two conventional NGLs. 
The first is T-DHPE (Galβ-3GalNAc-DHPE) designated T-DH generated by reductive 
amination and the second is T-AOPE (Galβ-3GalNAc-AOPE) designated T-AO 
generated by oxime ligation. In T-DH, the core GalNAc is in ring-open form. In T-AO, 
a proportion of GalNAc is in ring-closed form, but in β-configuration (310) (Figure 
4.9A).   
 
These three NGLs, together with the SM1a as the positive control and Lac.AD as a 
negative control were chromatographed on a HPTLC plate. The plate was visualized 
by primulin staining (Figure 4.9B). Clearly the glyco-amino acid derivative T-Ser-
DHPA had different mobility from the two glycan derivatives, T-DH and T-AO. Two 
replicate plates were probed for binding by mAb AE3 and the plant lectin PNA 
(Figure 4.9C and D). The T-Ser-DHPA and SM1a were bound by mAb AE3. The 
glycan NGL derivatives, T-DH and T-AO, and the negative control Lac.AD gave no 
detectable binding. This binding pattern was very similar to that of PNA.  
 
These results show that the T disaccharide-containing glyco-amino acid with intact 
GalNAcα- core is recognized by mAb AE3, whereas the ring-opening and the β-
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configuration of the core GalNAc in T-DH and T-AO, respectively abolish binding by 
mAb AE3.  
 
Figure 4.9 Chromatogram binding analysis of mAb AE3 and PNA with two T disaccharide-related NGLs. 
(A) Sequences of the T glycan-derived NGLs T-DH and T-AO, a glyco-amino acid derived T-Ser-DHPA and 
controls Lac.AD and SM1a. The anomeric configurations of T-AO and T-Ser-DHPA were shown in red. (B) 
HPTLC analyses of the NGLs and glycolipid visualized by primulin lipid staining. (C and D) Binding analysis of 
mAb AE3 and PNA on replicate HPTLC plates to A. The plates were developed by CHCl3/MeOH/H2O, 60:35:8 
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(v/v) as solvent. Then the plates were incubated with mAb AE3 followed by biotinylated anti-mIgM or biotinylated 
PNA directly. Detection of binding was in the legend to Figure 4.5.  
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4.7 Discussion 
 
Early work on mAb AE3 in the 1990s had indeed suggested that the T disaccharide 
(Galβ-3GalNAc) is involved in mAb AE3 binding but it was concluded that it might be 
only a part of a larger antigenic determinant (393). Our new results show that the 
core GalNAc must be intact and in α-configuration for mAb AE3 recognition. In the 
initial large screening microarray analysis (Section 4.1), the T-disaccharide was 
represented, but as DH- and AO-NGLs. These two probes are in ring-open and ring-
closed β-configuration, respectively. Thus our new results account for the lack of 
mAb AE3 binding to these.  
 
In the course of investigating the binding specificity of mAb AE3 in relation to the O-
glycan core region, we collaborated with other labs using recombinant or synthetic 
glycoproteins carrying different glycoforms including T disaccharide. As discussed 
below, their results corroborate our new findings.  
 
Professor Joy Burchell at King‘s College London has shown that mAb AE3 could bind 
to the T disaccharide α-linked to polyacrylamide [T-PAA, (396)], and to recombinant 
MUC1 expressing T-disaccharide (designated MUC1-T) (Figure 4.10, Burchell and 
Taylor-Papadimitriou unpublished). A glycosylation variant, MUC1-Tn with only 
GalNAc-linked MUC1, was not bound, nor were MUC1-sialylated T (MUC1-ST) with 
Neu5Acα-3Galβ-3GalNAc or the non-glycosylated MUC1. The Laboratory of 
Professor Ola Blixt in University of Copenhagen performed microarray analysis of 
mAb AE3 using a series of synthetic MUC5Ac-based glycopeptides, including non-
glycosylated and various glycosylation variants of the glycopeptide, Tn-, T-, STn- 
(Neu5Acα-6GalNAc-), 3ST- (Neu5Acα-3Galβ-3GalNAc-), 6ST- [Galβ-3(Neu5Acα-
6)GalNAc-] and diST- [Neu5Acα-3Galβ-3(Neu5Acα-6)GalNAc-]. The binding of mAb 
AE3 was restricted to the MUC5Ac-T (Figure 4.11, Blixt unpublished).  
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Figure 4.10 ELISA binding assay of mAb AE3 to different glycoforms (T-, ST-, Tn) of MUC1, naked MUC1 
and polyacrylamide (PAA) conjugated T and ST. Results obtained from Joy Burchell (unpublished). 
 
 
Figure 4.11 Microarray analysis of mAb AE3 with 15 glycans and 30 mucin-type glycoproteins. The 
glycoproteins are based on MUC2, MUC5 or MUC6, with different combinations of glycoforms. Results obtained 
by curtsey of Ola Blixt (unpublished).  
 
The naturally occurring glyco-amino acids, as part of O-glycopeptides, all have α-
linkage between the core GalNAc and the polypeptide backbone. The T-PAA also 
has an α-linkage in the core region. In order to confirm that the configuration of the 
core GalNAc is important for mAb AE3 binding, Blixt lab performed microarray 
analysis using more than 310 sequence-defined synthetic glycan probes which 
encompassed a variety of mammalian type sequences, representative of complex-
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type N-glycans, core and peripheral regions of O-glycans, blood group antigen-
related sequences and gangliosides. The α- and the β- isomers of T disaccharide 
were printed on the microarray with a propyl spacer (designated Sp8, which is -CH2-
CH2-CH2-NH-). The α-isomer, Galβ-3GalNAcα-O-Sp8, was the only probe that gave 
positive binding with mAb AE3. There was no detectable binding to the β-analogue 
(Figure 4.12, Blixt unpublished). This result corroborates our finding that the 
anomeric configuration of the core GalNAc is important in the recognition by mAb 
AE3. 
 
Taken together, the results above and the loss of AE3 antigen after treatment of cells 
with endo-α-N-acetyl-D-galactosaminidase observed earlier (383) show that the α-
linked T disaccharide Galβ-3GalNAcα-O- is indeed a moiety recognized by mAb AE3. 
Modification to either of the two monosaccharide residues including sialylation of the 
galactose, ring-opening, or splitting of the core GaNAc obviates the mAb AE3 
recognition.   
 
 
Figure 4.12 Microarray analysis of mAb AE3 with more than 310 sequence-defined glycans. These glycans 
were covalently immobilized on solid membranes. Two sequences below the chart are the AE3 antigen-positive 
probe T-α and a close comparison, T-β, which lacks AE3 binding activity. The microarray contains a variety of 
mammalian type glycan sequences, representative of complex-type N-glycans, core and peripheral regions of O-
glycans, blood group antigen-related sequences and gangliosides. Results obtained by curtsey of Ola Blixt 
(unpublished). 
 
The results above do, however, need to be reconciled with our previous data that 
show both the natural and synthetic forms of the sulphated glycolipid SM1a to be 
bound by mAb AE3. Therefore, there are two structurally and biosynthetically distinct 
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carbohydrate sequences bound by mAb AE3 (Structures A and B in Scheme 4.3). 
One is the T-disaccharide with GalNAc in α-configuration (Structure A in Scheme 4.3) 
and the other is a sulpho-oligosaccharide sequence with GalNAc in β-configutaion 
(Structure B in Scheme 4.3). This was the impetus for me to attempt to isolate an O-
glycan (Scheme 4.3C) containing such a sequence. I performed microarray analyses 
with mucin type glycoproteins, identified an abundantly available AE3 antigen-
positive glycoprotein preparation, Cyst 756, and carried out antigenic analyses of the 
reductively and non-reductively released O-glycans therefrom. We reasoned that 
although the conjugation of both the reduced and the reducing O-glycans to ADHP 
by reductive amination would sacrifice the core GalNAc, the remaining backbone 
sequences would be available for binding with mAb AE3. However, neither 
immunoreactivity nor MS of the NGLs were suggestive of these sequences. These 
findings suggest that such O-glycans, if present, must be extremely minor 
components on the mucin preparation investigated, which in fact was not among the 
most antigenically active substances in the glycoprotein array. 
 
 
Scheme 4.3 Two glycan sequences (A and B) recognized by mAb AE3 and the proposed O-glycan 
sequence recognized by AE3 (C).  
 
Evidence for the existence of two kinds of AE3 active antigens has been obtained 
from immunohistochemical analyses in Joy Burchell Laboratory (Figure 4.13, Burchell 
and Taylor-Papadimitriou unpublished) using two MUC1-reactive antibodies in 
addition to mAb AE3. HMFG2, an antibody reacting with a wide range of MUC1 
glycoforms, showed strong and homogeneous binding to the membrane. The mAb 
AE3 showed not only strong immunoreactivity in areas bound by HMFG2, but also to 
cytoplasmic components. Another antibody, 1B9, which is known to bind to T-MUC1, 
gave more heterogeneous membrane-associated staining. The results suggest that 
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mAb AE3 binds to two types of components in breast cancer tissue; these may be T 
antigen-carrying MUC1 and glycolipids. This will require investigation. 
 
 
Figure 4.13 Immunostaining of mAb AE3 and two other T-antigen targeting antibodies HMFG2 and 1B9 to 
primary breast cancers. Formalin fixed paraffin embedded sections of primary breast cancers were used. 
Results obtained by curtsey of Joy Burchell (unpublished). 
 
Two avenues are being considered to prove the existence of the two types of AE3 
antigen. One is to extract these AE3 antigen-positive components from breast tumour 
tissues and determine their glycan sequences. The other is to synthesize the 
proposed core-3-based O-glycan sequence (Scheme 4.3C) by a chemoenzymatic 
approach and examine its AE3 antigen activity. Assignment of the sequences of the 
two AE3 antigens would help to reveal the key glycosyltransferases required for their 
synthesis and will lead to genetic studies of the corresponding genes that are altered 
in epithelial oncogenesis. 
 
Another study under current investigation in our collaborator Professor Mark 
Greene‘s Lab in University of Pennsylvania is the crystallographic studies of mAb 
AE3 complexed with the two different glycan sequences. It is hoped that a 
comparison of the complexes generated, will elucidate the structural basis of the 
apparent dual specificity of mAb AE3.  
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Chapter 5  
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Two cancer-associated carbohydrate antigens F77 and AE3 were studied in this 
thesis. Their higher levels of expression in cancer cells and tissues than in normal 
raise the possibility of their involvement in cancer biology through interaction with 
endogenous binding receptors. The detailed understanding of the two antigens, the 
key glycosyltransferases and the two antibodies also gives rise to opportunities for 
exploring clinical applications, as cancer biomarkers and therapeutic agents. This 
chapter is concerned with these aspects. 
 
5.1 Possible biological relevance of antigens of F77 and 
AE3 
 
In the pages that follow, I discuss the possible involvement of the two antigens, F77 
and AE3 and their corresponding glycosyltransferases in the pathobiology of cancer 
cells. 
 
5.1.1 F77 antigen and related carbohydrate sequences 
 
The F77 antigen encompasses the type 2 blood group H sequence β1,6-linked to a 
poly-LacNAc backbone. As reviewed in Chapter 3, there is elevated expression of 
branching N-acetylglycosaminyltransferases, GCNTs, and persistent expression of 
both type 2 blood group H antigen and corresponding α1-2 fucosyltransferase FUT1 
in prostatic cancer tissues and cell lines compared to normal prostate tissues and 
cells. In a recent study, using the cancer progression model of low (androgen-
dependent) and high passage (androgen-independent) LNCaP cells, Bennun et al 
showed that the major glycosylation difference between the two states was the 
increased expression of type 2 blood group H and Ley antigens. There was elevated 
FUT1 activity in the more aggressive high passage cells (397). Similarly, real time 
PCR showed FUT1 expression was elevated in prostate cancer tissue relative to 
normal tissue (398). The expression of blood group H may also arise from loss of 
expression of blood group A and B antigens, which unmasks blood group H antigens, 
among these is F77 antigen. 
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The biological relevance of the blood group H expression on cancer cells has not 
been well understood. In different biological contexts, some correlations have been 
described with respect to apoptotic potential of cancer cells and expression of blood 
group H antigen. It has been reported that mAb F77 can induce modest apoptosis of 
prostate cancer cells (341). However, in a colon carcinoma model, poorly tumorigenic 
REG cells transfected with human (FUT1) or rat α1,2-fucosyltransferases (FTA and 
FTB) were more resistant to apoptosis; knockdown of these enzymes in the 
spontaneously tumorigenic PRO cells increased sensitivity to apoptosis induced by 
serum deprivation (399). The anti-apoptotic effect of the α1,2-fucosylated antigens 
was suggested to be associated with the evasion of CD4 lymphocyte-mediated 
immune surveillance (399). 
 
The F77 antigen may be involved in the modulation of the growth of prostatic gland. It 
was found that in serum-free culture medium, the addition of the type 2 blood group 
H specific lectin, UEA-I, significantly reduced testosterone-stimulated growth and 
branching morphogenesis of rat ventral prostates compared with the addition of other 
lectins (400). This suggested that blood group H antigen and the corresponding 
fucosyltransferases may somehow be involved in normal prostatic development. It is 
tempting to predict that the type 2 blood group H may be also involved in the growth 
of prostate cancer given that blocking the F77 antigen by mAb F77 has been noted to 
inhibit tumour growth (341). 
 
It is also possible that F77 antigen is involved in prostate tumour metastasis. As 
reviewed in Section 1.2.3, the decreased expression of blood group A and B is 
associated with increased cellular motility (165,166). In particular, loss of capping of 
the H antigen by the blood group A and B monosaccharides in prostate cancer has 
been reported (380,381,401). It is thus possible that F77 antigen facilitates tumour 
metastasis by promoting prostate cancer cell motility. 
 
The proteins carrying the F77 antigen are not known. One of the carrier proteins has 
been detected from the extracts of prostate cancer cells (Hongtao Zhang in Mark 
Greene‘s laboratory, unpublished), as mentioned in Chapter 3. But the identity of it is 
not clear. Some glycoproteins have been reported to carry blood group antigens, 
such as a splice variant of CD44 and integrin. These glycoproteins are involved in 
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cell-cell and cell-matrix adhesions. Alteration of glycosylation of these molecules can 
potentially influence their biological functions such as in tumour cell invasion and 
metastasis. In a highly tumourigenic clone of rat colon carcinoma, blood group H 
antigen was found to be largely carried by a splice variant of CD44 (402). It was 
found that the tumorigenicity could be influenced by blood group H antigen 
modification of CD44 (402). Integrins were found to be a major carrier of the type 2 
blood group A and B antigens in some human colon cancer cell lines (403). 
Expression of blood group A or B antigen on integrins α3, α6 or β1 was suggested to 
affect the interactions between the α and β subunits, thereby changing the matrigel-
dependent haptotactic motility (which is a measure of invasive activity of tumour cells) 
of colonic tumour cells (165,166). The glycosylation of integrins was also found 
important in the interaction between integrins and laminin in the extracellular matrix 
(404). Furthermore, integrin-mediated adhesion and growth can be promoted by 
expression of hyaluronic acid (Figure 1.1) and large tumour-associated glycoproteins 
such as mucins . Evidence has been presented that these large molecules can 
mechanically push matrix-bound integrins to enter a focal adhesion where integrins 
are clustered and integrin-dependent growth factor signalling is elicited. This was 
believed to be independent of the biochemical interactions of the glycans with their 
binding proteins (405). 
 
Although from the discussion above it can be inferred that F77 antigen participates in 
a number of ways in prostate cancer progression, the biological receptor of F77 
antigen has not been described. Here I propose that the biological functions of F77 
antigen and its poly-LacNAc backbone sequences are mediated, at least in part by 
galectins. Proteins of the galectin family has been reported to be variously involved in 
cancer pathology, including cell proliferation, apoptosis, angiogenesis, and 
metastasis. Particularly, it has been known that many prostate cancer cell lines, 
including PC3, express galectin-3 (406). The galectin-3 has also been reported to be 
expressed in human prostate cancer tissues (406,407) but some results using 
various polyclonal or monoclonal antibodies have been contradictory (408). In a 
recent study, galectin-3 was uniformly detected in the basal cell layer of prostate 
cancer tissues (409). Basal cells are suggested to be cells of origin of prostate 
cancers (410). Indeed, in prostate cancer cells, knockdown of galectin-3 was 
associated with reduced cell proliferation, migration and invasion in vitro, and with 
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decreased tumour formation and increased apoptosis in vivo (409,411). Galectin-1, 
which was reported to be the most abundant galectin in prostate cancers, was also 
positively correlated with the disease progression (412). Immunostaining of galectin-1 
on capillary endothelial cells was increased in prostate tumour tissues compared to 
the non-tumoural stroma area (413). Expression of this endogenous lectin was highly 
associated with angiogenesis. Knockdown of galectin-1 reduced the formation of new 
vasculature in prostate cancer (412). Recently it was found that binding of galectin-1 
to β1,6-linked poly-LacNAc on VEGFR2 could initiate VEGF-like signalling, and could 
lead to the tumour neovascularization (152). 
 
There are many reports on galectins in cancer events mediated by interaction with 
poly-LacNAcs on N-glycans as reviewed in Section 1.2.2. Relatively few reports have 
focused on interactions of galectins with poly-LacNAcs on O-glycans. In bladder 
tumour cells which were shown to highly express the branching enzyme GCNT1, 
poly-LacNAc containing O-glycans were detected on MHC class I-related chain A 
(MICA). Galectin-3 binding to core 2 O-glycans on MICA reduced the affinity of MICA 
to its biological receptor NKG2D (natural killer group 2 member D) on NK cells (374). 
In addition, MUC1 was found to be expressed on both bladder and prostate tumour 
cells. On these tumour cells expressing GCNT1, MUC1 was found highly O-
glycosylated, carrying poly-LacNAc chains. Engagement of galectin-3 with its ligands 
on MUC1 attenuated the interaction of tumour cells with NK cells, leading to the 
reduced granzyme B secretion by NK cells. The interaction of galectin-3 with MUC1 
also interfered with the access of tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL) to the tumour cell surface. Thus poly-LacNAc on O-glycans 
could mediate the evasion of tumour cells from the NK cell-mediated killing, 
facilitating tumour dissemination through the circulation (414,415).  
 
Although multiple galectins are implicated in the pathobiology of prostate cancer, 
there is currently a lack of evidence of galectin interactions with the branched blood 
group H sequence, although it is well-known that most galectins bind well to poly-
LacNAc sequences. Prediction of the interaction between F77 antigen and galectins 
is based on two pieces of evidence. First, earlier studies of Ten Feizi‘s lab showed 
that blood group H antigen on a linear backbone was clearly bound by galectin-1; the 
branched poly-LacNAc sequences could also be bound (18). Second, Cummings‘ 
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group corroborated those findings by microarray analyses of galectins 1, 2 and 3 with 
sequence-defined glycans. It was found that these galectins, at different 
concentrations, could bind to blood group H on linear poly-LacNAc backbones (17). It 
is therefore reasonable to predict that the F77 antigen which combines blood group H 
and the branched poly-LacNAc would also interact with galectins. We will shortly 
investigate this. 
 
5.1.2 AE3 antigen and related carbohydrate sequences 
 
One of the sequences recognized by mAb AE3 is T disaccharide α-linked to serine or 
threonine (Galβ-3GalNAcα-Ser/Thr). It is a well-known pan-carcinoma antigen, 
variously designated as Thomsen-Friedenreich antigen, TF antigen, T antigen or 
core 1. This antigen is found on the surface of about 90% of all human carcinomas 
including colon, breast, bladder, prostate, liver, ovary and stomach (416), but is 
lacking on normal adult tissues (417). The expression pattern of T antigen was found 
to overlap considerably with AE3 antigen on many epithelial cancers (385-389), 
implying a relationship between the T disaccharide and the antigens that mAb AE3 
recognizes. The mechanism for the increased expression of T antigen in cancers is 
not fully understood. It is likely that the expression of such a structure is the 
consequence of the alterations of several glycosyltransferases in conjunction with 
other mechanisms such as the increased availability of substrate UDP-Gal (416). 
This needs investigation. 
 
In spite of the high prevalence of T antigen in tumour cells, little is known about the 
carrier proteins. A recent study using an enzymatic approach to label the T antigen 
on human breast adenocarcinoma MCF-7 cells identified more than 700 putative T 
antigen-carrying glycoproteins (418). Among these glycoproteins, MUC1 has been 
extensively investigated. Immunohistochemical studies revealed that MUC1 was the 
predominant carrier of T antigen in gastric and colorectal adenocarcinomas (419). In 
one study it was observed that galectin-3 in the circulation promoted adhesion of 
human breast or colon cancer cells to human umbilical vein endothelial cells through 
an interaction with MUC1 carrying T antigen (420). The interaction was suggested to 
change the distribution of MUC1 on tumour cell surface, exposing cell adhesion 
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molecules, which would otherwise be ―shielded‖, and thus allowing epithelium to 
endothelium interaction (420).  
 
Given its broad distribution in cancers and lack of expression in normal tissues, the T 
antigen has been suggested to be associated with tumour formation. It has been 
implicated in cancer cell proliferation, metastasis and angiogenesis (416). 
Interestingly, investigations of these associations of T antigen in cancer cell biology 
so far have also focused on galectin-mediated interactions, especially galectin-3. 
Expression of galectin-3 could be induced on endothelial cells by T antigen-bearing 
glycoproteins or cancer cells. Galectin-3 could then mediate docking of T antigen-
expressing tumour cells onto endothelium (421). Galectin-3 was also found to be 
expressed on breast and prostate cancer cells. It could help the homotypic 
aggregation of tumour cells in the circulatory system (422,423). In addition to tumour 
cell-endothelium interactions, galectin-3 has been suggested to facilitate the evasion 
of tumour cells from immune surveillance by inducing apoptosis of T cells (424,425). 
 
However, there has been evidence contradicting the results above. A detailed study 
of galectins 1, 2 and 3 using glycan microarray analysis indicated that galectin-1 and 
-3 did not bind significantly to T antigen and suggested T antigen may not be the 
glycan that was responsible for the effects reported for the galectins (17). This needs 
to be further investigated as the highly clustered presentation of T antigen on the 
cancer cell surface may enhance the avidity for the galectins. A T antigen-carrying 
glycopeptide was recently isolated from Pacific cod and was shown to bind to 
galectin-3 with picomolar affinity. The glycopeptide was able to inhibit galectin-3-
mediated angiogenesis, tumour-endothelial cell interaction, metastasis and T cell 
apoptosis (426). Earlier studies reported that galectin-3 interacted with human serum 
albumin carrying T antigen; this interaction could be inhibited by either a T antigen-
targeting peptide (designated P30) or a T antigen-mimicking glyco-amino acid 
lactulosyl-L-leucine (421,422). Further studies demonstrated that T antigen-mediated 
tumour cell adhesion and metastasis could be inhibited by antibodies (such as JAA-
F11) against T antigen  (427) or galectin-3 (428). It would be interesting to test if mAb 
AE3 shows inhibitory effects similar to those of T antigen-targeting antibodies. 
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The other carbohydrate sequence that mAb AE3 recognizes is the sulphoglycolipid 
SM1a. So far this glycolipid has only been described as a minor component in rat 
kidney (429) and in the monkey kidney cell line Verots S3 (349). SM1a was 
postulated to be a precursor of the di-sulphated glycolipid analogue SB1a (349), 
which was shown to be abundantly expressed on the surface of human 
hepatocellular carcinoma cell line PLC/PRF/15 but not detectable in glycolipid 
extracts from cirrhotic liver or normal liver using a mAb against SB1a (430). SB1a 
glycolipid was shown to mediate binding of human colon carcinoma CCK-81 cells to 
galectin-4 coated plates. This binding of the cancer cells was inhibited by antibodies 
against SB1a or galectin-4 (431). The sulphated O-glycan analogue of SM1a on 
mucin type glycoprotein has not been described to our knowledge. The involvement 
of SM1a and the proposed O-glycan analogue based on core 3 in cancer pathology 
is yet to be investigated. 
 
In sum, although the sequences of the two carbohydrate antigens F77 and AE3 are 
distinct, one thing in common is both of them can be potentially recognized by 
galectins. This will be investigated in the follow-up studies.  
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5.2 Potential clinical applications of the antigens and 
antibodies of F77 and AE3 
 
In the pages that follow, I discuss possible uses of the F77 and AE3 systems as 
biomarkers or in cancer therapy. 
 
5.2.1 Diagnostic and prognostic biomarkers 
 
There are limitations to the direct use of F77 antigen as a serum biomarker because 
of the presence of the antigen on red blood cells. As referred to in Chapter 3, there is 
potential, however, to explore the F77 antigen expressing glycoproteins as 
biomarkers, given that F77 has now been detected on glycoproteins of prostate 
cancer cells. Although it is still not known whether F77 antigen is present on N-
glycans, it is conceivable that mAb F77 would bind to the N-glycan sequences a and 
b depicted below. Highlighted in red are the residues potentially involved in the 
recognition of mAb F77.  
 
 
 
Both a and b are type 2 blood group H-based sequences. Structure a is a type 2 
blood group H on poly-LacNAc β-6 linked to N-glycan backbone on the 6-linked Man 
branch. It is the N-glycan equivalent of the F77 antigen sequence characterized on 
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O-glycans and glycolipids. In addition, the type 2 blood group H sequence directly 
linked to the 6-branch Man expressed on N-glycan as depicted in structure b may 
also be bound.  
 
The question then arises as to whether such N-glycans and O-glycans of the type 
described in Chapter 3 can occur on glycoproteins, such as the prostate cancer-
associated glycoproteins PSA, prostate-specific membrane antigen (PSMA), and 
prostate stem cell antigen (PSCA). If they indeed contain F77 antigen-positive 
sequences, targeting the F77 glycoforms of the glycoproteins could potentially 
improve the sensitivity and specificity of the current assays. In the past, evidence has 
been presented for the elevated expression of blood group H (Fucα1,2-Gal-) antigen 
on PSA in sera of prostate cancer patients, relative to that of patients with benign 
prostatic hyperplasia (398).  
 
As mentioned in Section 5.1.2, the T antigen recognized by mAb AE3 is broadly 
expressed in many cancers but rarely in normal tissues. Thus it has been extensively 
investigated as to whether this carbohydrate motif can be used as a diagnostic or 
prognostic biomarker (432). Historically, the detection of T antigen has relied on 
lectins such as Amaranthus caudatus lectin, Artocarpus integrifolia/jacalin and PNA, 
and mAbs such as A78-G/A7 and HH8. However, most of these reagents are not 
purely specific to Galβ-3GalNAcα- sequence. Lectins of A. caudatus and A. 
integrifolia/jacalin can bind to GalNAcα-, as in Tn antigen, and α2,3-linked sialyl-T 
antigen NeuAcα-3Galβ-3GalNAc (433,434). PNA and antibody A78-G/A7 are able to 
bind to Galβ-3GalNAcβ- such as asialo-GM1 (433,435). The antibody HH8 could 
accommodate C6 substituted GalNAc (core 2) (436). The differing binding 
specificities of these reagents may have led to contradictory results on the value of T 
antigen in prognosis and metastasis. Having said that, generally higher levels of T 
antigen expression have been associated with poorer prognosis in many types of 
cancers (437). In this regard, although mAb AE3 is not purely specific to the α-linked 
T disaccharide (Galβ-3GalNAcα-) either, it is clear from our investigation that asialo-
GM1 or C6 substituted GalNAc are not bound by mAb AE3. It would be interesting 
therefore to test whether mAb AE3 is able to better detect α-linked T antigen than the 
above-mentioned  antibodies or lectins. 
 
 195 
 
An alternative to detecting glycans or glycoproteins directly is to analyse the antigen 
expression on circulating tumour cells (CTCs). This can be applied to both F77 and 
AE3 antigens. Our collaborators are now investigating if there occur CTCs containing 
F77 antigen in patients with prostate cancer. If CTCs can be detected, it will be 
desirable to evaluate whether their presence correlates with prostate tumour 
progression. 
 
Glycosyltransferases are another type of good candidate for biomarkers. As 
suggested by the glycosyltransferase transfection study (366) the branching 
glycosyltransferases GCNTs and the fucosyltransferase FUT1 play a key role in the 
biosynthetic pathway of the F77 antigen. As these glycosyltransferases are essential 
for the synthesis of F77 antigen, their levels of expression in the tumour cells may be 
correlated with prostate cancer progression and thus be of prognostic value.  
 
Another strategy is to look for autoantibodies, which have been considered as prime 
candidates for biomarkers in early stage cancer (242). The presence of 
autoantibodies against F77 antigen in sera of prostate cancer patients requires 
investigation. In order to perform this investigation, the blood samples should be 
collected at 37 °C to avoid absorption of the potential autoantibodies to red cells. 
Clearly, patients carrying these autoantibodies are likely to be only mild cases, 
otherwise large amounts of autoantibodies would cause anaemia given their ability to 
agglutinate red cells  and would have been detected. The autoantibodies against the 
AE3 antigen, T disaccharide, may be used as diagnostic biomarkers. It was reported 
that all humans have naturally occurring antibodies against T antigen (438). Early 
studies suggested that these antibodies were probably elicited by our own intestinal 
microbiome, which contain strains of bacteria that express T antigen (439). Level of 
autoantibodies against T antigen can be used as an indication of the stage of cancer. 
Higher levels of autoantibodies in sera of patients with stomach and breast cancer 
were found to correlate with better survival rates (440,441). Perhaps this is a 
reflection of lower levels of the circulating T antigen. In addition, glycosylation pattern 
of the IgG isotype of autoantibodies have also been suggested to have diagnostic 
and prognostic value in gastric cancer (442,443). This needs systematic investigation. 
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5.2.2 Therapy 
 
The two antibodies F77 and AE3 do offer therapeutic possibilities. Antibody AE3 with 
specificity to T antigen deserves investigation in tumour therapy and imaging. 
Recently an antibody JAA-F11 which is highly specific to α-linked Galβ-3GalNAc has 
shown promising results in preclinical settings (444,445). It has strong anti-
metastasis activity in vivo and in vitro (427,445,446). JAA-F11 stained 32 of 41 
human breast cancer cell lines, irrespective of their estrogen, progesterone or HER2 
receptor status (447). This antibody was also capable of imaging human triple-
negative breast tumours in mice (447). Therefore as an antibody targeting the same 
antigen, it would be desirable to compare the capability of mAb AE3 in the same 
settings as JAA-F11.  
 
Although direct applications of mAb F77 in tumour imaging and tumour therapy are 
precluded on account of binding of this IgG3 antibody to red cells, engineering of the 
antibody for cancer therapy is a possible strategy. Efforts are being made to 
generating single chain variable region (scFv) and humanized forms of mAb F77 by 
our collaborators. There is considerable potential to capitalize on the cold reactive 
(‗cold agglutinin‘) property of the native antibody, namely the diminished antigen 
binding at temperatures above 20 ˚C. A monomeric scFv F77 antibody will further 
reduce the binding affinity. Therefore at body temperature, it is possible that the low 
affinity scFv would not agglutinate human red cells. If this is indeed the case, creating 
a hybrid molecule fusing the F77 scFv and a second prostate-specific scFv would 
target different antigenic determinants on prostate tumour cells. This hybrid antibody 
could also be used for immunodetection of human prostate cancer. 
 
Another avenue has been to engineer the T lymphocytes and other immune cells to 
direct them to cancer cells using chimeric antigen receptors (CARs). These receptors 
are engineered recombinant transmembrane molecules that often consist of scFv of 
an antibody and a transmembrane- and cytoplasmic domain such as CD3-δ, to 
transduce signals to activate the T cells. As CARs can target not only processed 
antigens but also native cell surface antigens such as glycans and glycolipid 
structures, T cells grafted with CARs open immunotherapy possibilities of directing at 
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cancer-associated carbohydrate antigens. Examples of CARs targeting glycans 
currently under investigation include those targeting GD2, GD3 and Ley (448). In 
order to confer stronger signalling properties and persistence to the T cells, a second 
generation of CARs has been designed by fusing the antigen-binding site with the 
activating receptor and the cytoplasmic domain of a costimulatory receptor such as 
CD28, 4-1BB and OX40 (Scheme 5.1A). Recently, engineered T cells containing 
scFv of an anti-GD3 mAb (MB3.6) in frame with δ-chain and CD28 dual signalling 
showed great growth inhibitory of subcutaneously transplanted melanoma cells in the 
presence of IL-2 (449). Many of these second-generation CARs are in clinical trials 
(448). One of the big challenges to overcome is the paucity of truly tumour-restricted 
antigens. Recently a new strategy has been reported by splitting the activating and 
costimulatory signals, and installing two different receptors, a CAR and a chimeric 
costimulatory receptor (CCR) to a T cell. The two receptors target two different 
antigens. Although neither antigen is strictly tumour-specific, the co-expression of the 
two tumour-associated antigens can efficiently differentiate the tumour cells from 
normal cells. Using this strategy, Sadelain group produced T cells carrying CAR and 
CCR against PSCA and PSMA, respectively (450). They selected a low-affinity scFv 
targeting PSCA to generate a CAR with diminished activities such that T cells could 
not be activated without the costimulatory signal from CCR. The engineered T cells 
specifically targeted double positive prostate cancer cells and subsequently killed 
these, leaving tumour cells expressing only one antigen intact (450). We propose the 
potential application for mAb F77 is to create engineered T-cells transduced with 
both a CAR containing scFv of F77 and a CCR that recognizes a second prostate 
cancer-associated antigen, such as erbB3. By critical adjustment of activating signals, 
a F77 CAR could be generated with low binding activity to F77 antigen. Therefore 
normal cells such as red cells expressing F77 antigen alone would not activate T 
cells (Scheme 5.1B). The hypothesis is that when prostate cancer tumour cells 
expressing both F77 antigen and erbB3 are recognized, the costimulatory signal from 
the recognition by CCR, in conjunction with the signal from CAR, would activate T 
cells, leading to the specific attack of tumour cells (Scheme 5.1C). 
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Scheme 5.1 Scheme of the engineered T cell with second-generation CAR and the strategy for designing 
T cells with two receptors: CAR and CCR to spare normal cells and selectively attack tumour cells. (A) A 
second-generation CAR is usually composed of an scFv, a CD3δ activating subunit and a costimulatory motif 
which can be CD28, 4-1BB or OX40. A strategy is proposed to specifically target tumour cells by generating T 
cells transduced with a CAR that recognizes F77 antigen with low affinity and a CCR (with two costimulatory 
motifs CD28 and 4-1BB) that binds with high affinity to another antigen (such as erbB3). When these T-cells 
encounter normal cells, such as red cells expressing F77 antigen as in (B), they cannot be activated because the 
signal from the low-affinity CAR alone is not strong enough. When the engineered T-cells encounter tumour cells 
expressing both antigens as in (C), they receive both CAR and CCR signals and become activated. 
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5.3 Future prospects 
 
The studies in this thesis have fully characterized the prostate cancer-associated 
antigen F77, as well as partially characterized the broadly distributed epithelial 
cancer-associated antigen AE3. As mAb AE3 has been found to recognize two 
distinct glycan sequences (structures a and b in Scheme 4.3), and the likely O-glycan 
analogue of structure b has proven difficult to isolate, future work will be focused on 
the chemo-enzymatic synthesis and antigenic analysis of the proposed AE3-active 
O-glycan: 
 
One of the future studies planned, which I am interested to pursue, is to examine 
whether the F77 and AE3 antigens are ligands for galectins, and whether mAbs F77 
and AE3 can inhibit recognition by galectins. It is hoped this follow-up study will 
contribute to a better understanding of these antigens in epithelial cancer progression. 
 
With knowledge of the structure of the two antigens F77 and AE3, the way is open to 
explore rationally their applications as biomarkers. The two well-characterized mAbs 
F77 and AE3 can be used as tools, to detect CTCs and specific glycoforms of 
glycoproteins; and these in turn would serve as biomarkers in monitoring cancer 
progression during treatment. The two antigens and the related glycan sequences 
generated in this thesis project are valuable reference probes for glycan arrays. 
These can be used in serological studies in the search for tumour-associated 
autoantibodies. There are good prospects for such autoantibodies as biomarkers in 
cancer diagnosis. 
 
With the advent of technologies for engineered T cells, especially with the two-
receptor strategy, there is considerable potential for exploiting scFvs of antibodies 
F77 and AE3 in cancer therapy.  
 
In sum, the two antibodies and the corresponding antigens have tremendous 
biological and functional implications. Further research should be carried out to 
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understand how the aberrant glycosylations occur during cancer progression, and to 
elucidate details of the contributions of these glycan sequences to the neoplastic 
processes, and to determine whether therapies targeting these modifications can 
lead to beneficial clinical outcomes.   
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Appendix S1 Oligosaccharide probes included in the screening array (Glycosciences 
Array Set 32-39) and the binding signals (means of the fluorescence intensity) 
elicited with mAb F77 and 89-F anti-B at 5 fmol probe per spot. 
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